Old Dominion University

ODU Digital Commons
Theses and Dissertations in Biomedical
Sciences

College of Sciences

Spring 2009

Mechanisms of Regulation of Proximal Tubule Sodium
Transporters in Obesity-Induced Hypertension
Marta A. Ambrozewicz
Old Dominion University

Follow this and additional works at: https://digitalcommons.odu.edu/biomedicalsciences_etds
Part of the Diseases Commons, and the Physiology Commons

Recommended Citation
Ambrozewicz, Marta A.. "Mechanisms of Regulation of Proximal Tubule Sodium Transporters in ObesityInduced Hypertension" (2009). Doctor of Philosophy (PhD), Dissertation, , Old Dominion University, DOI:
10.25777/hvs7-v927
https://digitalcommons.odu.edu/biomedicalsciences_etds/2

This Dissertation is brought to you for free and open access by the College of Sciences at ODU Digital Commons. It
has been accepted for inclusion in Theses and Dissertations in Biomedical Sciences by an authorized administrator
of ODU Digital Commons. For more information, please contact digitalcommons@odu.edu.

MECHANISMS OF REGULATION OF PROXIMAL TUBULE
SODIUM TRANSPORTERS IN OBESITY-INDUCED
HYPERTENSION
by

Marta A. Ambrozewicz
M.D., 1993, Medical Academy of Gdansk, Poland
A Dissertation Submitted to the Faculty of
Eastern Virginia Medical School and Old Dominion University
in Partial Fulfillment of the
Requirement for the Degree of

DOCTOR OF PHILOSOPHY
BIOMEDICAL SCIENCES
EASTERN VIRGINIA MEDICAL SCHOOL
and OLD DOMINION UNIVERSITY
May 2009

Approved by:

^ n c a D. Dobrian (Director)

Frank A. Lattanzio ^Member)

Russell L. Prewitt (Member)

ABSTRACT
MECHANISMS OF REGULATION OF PROXIMAL TUBULE SODIUM
TRANSPORTERS IN OBESITY-INDUCED HYPERTENSION

Marta A. Ambrozewicz
Eastern Virginia Medical School and
Old Dominion University, 2009
Director: Dr. Anca D. Dobrian

Hypertension is one of the common complications of obesity. Using a rat
model of diet induced obesity and hypertension we investigated some of the
mechanisms that are involved in regulation of blood pressure in obesity. The first
aim of this study was to determine the role of proximal tubule transporters on the
renal sodium handling in obese hypertensive (OP) and lean normotensive (OR)
rats. An acute increase in renal perfusion pressure resulted in a blunted
natriuretic response in OP vs. OR rats and indicated that increased sodium
reabsorption in the proximal tubule is casual, at least in part, for hypertension in
OP rats. Subsequently, protein expression and activity of Na,K-ATPase and
NHE3 were increased in obese rats compared to lean rats. Moreover, in OP rats
more NHE3 was associated with its active pool located in the microvillus region.
Together, these results suggest that hypertension in obese rats is characterized
by the impaired pressure-natriuresis and diuresis that can be explained by the
increased activity of proximal tubule sodium transporters.
Previous results from our lab determined that peroxisome proliferator
activated receptor y (PPARy) has reduced expression and activity in the kidney of

OP vs. OR rats. Therefore, in the second aim we investigated the effect of
PPARy ligand activation on expression and activity of proximal tubule Na+
transporters in OP and OR rats. In addition, by employing in vitro studies using
proximal tubule epithelial cells, we determined whether pioglitazone exerts its
effect via direct PPARy activation. Pioglitazone reduced systolic blood pressure
in obese rats while having no effect in lean rats. However, it increased sodium
retention in the lean group. Pioglitazone increased Na,K-ATPase activity in OP
rats, while its protein expression was increased in both groups. In contrast, NHE3
activity was reduced in obese rats treated with pioglitazone and protein
expression was decreased in both groups. Pioglitazone did not have an effect on
NHE3 localization in obese rats, but in lean rats, it had tendency to redistribute
NHE3 towards the more active membrane pool. In cells transiently transfected to
overexpress or silence PPARy, we demonstrated that pioglitazone reduced Na,KATPase and NHE3 abundance via PPARy activation. Collectively, the results
indicated that pioglitazone reduced blood pressure in the obese group most likely
by decreasing activity of NHE3. However, other factors besides trafficking are
involved in the transporter regulation. Pioglitazone did not reduce blood pressure
in lean rats, suggesting that the metabolic milieu is an important determinant of
the pioglitazone differential effect on the blood pressure and on the proximal
tubule transporters.
Nitric oxide (NO) plays an important role in regulating pressure natriuresis
and diuresis and its availability seems to be altered in obese animals and
humans. The third aim was designed to examine the role of NO on blood

pressure, pressure natriuresis and expression of sodium transporters NHE3 and
Na,K-ATPase in OP and OR rats. To determine the role of NO, we performed in
vivo study using L-NAME for chronic NO inhibition. The NO inhibition did not
change glomerular filtration rate in either of the groups. Natriuresis and diuresis
was significantly decreased only in treated OR rats. Also, NHE3 protein
expression and activity were significantly elevated in treated vs. non-treated OR
rats, with no significant changes in OP rats. Moreover, L-NAME caused a shift of
NHE3 to the active pool located in microvillus region in OR group only. In
conclusion, normotensive OR rats are more susceptible to NO deficiency and the
mechanism involves an increase in activity of NHE3 with the transporter
redistribution playing a significant role. In addition, we investigated in cell culture
whether hormones elevated in obesity can modulate Na,K-ATPase and NHE3 via
cGMP production. In vitro experiments provided some evidence that angiotensin
II and insulin interact with the NO signaling pathway at the level of cGMP. cGMP
could affect transporter activity by phosphorylation which could account for the
effects determined in vivo.
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SECTION 1
INTRODUCTION AND BACKGROUND

1.1 Obesity

It is possible that millions of years ago, when food and water were not
easily available, individuals developed a very efficient system to utilize and store
energy, salt and water. Conversely, descendants of those same individuals, living
in a new environment of plentitude, would develop obesity. Obesity can be
defined as a disease in which an excessive accumulation of energy in the form of
body fat may adversely affect the health of the individual. The most widely used
and accepted metric for identifying obesity is having a Body Mass Index (BMI)
greater than 30. However, growing evidence suggests that a central (abdominal)
fat distribution pattern as reflected by waist circumference is also an important
factor in assessing obesity (Wang et al. 2005). Obesity is not a single disorder
but a part of a group of diseases called "complex diseases". The phenotype of
complex diseases reflects the multifactorial effect of all contributing genes
(polygenic) and all environmental factors (Motulsky 2006). There are 2 distinct
genetic mechanisms involved in obesity. One is caused by the infrequent
presence of certain genes, which produce rare syndromes associated with
significant obesity such as Prader-Willi or Bardet-Biedl syndrome. However,
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obesity is much more commonly mediated by the presence of other
"susceptibility" genes. More than 50 such genetic sites have been identified and
in their presence obesity will develop only if there is a favorable environment
(Rankinen etal. 2006). These genes control different processes, such as
regulation of fat distribution, metabolic rate, response to exercise and diet, control
of feeding, and food preferences, etc. But the striking rise in the incidence of
obesity, which has happened in the last few decades, is most probably not
because of changes in the genetic background of the human race, since these
changes take thousands of years to evolve. This "epidemic" is mainly caused by
rapid lifestyle changes involving eating habits and exercise (Ravussin etal. 1988,
Rissanen etal. 1991, Blundell & Macdiarmid 1997).
Although obesity is not a recent phenomenon, the epidemic of obesity is
and continues to escalate in the United States (Ogden etal. 2006) and in much
of the developed (Berghofer et al. 2008) and developing world (Hossain et al.
2007). According to data from the 2003-2004 National Health and Nutrition
Examination Survey (NHANES), ~73% of men and ~60% of women are
overweight or obese, with prevalence varying among the three major racial/ethnic
groups in the U.S. (Ogden etal. 2007) and increasing rapidly. All in all, an
estimated 145 million adults in the United States are overweight or obese. As
prevalence of obesity increases, the rising economic costs of obesity continue to
be a major health burden for national health economies (Thorpe 2009). Recent
estimates indicate that obesity accounted for 9% of total health care costs in the
U.S. in 1998, with diseases such as coronary heart disease, type II diabetes and

osteoarthritis accounting for 93 billion dollars of total obesity-attributable medical
costs in 2002 (Colditz 1999, Finkelstein etal. 2003).

1.1.1 Obesity and associated co-morbidities

Higher body weights are associated with several cardiovascular risk
factors including hypertension (Field etal. 1999, Brown etal. 2000), dyslipidemia
(Brown et al. 2000) and hyperinsulinemia (Despres 1993). These risk factors
could represent intermediate steps in the pathway between obesity and coronary
heart disease or obesity could be an independent risk factor for cardiovascular
disease (CVD) (Eckel & Krauss 1998, Kim et al. 2000, Grundy 2002). Being
overweight or obese substantially increases the risk of other chronic diseases
beside CVD such as stroke, diabetes mellitus, gallblader disease, osteoarthritis,
sleep apnea and respiratory problems, as well as cancers of the endometrium,
breast, prostate and colon (National Heart Lung and Blood Institute: Obesity
Guidelines).
Previously, adipose tissue was thought to be a passive depot for storing
excess calories. Recently however, it was discovered that in addition to storing
excess energy as fat, adipose tissue has much more complex and dynamic
functions and acts as an endocrine organ secreting various factors into the blood,
termed adipokines (Rajala & Scherer 2003). These factors include leptin,
adiponectin, resistin, angiotensin II, prostoglandins, plasminogen activator
inhibitor-1, tumor necrosis factor-a, macrophage migration inhibitory factor etc.

4
and the list of these factors is growing rapidly. Most of these factors have
important roles in energy homeostasis, insulin sensitivity, immune function,
inflammation, and even in tumor progression in the local oncogenic
microenvironments (Rajala & Scherer 2003). These secretory and non-secretory
components of the adipose tissue may impact on the complications related to
obesity directly or may affect the above mentioned risk factors.

1.1.2 Obesity and hypertension

As described earlier, the effects of obesity on cardiovascular health and
disease are many, one of the most profound of which is hypertension. It was
estimated that after adjustment for other risk factors such as age, BMI, degree of
weight cycling, physical activity, smoking, and alcohol consumption each
kilogram increase in body weight increased the risk of developing hypertension
by 4.4% (Field et al. 1999). And it came as no surprise that with the significant
rise in obesity in this last decade occurred a corresponding increase in the
prevalence of hypertension (Field et al. 1999). However, clinical studies
demonstrated that weight loss can effectively lower blood pressure (Schotte &
Stunkard 1990, Wassertheil-Smoller era/. 1992).
It is also important to recognize that long-duration obesity does not appear
necessary to elevate BP, as shown in obese, normotensive children (Sorof &
Daniels 2002). Nevertheless, association between obesity and hypertension is
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widely recognized, but the mechanisms responsible for weight-related changes in
blood pressure have not been entirely elucidated.

1.2 Hypertension

More than 1 billion individuals worldwide, including 50 million Americans,
have high blood pressures warranting some form of treatment (WHO 2002,
Hajjar & Kotchen 2003, Kearney et al. 2005). Higher-than-optimal blood pressure
is the number one attributable risk for death throughout the world and
approximately 7.1 million deaths per year are credited to uncontrolled
hypertension (WHO 2002). As life expectancy increases, hypertension is
becoming an even more important medical and public health issue as blood
pressure rises with aging in industrialized countries. The most recent National
Health and Nutrition Examination Survey (NHANES) survey conducted in 20052006 revealed that almost 29 percent of the population in the United States is
hypertensive having a blood pressure (BP) greater than 140/90 or using
hypertensive medications (Ostchega et al. 2008). Primary (essential)
hypertension, which accounts for 95 percent of all cases of hypertension, has
been traditionally defined as high blood pressure for which no obvious secondary
cause (e.g., renovascular disease, aldosteronism, pheochromocytoma, or
individual gene mutations) can be determined. Moreover, risk estimates from the
Framingham Heart study suggest that approximately 78% of hypertension in men
and 65% in women can be attributed directly to an overweight condition and
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obesity (Garrison etal. 1987). Therefore, rather than a special case, obesity
hypertension should be considered the most common form of essential
hypertension.

1.2.1 Blood pressure regulation

The most important function of blood pressure is to provide the driving
force that moves blood through the vascular system in order to supply the needs
of the tissues. Consequently, the regulation of blood pressure is a complex
physiologic function that depends on the integrated actions of multiple
cardiovascular, renal, neural, endocrine, and local tissue control systems. Blood
pressure regulation, as is true for most physiologic control systems, involves
short-term and long-term mechanisms. Following a sudden change in blood
pressure, acute control occurs within seconds as a result of: 1) the arterial
baroreceptors, which detect changes in blood pressure and send appropriate
autonomic reflex signals into the vasomotor center of the brain and then back to
the heart and blood vessels to return the blood pressure toward normal; 2) the
chemoreceptors, which detect changes in oxygen or carbon dioxide in the blood
and similar to baroreceptors initiate autonomic feedback responses that influence
blood pressure; and 3) the central nervous system, which responds within a few
seconds to ischemia of the vasomotor centers in the medulla, especially when
blood pressure falls below about 50 mm Hg. Each of these nervous control
mechanisms works rapidly and can have potent effects on blood pressure but
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they correct a blood pressure abnormality only in part but never restoring it
completely to the normal values.
Within a few minutes or hours after a blood pressure disturbance, when
the nervous mechanism usually become less and less effective, several
additional control systems are activated, including 1) a shift of fluid from the
interstitial spaces into the blood stream in response to decreased blood pressure
(or a shift of fluid out of the blood into the interstitial spaces in response to
increased blood pressure); 2) the renin-angiotensin system (RAS) which is
activated when blood pressure falls too low and suppressed when blood
pressure increases above normal (Fig.1); 3) multiple vasodilator systems that are
suppressed when blood pressure decreases and stimulated when blood pressure
rises above normal. However, the renal-body fluid system is a dominant
mechanism for long-term arterial pressure control (Guyton & Hall 2006).

1.2.2 Pressure natriuresis and diuresis

Normally, an increase in blood pressure would raise sodium and water
excretion, a phenomenon usually referred to as pressure natriuresis and diuresis
(Fig. 2). Under most conditions this mechanism acts to stabilize blood pressure
and the body fluid volumes. For example, when blood pressure is increased
above the renal equilibrium point, because of increased total peripheral
resistance or increased cardiac pumping ability, this also increases sodium and
water excretion via pressure natriuresis if kidney function is not impaired.
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Figure 1 Components of the renin-angiotensin system.
A decrease in renal perfusion pressure causes the juxtaglomerular cells of the
afferent arteriole to secrete renin. Renin catalyzes the conversion of
angiotensinogen to angiotensin I in plasma. Angiotensin-converting enzyme
(ACE) catalyzes the conversion of angiotensin I to angiotensin II, primarily in the
lung. Angiotensin II is physiologically active and acts as a vasoconstrictor and
also stimulates the synthesis and secretion of aldosterone by the adrenal cortex.
Aldosterone increases Na+ reabsorption. Angiotensin II is rapidly inactivated by
angiotensinases.
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Figure 2 Graphical analysis of the infinite gain characteristic of the renal-body
fluid feedback system on pressure control.
There are two separate curves that intersect each other: renal output curve (red)
for water and salt in response to increasing arterial pressure and the line (black)
which represents the net water and salt output. Redrawn from Textbook of
Medical Physiology (Guyton & Hall 2006).
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As long as fluid excretion exceeds fluid intake, extracellular fluid volume will
continue to decrease, reducing venous return and cardiac output, until blood
pressure returns to normal and fluid balance is reestablished. An important
feature of pressure natriuresis is that various hormonal and neural control
systems can greatly amplify or blunt the basic effects of blood pressure on
sodium and water excretion. For example, during chronic increases in sodium
intake only small changes in blood pressure are needed to maintain sodium
balance in most people. One reason for this insensitivity of blood pressure to
changes in salt intake is decreased formation of antinatriuretic hormones such as
angiotensin II and aldosterone, which enhance the effectiveness of pressure
natriuresis and allow sodium balance normally maintained with minimal increases
in blood pressure. On the other hand, excessive activation of these antinatriuretic
systems can reduce the effectiveness of pressure natriuresis, thereby
necessitating greater increases in blood pressure to maintain sodium balance
(Guyton & Hall 2006).
One important feature of pressure natriuresis is that it continues to operate
until blood pressure returns to the original equilibrium point. In other words, it
acts as part of an infinite gain feedback control system (Fig. 2) (Guyton 1990). It
is the only infinite gain feedback system for blood pressure regulation in the
body, so far known, and it is this property which makes it a dominant long-term
controller of blood pressure (Fig. 2) (Guyton & Hall 2006). Moreover, in all forms
of human or experimental hypertension studied thus far, there is a shift of
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pressure natriuresis that appears to initiate and sustain the hypertension (Hall
2003).

1.2.3 Hypertension in obesity

It is well documented that blood pressure increases with weight gain and
decreases with weight loss (Garrison etal. 1987, Jones etal. 1999, Stevens et
al. 2001). Some of the characteristics of primary hypertension caused by excess
weight gain and obesity include: an expansion of extracellular fluid volume, as
well as increased tissue blood flow in many tissues, including the heart, kidneys,
gastrointestinal tract, and skeletal muscles and an increase in cardiac output
(Hall etal. 1993, Carroll etal. 1995).
In addition, there is increasing evidence that obesity may provide the
impetus for sympathetic nervous system (SNS) activation. This is especially
important in the kidney since pharmacologic blockade of adrenergic activity
lowers blood pressure to a greater extent in obese, compared to lean individuals.
Also renal denervation markedly attenuates sodium retention and hypertension
associated with a high-fat diet in experimental animals (Hall 2003). The
mechanisms of sympathetic nervous system activation in obesity have not been
fully elucidated, but one of the more promising candidates is hyperleptinemia
(Hall et al. 2001). As mentioned before, leptin is produced by adipocytes and acts
on the hypothalamus and other regions of the brain, such as the brainstem, to
reduce appetite and increase sympathetic nervous system activity (Hall etal.
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2001). In rodents, increasing plasma leptin concentration to levels comparable to
those found in severe obesity not only increases sympathetic nervous system
activity, but also raises blood pressure (Shek etal. 1998, Carlyle et al. 2002).
Moreover, the hypertensive effects of leptin are enhanced when NO synthesis is
inhibited (Kuo ef al. 2001).
Obese individuals, especially those with visceral obesity, although having
expansion of extracellular fluid volume, often have mild to moderate increases in
plasma renin activity, angiotensinogen, angiotensinogen converting enzyme
activity, angiotensin II, and aldosterone levels (Hall 2003). An important role for
angiotensin II in stimulating renal sodium reabsorption and in mediating obesity
hypertension is supported by studies in experimental animals demonstrating that
angiotensin II receptor blockade or angiotensinogen converting enzyme activity
(ACE) inhibition blunts sodium retention, volume expansion, and decreases
blood pressure during the development of obesity (Robles et al. 1993, Boustany
et al. 2005).
Most of all, in hypertension induced by obesity there is considerable
evidence in humans that renal dysfunction, characterized by increased tubular
sodium reabsorption and impairment of pressure natriuresis plays a key role in
increasing blood pressure (Hall etal. 1993). The increased tubular reabsorption
is closely related to the increase activity of the sympathetic nervous system and
activation of the renin-angiotensin system in obesity. Other contributing factors
are structural changes that cause the physical compression of the kidneys by fat
accumulation within and around the kidneys and by the increased abdominal
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pressure. Hyperinsulinemia, which occurs as a compensation for insulin
resistance, is postulated to mediate increased blood pressure in essential
hypertension via multiple mechanisms, such as stimulation of sympathetic
nervous system activity and the renal tubular sodium reabsorption (Hall 1993).
However, chronic hyperinsulinemia, in the absence of obesity, did not raise blood
pressure in either dogs or humans and did not enhance the hypertensive effects
of other pressor substances such as norepinephrine or angiotensin II (Hall et al.
1995). A study by Fujiwara and coworkers reported that altered pressure
natriuresis and hypertension is associated with insulin resistance and impaired
production of NO in cortex and medulla of the obese Zucker rats (Fujiwara et al.
1999).
Hall implied that a shift of pressure natriuresis and increased sodium
reabsorption is caused by altered renal hemodynamics, increased sodium
reabsorption, or both due to the mechanisms postulated above (Hall et al. 1993,
Hall, J. E. 1994) such as increased sympathetic nerve activity, increased levels
of angiotensin II, increased leptin and most likely increased levels of insulin.
However, there was no renal vasoconstriction observed in obese dogs which
could lead to a decrease in sodium filtered load. In fact, obese dogs were volume
expanded and their glomerular filtration rate, filtered sodium load, and renal
blood flow were elevated (Hall et al. 1993).

1.2.4 Animal models of obesity hypertension

Although association between obesity and hypertension is widely
recognized, the mechanisms responsible for weight-related changes in blood
pressure have not been elucidated. Animal models of obesity provided us with
the opportunity to study the physiological and genetic basis of obesity and also to
explore environmental aspects of the disease. There are a few models of single
gene mutations available such as ob/ob and db/db mice and Zucker rats (fa/fa)
with mutations in the leptin gene (ob/ob mouse) and leptin receptor (db/db; fa/fa
rat). However, in humans, single gene mutations are of limited importance when
considering the increasing obesity epidemic, as they account for less than 2% of
obesity. In light of this, several polygenic models have been developed and
characterized. Nevertheless, the cardiovascular and renal changes in most of
these models have not been characterized. Among the ones that have been
studied, most do not mimic the cardiovascular, renal, and neurohumoral changes
found in obese humans (Kurtz et al. 1989).
As described before, one hypothesis for the rapidity of the obesity
epidemic in humans is the possibility that our regulatory systems become
overwhelmed by high-fat palatable foods which have become increasingly
available (Blundell & Macdiarmid 1997). In addition, in contrast to genetic models
of obesity, weight gain induced by long-term high-fat diet causes a reproducible
rise in blood pressure in dogs, rabbits, and rats (Hall et al. 1993, Carroll et al.
1995, Rocchini et al. 1999). Dobrian et al. characterized a rat model of diet-
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induced obesity that developed hypertension accompanied by vascular and renal
changes similar to those observed in obese hypertensive humans (Dobrian et al.
2000). In this model which was used for the present study, Sprague-Dawley rats
were fed a purified moderately high-fat (MHF) diet that contains 32% kcal fat, a
value similar to the average Western diet, and showed a bimodal pattern in body
weight gain. Approximately half of the rats gain weight rapidly- obesity prone
(OP) and developed mild hypertension while the other half gain weight at a rate
similar with chow-fed rats- obesity resistant (OR) group and were normotensive
as described earlier. This model of diet-induced obesity shares a number of
common features with human obesity. These include high blood pressure,
activation of the renin-angiotensin system, and dyslipidemia (Dobrian et al.
2000), an increase in oxidative stress, a decrease in plasma and urine
nitrate/nitrite content, suggesting a decreased NO production or bioavailability
(Dobrian etal. 2001); hyperinsulinemia was also observed (Dobrian et al. 2004)
as well as hyperleptinemia (Dobrian et al. 2003).

1.3 Sodium transport

Na+ is the most abundant cation in extracellular fluid and since its salts
account for over 90% of the osmotically active solute in the plasma and interstitial
fluid, the amount of Na+ in the body is the most important determinant of the
extracellular fluid volume. Hence, reabsorption of Na+ plays a major role in body
electrolyte and water metabolism. In addition, Na+ transport is coupled to the
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movement of CI", H \ other electrolytes, glucose, amino acids, organic acids,
phosphate, and other substances across the tubule walls. In the proximal
tubules, the thick portion of the ascending limb of the loop of Henle, the distal
tubules, and the collecting ducts, Na+ moves by cotransport or exchange from
the tubular lumen into the tubular epithelial cells down its concentration and
electrical gradients and is actively pumped from these cells into the interstitial
space. Thus, Na+ is actively transported out of all parts of the renal tubule except
the thin portions of the loop of Henle. Then, Na+ is pumped into the interstitium
by Na,K- ATPase. Normally about 60% of the filtered Na+ is reabsorbed in the
proximal tubule, primarily by the Na+/H+ exchange. Another 30% is absorbed via
the Na+-2CI-K+ cotransporter in the thick ascending limb of the loop of Henle, and
about 7% is absorbed by Na+-CI" cotransport in the distal convoluted tubule. The
remainder of the filtered Na+, about 3%, is absorbed via the ENaC channels in
the collecting ducts. Thus, the kidneys reabsorb approximately 99.6% of the
filtered Na+ and it comes as no surprise that there are multiple regulatory
mechanisms to control the excretion of this ion. The body regulates Na+ transport
using three major mechanisms: 1) glomerulotubular balance, 2) factors that
increase Na+ reabsorption such as the renin-angiotensin-aldosterone system,
sympathetic nerve activation and antidiuretic hormone, and 3) factors that
decrease Na+ reabsorption such as atrial natriuretic peptide, prostaglandins,
bradykinin and dopamine. Through the operation of these regulatory
mechanisms, the amount of Na+ excreted is adjusted to equal the amount
ingested over a wide range of dietary intakes, and the individual stays in Na+
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balance. Therefore, the kidney ultimately governs the extracellular fluid volume
and consequently is the principal agent in the long-term control of blood pressure
(Boron & Boulpaep 2002).

1.3.1 Sodium/hydrogen exchanger type 3 (NHE3)

In the proximal tubule the essential components of absorption are luminal
membrane Na+/H+exchanger and basolateral Na,K-ATPase as mentioned
earlier. Sodium is reabsorbed from the proximal tubule across the apical
membrane via sodium-hydrogen exchangers, and it is actively pumped out of the
cell by the basolateral sodium pump, Na,K-ATPase, which generates the
gradient for Na+ entry across the apical membrane. The inward gradient for Na+
is used to drive several secondary active transporters. Quantitatively speaking,
the most important Na+-coupled transporter in proximal tubule is the Na+/H+
exchanger.
The sodium hydrogen exchangers (NHEs), also called antiporters, are
widely expressed in the epithelial membrane and play an important role in salt
and water reabsorption by virtue of the Na+/H+ exchange. NHEs belong to the
gene family called SLC9A comprising nine isoform NHE1-9 (Donowitz & Li 2007).
The first five isoforms are expressed largely at the plasma membrane, while the
other isoforms (NHE6-9) have been shown to reside predominantly intracellular^
(Donowitz & Li 2007). The NHE1 isoform is the 'housekeeping' isoform of the
exchanger and is ubiquitously expressed in the plasma membrane of virtually all
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tissues (Fliegel 2005). The NHE2-NHE5 isoforms are also localized to the
plasma membrane, but have more restricted tissue distributions. NHE2 and
NHE3 are predominantly located in the apical membrane of epithelia and are
highly expressed in the kidney and the intestine (Biemesderfer et al. 1993,
Hoogerwerf et al. 1996, Biemesderfer et al. 1997). In kidney, as found by
immunohistochemistry analysis, NHE1 is expressed along the basolateral
plasma membrane of most renal epithelial segments (Paillard 1997). At the same
time NHE3 has been localized to the apical membrane of the proximal
convoluted tubule in the cortex and to the thick ascending limb of the loop of the
Henle in the medulla (Biemesderfer et al. 1993, Amemiya et al. 1995).

1.3.1.1 Structure and functional properties of NHEs

Structurally, human NHEs have between 645 and 898 amino acids with 12
putative encoded membrane-spanning domains (msd), the first being a cleaved
signal peptide as demonstrated for NHE3 (Zizak et al. 2000, Zachos et al. 2005).
The transmembrane N-terminus of about 500 aa is a transport domain that
carries out electroneutral exchange of 1 Na+ for 1 H+. The long, hydrophilic,
cytosolic C-terminus domain (~300aa) regulates activity of the amphipathic Nterminal domain is a target for phosphorylation by protein kinases and also
participates in binding with regulatory proteins (Wakabayashi et al. 2000). The
transport characteristics of NHEs include substrate specificity, ATP dependence,
and their sensitivity to the diuretic amiloride (Kiela. et al. 2006), with NHE1 and
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NHE2 isoforms being the most sensitive to amiloride inhibition (IC5o~1|aM), and
NHE3 being relatively amiloride resistant with IC50 >100jJVI (Kiela etal. 2006).
Transport kinetics for NHE3, as well as all others NHEs, is consistent with
simple, saturating, Michaelis-Menten kinetics.

1.3.1.2 Regulation of NHE3

Basic short-term regulatory mechanisms of NHE3 are: changes in turnover
number and changes in trafficking, and recently described changes in
endocytosis/exocytosis rates (Donowitz & Li 2007). NHE3 activity is rapidly
stimulated by cc-adrenergic activation (Gesek etal. 1989), angiotensin II
(Morduchowicz et al. 1991), endothelin (Walter et al. 1995), and insulin (Gesek &
Schoolwerth 1991) and inhibited by dopamine and parathyroid hormone (Gesek
& Schoolwerth 1990). Those hormones are coupled to signaling pathways of
various protein kinases which phosphorylate a number of serine and threonine
residues that are located in the distal region of the C-terminal tail of NHE3
(Orlowski et al. 1992).
NHE3 is known to be phosphorylated under basal conditions (Donowitz & Li
2007). Its activity was inhibited by PKA and PKG by phosphorylation of Ser552
and Ser605 since mutations of those serines individually decreased and
mutations of both simultaneously blocked NHE3 inhibition (Zhao etal. 1999).
However, Kurashima et al. showed that only phosphorylation of Ser605 was
essential for PKA-induced NHE3 inhibition (Kurashima etal. 1997), with Ser634

playing an additional role for the effect of cAMP, and Ser552 not being
phosphorylated or functionally important. On the other hand, the effects of PKC
activation by phorbol esters were quite controversial, showing that while phorbol
ester induced NHE3 phosphorylation on identical serines on the cytoplasmic tail
on all the clones studied in NHE-deficient fibroblasts transfected with NHE3, the
final outcome was stimulation, inhibition or no effect on NHE3 activity
(Wiederkehr et al. 1999). Moreover, Yip et al. demonstrated that when
expressed in PS120 fibroblats NHE3 was inhibited by PKC stimulation without
any changes in the phosphorylation (Yip et al. 1997), suggesting that regulation
of NHE3 probably involves intermediate associated regulatory proteins such as
Na+/H+ exchanger regulatory factors (NHERFs) which are often absent in those
transfected cells. Several other kinases also either associate with or regulate
NHE3 activity and those are: cGMK kinase II known to inhibit NHE3 by a
phosphorylation process, phosphatidylinositol 3-kinase (PI3-K) known to
stimulate NHE3 activity, and calmodulin (CaM) kinase II (Donowitz & Li 2007).
From all those kinases mentioned, only the last one binds directly to NHE3 while
others: PKA, PKC, and PKG associate with NHE3 by PDZ domains of NHERFs
family (Donowitz & Li 2007). Besides protein kinase and NHE3 phosphorylation,
protein phosphatases (PP) may also play a role in NHE3 regulation. PP1 and
PP2A inhibitor okadaic acid was shown to stimulate NHE3 activity (Donowitz & Li
2007). In summary, while some regulation of NHE3 may involve changes in
NHE3 phosphorylation, some other regulations may occur independently of
NHE3 phosphorylation status but may require presence of additional factors

and/or complexes. However, regardless of the exact mechanism involved, the
functional consequences of NHE3 phosphorylation was its reduction in turnover
number and changes in trafficking described as an increase in endocytosis,
and/or a decrease in exocytosis.
Study by Biemesderfer and coworkers demonstrated that in the renal
proximal tubule brush border NHE3 was localized to two distinct pools: the
microvillar and the intermicrovillar microdomains with nearly equal levels of
NHE3 expression, and with the former domain containing the active form of
NHE3 and the latter the inactive form (Biemesderfer etal. 2001). NHE3 remains
in a state of dynamic equilibrium between cell surface and the intracellular
compartment; it can undergo internalization via clathrin-coated vesicles (Chow
W. et al. 1999) and exocytosis back to the apical membrane in a PI3-K
dependent manner (Lee-Kwon et al. 2001). Action of PKC (Janecki etal. 1998),
parathyroid hormone (Collazo etal. 2000), and dopamine (Hu et al. 2001) are
associated with a decrease in NHE3 surface expression and inhibition of the
transporter while growth factors (Donowitz et al. 2000) and endothelin (Peng et
al. 2001) have been shown to stimulate NHE3 activity by increasing the surface
protein pool in a PI3-K dependent manner. Collectively, these data support the
notion that NHE3 redistribution is an effective means of transporter regulation.
There are several models which analyzed changes in NHE3 trafficking. One of
them is acute pressure-induced natriuresis and diuresis. Yang et al. provided
evidence that acute hypertension was associated with redistribution of NHE3
protein from apical membranes to, at first, membranes enriched in intermicrovillar

cleft markers, and later to membranes containing markers of endosomes (Yang
et al. 2002). Moreover, a study by Magyar illustrated that with the development of
hypertension in spontaneously hypertensive rats (SHR) there was an
internalization of apical NHE3-protein which partially mimicked changes
observed during acute hypertension in normotensive Sprague-Dawley rats
(Magyar et al. 2000).
There is evidence that intrinsic NHE3 activity can be modified without
alteration in NHE3 abundance in transfected cells, renal cell lines and in renal
cortex (Moe 1999). This regulation of NHE3 generally involves changes in NHE3
Vmax (Donowitz & Li 2007) and is associated with NHE3 phosphorylation
although the precise mechanism remains unknown. It is also possible that those
changes can be explained by the presence of NHERFs.
The NHE3 C-terminus is necessary in all cases of NHE3 regulation
discussed previously and contains stimulatory domains which respond to growth
factors and okadaic acid, and inhibitory domain motifs for PKA, PKC and CaM. In
addition, NHE3 can directly bind NHERF1, NHERF2, PDZK1, Hsc70, dipeptidyl
peptidase IV (DPPIV), PP2A, megalin, and CaM kinase II (Donowitz & Li 2007).
In the cell, NHE3 rarely exists as a monomer or a dimer (~90-180kDa) but forms
complexes which range from 400kDa in the intracellular pool to ~1000kDa at the
plasma membrane (Akhter, S. etal. 2002). These complexes are dynamic and
are further changed by the stimuli participating in acute NHE3 regulation. The
dynamic nature of NHE3 complexes allows association/dissociation from the
cytoskeletal proteins, endocytosis/exocytosis and phosphorylation. These

mechanisms may act in concert to provide highly regulated turnover and activity
of NHE3 (Donowitz & Li 2007).
NHE3 is regulated by binding to various PDZ domains containing proteins
that are present in the brush border and act as scaffolds that connect the plasma
membrane with members of the ezrin/radixin/moesin (ERM) family, thereby
helping NHE3 link with the actin cytoskeleton. NHERFs (Na+/H+ exchanger
regulatory factors) are PDZ domain proteins in or near the apical membrane and
include NHERF1 and NHERF2 (both have 2 PDZ domains and an ERM binding
domain), as well as NHERF3/PDZK1 and NHERF4/IKEPP (both have 4 PDZ
domains) (Donowitz & Li 2007). NHE3 inhibition by cAMP in PS120 fibroblasts
requires the presence of NHERF1 that links NHE3 to the actin cytoskeleton via
binding to ezrin. In this case ezrin acts as a low-affinity protein kinase A
anchoring protein (AKAP) (Yun etal. 1997, 1998). In the case of cGMP mediated
inhibition of NHE3, NHERF2 acts as a G kinase-anchoring protein (GKAP)
forming a complex between NHE3, NHERF2 and cGMP-activated protein kinase
II (cGKII). This complex is anchored to the cellular cytoskeleton by the ezrinbinding domain of NHERF2 (Cha et al. 2005). Ca2+-dependent regulation of
NHE3 involves NHERF2, which binds a-actinin-4, a protein necessary for
aggregation of the NHE3-containing plasma membrane complexes that occur
after Ca2+ elevation and before NHE3 endocytosis (Kim etal. 2002). Thus,
proteins like NHERFs are critical for NHE3 regulation, and their presence can
explain a paradigm for multi-protein complexes required for regulation of cellular
processes. NHE3 can also directly bind to the ERM proteins which is necessary
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for basal trafficking, including basal exocytosis and delivery of newly synthesized
NHE3 to plasma membrane (Donowitz & Li 2007). This association of NHE with
the cytoskeleton seem to be yet another mechanism for the NHE3 regulation.

1.3.1.3 Long-term regulation of NHE3 and hypertension

In addition to the short-term NHE regulation that occurs in the kidney over
minutes in response to drugs, changes in dietary intake of sodium, and changes
in blood pressure/volume, these exchangers are also regulated over periods of
hours to many days. The long-term regulation of NHEs generally mimic kidney
disease related processes or responses to a disease or injury. The rat and
human NHE3 promoters have GC rich regions and the former also contains
atypical TATA and CCAAT boxes while the latter contains only TATA-like
sequences. The rat NHE3 promoter includes putative cis-acting elements such
as glucocorticoid and thyroid response elements, AP1, AP2 C/EBF, NF-1, Oct-1,
PEA3, and Sp1 transcription-binding sites (Kandasamy & Orlowski 1996). The
human NHE3 promoter contains transcription factor-binding sites for Sp1, AP-2,
MZF-1, CdxA, Cdx-2, steroid and nonsteroid hormone receptor half sites, and a
phorbol 12-myristate 13-acetate-response element (Malakooti era/. 2002). There
are few studies focused on transcriptional regulation of NHE3. For example,
glucocorticoid treatment significantly increased the luciferase activity of the
chimeric NHE3 gene in renal epithelial OK cells and LLC-PK1 cells, thereby
indicating that glucocorticoid regulation of NHE3 is mediated primarily by a

transcriptional mechanism (Kandasamy & Orlowski 1996). Interactions of multiple
transcription factors and/or response elements are supposed to either up- or
down-regulate NHE mRNA expression and thereby regulate the NHE3 gene
followed by changes in protein levels (Zachos etal. 2005).
Altered expression and activity of NHE3 in primary hypertension have
implied a potential role of this transporter in the pathogenesis of high blood
pressure. Spontaneously hypertensive rats (SHR) have elevated NHE3 activity
and abundance in isolated renal proximal tubules (LaPointe etal. 2002)
suggesting that increased renal reabsorption of sodium may contribute to
systemic sodium retention and development of hypertension. Studies in obese
Zucker rats suggested that reduction in D1-like receptor binding sites, defective
coupling with signaling pathway and reduced PKA activation may be responsible
for the failure of dopamine to inhibit NHE3 in proximal tubules of obese rats and
may contribute to their increase in sodium reabsorption and development of
hypertension (Hussain et al. 2001). As mentioned earlier, in our model of dietinduced obesity we observed activation of the renin-angiotensin system, and
elevated levels of insulin and leptin. Each one of those factors can have an effect
on expression and/or activity of NHE3 in the proximal tubule. In vivo, intravenous
angiotensin II was shown to stimulate bicarbonate absorption (presumably
mediated by NHE3) in proximal tubule by reducing cAMP (Liu & Cogan 1989).
Moreover, Xu et al. observed that in OK cells prolonged exposure to angiotensin
II increased NHE3 mRNA and stimulated NHE3 activity by stimulating NHE3
promoter activity (Xu et al. 2006). Acutely, insulin has been shown to increase
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NHE3 activity in OK cells and chronically, stimulation of NHE3 activity was
accompanied by an increase in protein and transcript levels in the same cell line
(Klisic ef al. 2002). More recently, it was demonstrated by Fuster et al. that
chronic insulin treatment activated NHE3 through phosphatidylinositol 3-kinaseserum and glucocorticoid dependent kinase 1 pathways (Fuster etal. 2007).
Although sodium retention observed in essential hypertension apparently
involves increased activity of NHE3 additional studies are necessary to elucidate
its contribution to sodium absorption in obesity-induced hypertension.

1.3.2 The sodium-potassium activated adenosine 5'-triphosphate (Na.K-ATPase)

The most abundant ion pump in higher organisms is the sodiumpotassium pump or Na.K-ATPase. It is found in the plasma membrane of
practically every eukaryotic cell and is responsible for maintaining the low sodium
and high potassium concentration in the cytoplasm using ATP hydrolysis. For
every molecule of ATP hydrolyzed, three Na+ ions from the intracellular space
and two K+ ions from the extracellular space are exchanged. Thus, Na.K-ATPase
contributes substantially to the maintenance of the resting membrane potential of
the cell and osmotic regulation of the cell volume. In addition, the
electrochemical Na+ gradient is the driving force for secondary transporter
system such as transport of sodium into intestinal and renal epithelial cells, as
well as the transport of other nutrients, such as glucose, amino acids, and ions,
like Ca2+. Na,K-ATPAse activity is irregularly distributed In the kidney: highest in

the outer medulla, intermediate in the cortex and lowest in the inner medulla and
is restricted to the basolateral membrane of epithelial cells (lannello et al. 2007).

1.3.2.1 Structure of Na.K-ATPase

The Na.K-ATPase belongs to the P-type ATPases, a family of enzymes
that is phosphorylated by ATP (Horisberger 2004). This pump is a heterodimer of
two major subunits: a oc-subunit and a p-subunit. However, other proteins, such
as members of the FXYD family of proteins, interact with this enzyme in some
tissues, such as heart, kidney, and brain and are referred to as the y-subunit.
The catalytic a-subunit has a molecular mass of 100-113 kDa, depending
on the component isoforms a1, a2, a3, and a4 which are expressed in a tissuespecific manner. The a1 is present ubiquitously, while the a2 is detected mainly
in skeletal muscle, heart, and certain neuronal cells (neurons and astrocytes).
The a3 isoform is expressed mainly in neurons, and a4 is expressed in sperm
(Blanco 2005). It is reasonable to believe that the tissue-specific distribution of
the oc-isoforms indicates that each isoform exhibits a particular function
associated with the tissue in which it is expressed. The a-subunit has 10
transmembrane segments and both N- and C-termini on the cytoplasmic site; it
transports the cations, hydrolyzes ATP and has binding sites for specific cardiac
glycoside inhibitors such as ouabain, as well as several phosphorylation sites.
The p-subunit is a ~40 kDa glycoprotein. The mass of the protein moiety
depends on the presence of p1, p2, or p3 isoforms. It crosses the membrane only

one time and the N-terminus is localized on the intracellular side of the
membrane. The p-subunit acts a molecular chaperone for the correct membrane
insertion and packing of the newly synthesized catalytic a-subunit, modulates the
transport properties of mature Na,K-ATPase, and may play a role in processes
related to cell polarity (Geering 2008).
The third subunit of Na,K-ATPase, the y-subunit is a family of proteins
which are tissue-specific auxiliary subunits of Na,K-ATPase and are referred to
as FXYD proteins (Geering 2008). They are not required for Na,K-ATPase
normal activity, however, they can modify it. The seven members of the
mammalian FXYD proteins family are small membrane proteins containing the
FXYD motif and two conserved glycine residues in the transmembrane domain
together with the serine residue. One of these proteins (FXYD2) has indeed been
known as the y-subunit of the Na,K-ATPase, but all members of this group have
now been shown to be associated with the a/p-subunitof Na+,K+-ATPase and
modulate some aspect of its function by changing its substrate affinity and by
providing protection against thermal inactivation of Na,K-ATPase (Geering 2008).
In the kidney, the main FXYD proteins expressed are: FXYD2 subunit and
FXYD4 (or CHIF, corticosteroid hormone induced factor). FXYD2 is mainly
expressed in proximal tubules and in the thick ascending limb of the loop of
Henle which are the renal segments reabsorbing most of the filtered Na+ load.
FXYD4 is located in the outer and inner medullary collecting ducts and in the
cortical collecting duct (Geering 2006). FXYD2 and FXYD4 have the most
prominent, opposite effects on the Na+affinity of Na,K-ATPase. Whereas FXYD2

decreases, FXYD4 increases affinity of Na,K-ATPase for intracellular Na which
is consistent with the role of those proteins in the efficient reabsorption of sodium
in the nephron segments with the high and low Na+ load, respectively (Geering
2006).

1.3.2.2 Mechanism of Na.K-ATPase regulation

In general, Na.K-ATPase activation is tissue- and isoform-specific and in
the rat kidney only oc-1 and [3-1 subunits are expressed (Therien et al. 1996).
Regulation of the Na.K-ATPase activity can occur by different cellular
mechanisms and can be achieved by modulation of the number of enzyme
molecules present at the plasma membrane or by influencing the activity of the
Na.K-ATPase already located at the cell surface. For long-term regulation, the
amount of the enzyme at the plasma membrane can be modified by changes in
the rate of synthesis or degradation of the individual Na.K-ATPase polypeptides
while for short-term regulation this could be done by mobilization of Na pump
molecules from the endosomal pools to the cell surface (Therien & Blostein
2000). Alternatively, the activity of the Na.K-ATPase at the cell surface can be
directly regulated providing a rapid adjustment in its function. Several effectors
have been implicated in this acute response; the primary one is the intracellular
Na+ concentration. Moreover, the activity of kidney tubule Na.K-ATPase is under
control of hormones which can regulate natriuresis and Na+ reabsorption in renal
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cells such as catecholamines, peptide hormones and steroid hormones which
have been shown to exert short- and long-term effects on Na,K-ATPase acivity.
Aldosterone, a steroid hormone synthesized and released by the adrenal
cortex has long been known to promote Na+ reabsorption and K+ release in
kidney epithelial cells. The long-term effect of aldosterone on Na,K-ATPase is to
increase expression of transporter which is generally mediated by changes in
mRNA/protein synthesis induced by direct interactions of receptor/corticosteroid
complexes with the nuclear DNA. However, the short-term effects of aldosterone
are thought to be mediated not by the nuclear receptor but instead by
membrane-specific receptors (Therien & Blostein 2000) and is dependent on or
independent of intracellular Na+ concentration. An example of a Na+-dependent
effect is the translocation of Na,K-ATPase to the plasma membrane (Therien &
Blostein 2000).
Among the catecholamines that affect Na,K-ATPase activity are dopamine
and norepinephrine which often act antagonistically. Dopamine is a natriuretic
factor synthesized in the kidney proximal tubule. Dopamine inhibits Na,K-ATPase
activity in this segment of the nephron, through the dopamine receptors, DAi and
DA2, via a G protein-linked, PKC-dependent pathways (Bertorello & Aperia
1990). In the distal segments dopamine also inhibits Na,K-ATPase but acting
mainly through DAi receptors and PKA-associated pathways (Satoh etal. 1993).
It has to be noted, that in the rat isolated proximal tubule cells dopamine
activated PKC and inhibited Na,K-ATPase activity by direct phosphorylation of
Na,K-ATPase at a serine residue that induced transporter internalization via
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clathrin-dependent endocytosis (Chibalin etal. 1999). On the other hand, the
PKA-activated pathway of dopamine inhibition seems to involve phosphorylation
of both the sodium pump and the so-called dopamine and cAMP-regulated
phosphoprotein (DARPP-32), the latter being an inhibitor of a protein
phosphatase (Aperia etal. 1991).
In contrast to dopamine, other catecholamines including norepinephrine,
vasopressin, and angiotensin II stimulate Na,K-ATPase activity in various tissues
including the kidney. In the kidney proximal tubules, stimulation of the sodium
pump by a-adrenergic agents has been shown to involve protein phosphatase 2B
(PP2B), a Ca2+- and calmodulin-dependent phosphatase also called calcineurin.
Because the actions of norepinephrine in the kidney appear to oppose the
inhibitory effects of dopamine, it has been suggested that the Na,K-ATPase is
regulated in this organ by the antagonizing actions of calcineurin, which would
serve to keep the pump in an active, dephosphorylated state, and protein
kinases, which would maintain the enzyme in an inactive, phosphorylated form
(Therien & Blostein 2000). Efendiev et al. demonstrated that in a cell culture
model of proximal tubule epithelial cells -LLC PK1, angiotensin II stimulated
Na,K-ATPase activity by activating the PKC beta isoform followed by
phosphorylation of a1-subunit at Ser11 (Efendiev, & Pedemonte 2006) and
possibly its recruitment to the plasma membrane.
Insulin is a peptide hormone that can exert short- and long-term effects on
Na,K-ATPase regulation. There are several mechanisms by which insulin can
activate Na,K-ATPase. One example is an increase in intracellular Na+
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concentration; another is a change in the apparent affinity of the enzyme for Na+
(Feraille et al. 1994). However, the mechanism of short-term regulation of Na,KATPase by insulin is not clear. The effect of insulin on Na,K-ATPase activity in
fibroblasts depends on PI3-K, the zeta isoform of PKC, and p38MAP kinase
(Sweeney & Klip 1998, Sweeney et al. 1998). Feraille and coworkers have
shown that insulin-induced stimulation of Na,K-ATPase was associated with
phosphorylation of Tyr10 residue on the a-subunit of Na,K-ATPase (Feraille et al.
1994). From the studies summarized above, it is evident that the effect of the
hormones that regulate Na,K-ATPase are mediated by signaling intermediates
targeting certain protein kinases and phosphatases.
Agents that increase cellular cAMP, as well as exogenous derivatives of
cAMP, lead to Na,K-ATPase stimulation in the proximal convoluted tubules and to
Na,K-ATPase inhibition in the medullary thick ascending limb of the loop of Henle
and the cortical collecting duct (Therien & Blostein 2000). This response seems
to be mediated, at least in part, by protein kinase A (PKA)-directed
phosphorylation of Ser943 of the Na,K-ATPase a-subunit (Fisone etal. 1994).
Moreover, cAMP-PKA induced the recruitment of active Na,K-ATPase units to
the plasma membrane of the rat proximal tubule (Carranza et al. 1998).
Phosphorylation of the Na pump a-subunit is reversible, as demonstrated by the
decrease in Na,K-ATPase activity after activation of a dopamine- and cAMPregulated phosphoprotein (DARPP-32), an endogenous inhibitor of protein
phosphatase 1 (PP1) (Aperia et al. 1991). Nevertheless, DARPP is expressed at
low levels in proximal tubules and this fact most probably precludes its role of

Na,K-ATPase regulator in this segment of the nephron. However, a
phosphorylation/dephosphorylation event may dynamically regulate the activity of
the Na,K-ATPase.
Some observations show that in the proximal nephron and in cultured
canine kidney cells, Na,K-ATPase is inhibited by phorbol esters or diacylglycerol
analogs, in a process that involves protein kinase C (PKC) activation (Bertorello
1992) and, possibly, the phosphorylation of the Na+ pump a-subunit at Ser16
(Beguin etal. 1994). Ser23 has also been identified as a potential site for
phosphorylation (Logvinenko. etal. 1996) together with Ser11 and Ser18
(Feschenko & Sweadner 1995). The general consensus is that PKC
phosphorylation occurs primarily at the N-terminus of the a-subunit (Pedemonte
etal. 1997). This region exhibits the most sequence divergence, both among
species and isoforms. For example, Ser16 is present only in the cc1-isoform but
not on any other isoform, whereas Ser23 is present in the a1-subunit of the rat,
and a1-subunit of human, pig, and mouse do not have Ser18 in their N-terminal
region. In addition, the mammalian enzyme is phosphorylated at low levels at
Ser16, and in the rat, at higher levels on Ser23 (Feschenko & Sweadner 1995,
Efendiev & Pedemonte 2006). In contrast, phosphorylation of the a1-isoform by
PKA takes place at Ser943 in a highly conserved cytoplasmic region between
transmembrane segments 8 and 9. Thus the same residue might be involved in
the phosphorylation of different isoforms by this protein kinase.
Recently, Efendiev etal. demonstrated that human-type Na,K-ATPase
can be phosphorylated at the same serine residues by hormones affecting

enzyme activity in opposite ways (Efendiev & Pedemonte 2006). For instance, in
LLC PK1 cells, dopamine inhibited while angiotensin II stimulated Na,K-ATPase
activity and those opposite effects were mediated by the phosphorylation of
Ser11 of a1-subunit of Na,K-ATPase by activation of PKC zeta and PKC beta,
respectively. As mentioned before, the mechanism involved either endocytosis or
exocytosis of phosphorylated enzyme from the plasma membrane or the
intracellular compartment.
In the kidney, another kinase, protein kinase G (PKG), and the production
of cGMP appear to mediate the loss of salt and water produced by acetylcholine,
bradykinin, and atrial natriuretic peptide and to reduce Na,K-ATPase activity
(Therien & Blostein 2000). It is not clear whether direct phosphorylation of the
enzyme or secondary modulators are involved.

1.3.2.3 Na.K-ATPase in pathophysiological states

Na,K-ATPase activity is often altered in some models of obesity induced
hypertension. Bickel and coauthors demonstrated that in 2 and 4 month old,
hypertensive, insulin-resistant but non-diabetic, obese Zucker rats Na.K-ATPase
abundance was significantly increased in the proximal tubule (Bickel et al. 2001)
which was attributed to increased insulin levels. However, in slightly older (6
month old) obese Zucker rats, at early stages of diabetic nephropathy with insulin
resistance progressing to diabetes, abundance of Na,K-ATPase was not
changed at the proximal tubule while there was a decrease in the abundance of

apical transporters reflected in an almost 3-fold increase in the fractional
excretion of sodium (Bickel et al. 2002). In another study young, obese Zucker
rats which were hyperinsulinemic, hyperglycemic, and hypertensive displayed
impairment in dopamine Di receptor function. This caused an ineffective coupling
of the receptor with the G protein/effector enzyme complex signaling pathway
leading to a lack of PKA activation, and subsequently to an increase in the
activity of Na,K-ATPase (Hussain et al. 1999, 2001). In addition, it was reported
that increased blood pressure in obese Zucker rats is accompanied by impaired
pressure-natriuresis consistent with reduced dopamine-induced inhibition of
sodium transporters and, subsequently, decreased sodium excretion.This could
be provoked by hyperinsulinemia and/or other circulating factors associated with
obesity since response to dopamine-induced inhibition of Na,K-ATPase of
proximal tubule epithelial cells from both lean and obese Zucker rats expressing
functional Di receptors was blunted when those cells were incubated with obese
rat serum (Banday et al. 2004). Overall, further studies are necessary to address
the mechanism of Na,K-ATPase regulation in obesity induced hypertension and
how this relates to the impairment in pressure natriuresis.

1.4 Peroxisome proliferator-activated receptors (PPARs)

Peroxisome proliferator-activated receptors are members of the nuclear
hormone receptor superfamily of ligand-activated transcription factors. To date,
three different PPAR subtypes have been cloned and characterized: PPAR-oc,

PPAR-p/8, and PPAR-y.PPARs have been shown to be critical factors in
regulating diverse biological processes, including lipid metabolism, adipogenesis,
insulin sensitivity, immune response, cell growth and differentiation (Desvergne &
Wahli 1999, Fajas etal. 2001, Guan & Breyer2001, Willson etal. 2001). PPARs
participate in the pathogenesis of a cluster of human diseases designated the
metabolic syndrome, which includes insulin resistance, glucose intolerance,
obesity, dyslipidemia, hypertension, atherosclerosis, and microalbuminuria
(Ginsberg 2003, Gurnell etal. 2003, Scott2003).
Like other nuclear receptors, PPARy contains a central DNA-binding
domain (DBD), a C-terminal ligand-binding domain (LBD), and two transcriptionactivation function motifs (N-terminal ligand-independent AF-1 motif, C-terminal
ligand-dependent AF-2 motif) (Rosen & Spiegelman 2001). PPARs regulate
transcription of target genes by heterodimerizing with the retinoid X receptor
(RXR) upon ligand activation and binding to PPAR response element (PPRE) of
regulatory promoter regions of target genes (Tugwood et al. 1992, Gearing et al.
1993). This response element, generally of the direct repeat 1 (DR-1) type, is
composed of two half-sites that occur as a direct repetition of the consensus
sequence AGGTCA with a single nucleotide spacing between the two repeats
(Michalik etal. 2006). Following binding of the PPAR/RXR complex to PPRE,
different co-factors are recruited and may either induce (coactivators) or inhibit
(corepressors) target gene transcription (Nolte etal. 1998). Various ligands
engage different co-factors and result in different effects of the receptor on gene
transcription. It has been also shown that nuclear receptor co-repressors (NCoR)

and the related factors, such as silencing mediator of retinoic acid and thyroid
hormone receptors (SMRT), bind to unliganded nuclear receptors and repress
target gene expression until ligand triggers their dismissal accompanied by
recruitment of coactivators (Glass & Rosenfeld 2000). However, selective action
of a given PPAR isotype in vivo probably results from a complex interplay
between expression levels of the PPAR and RXR isotypes, affinity for a specific
promoter PPRE, ligands and cofactors availability, and possibly other
transcription factor binding in the vicinity of the PPRE.
A wide range of compounds have been identified as PPAR ligands.
PPARy is activated by various metabolites derived from arachidonic acid through
the lipoxygenase and cyclooxygenase pathways, such as 15-deoxy-A12,14prostaglandin J2 (15-PGJ2) and 15-hydroxyeicosatetraenoic acid (15-HETE)
(Willson & Wahli 1997, Nagy etal. 1998). FA-derived compounds from oxidized
LDL (9-HODE, 13-HODE) are also natural PPARy ligands (Shureiqi et al. 2003).
In addition, the thiazolidinediones (TZDs) including rosiglitazone (Avandia) and
pioglitazone (Actos) are synthetic, high-affinity ligands for PPARy (Willson &
Wahli 1997) and are insulin sensitizers used to treat hyperglycemia and type 2
diabetes.
PPARy is expressed as two isoforms y1 and y2 in rodents and three
isoforms y1, y2, and y3 in humans (Fajas etal. 1997, 1998). Adipose tissue and
large intestine have the highest levels of PPAR-y mRNA; kidney, liver, and small
intestine have intermediate levels (Fajas et al. 1997); PPAR-y2 and y3 are
predominantly expressed in adipose tissue in both mouse and human (Fajas et

al. 1997, 1998). In rodents, Verreth etal. found that compared with lean mice,
PPARy expression was downregulated in obese double-knockout mice, and that
diet restriction caused upregulation of PPARy (Verreth et al. 2004). Dobrian et al.
showed that PPARy mRNA expression and activity in the renal cortex and
medulla of obesity-prone rats were significantly lower compared with that in
obesity-resistant rats (Dobrian et al. 2004). Vidal-Puig et al. reported that
exposure to high fat diet increases adipose tissue expression of PPARy in normal
mice (Vidal-Puig et al. 1996). This implies that PPARy expression might be
stimulated by dietary fat until a determined threshold is reached and/or some
other factors such as insulin may prevent further induction of PPARy in obese
animals.

1.4.1

PPARY,

obesity, insulin resistance, and type 2 diabetes

PPARy has been implicated in the pathogenesis of obesity. PPARy is
expressed in various tissues with a higher level of expression in adipose tissue.
Moreover, PPARy target genes are generally involved in the lipogenic pathways
and the storage of fatty acids in adipose tissue which is consistent with a role for
PPARy in differentiation of adipose tissue both in vitro and in vivo (Michalik et al.
2006). A missense mutation in the gene for PPARy2 that resulted in the
conversion of proline to glutamine at position 115 was associated with severe
obesity in humans as well as accelerated adipocytes differentiation and greater

cellular accumulation of triglyceride compared to the wild-type PPARy2 (Ristow et
al. 1998). In contrast, a Pro12Ala substitution in PPARy2 was associated with
decreased binding affinity to the PPRE, reduced ability to transactivate
responsive promoters, and with lower body mass index in middle-aged and
elderly subjects (Deeb et al. 1998). In addition, treatment with TZDs resulted in
lowering of triglyceride levels but also influenced weight gain and redistribution
of body fat with an increase in subcutaneous depot (Guan & Breyer 2001). The
mechanisms which contribute to the pathogenic role of PPARy in obesity are not
known but leptin was proposed as one of the modulators as well as TNF-a and
uncoupling proteins (UCPs) (Guan & Breyer 2001). Nevertheless, these data
demonstrate that PPARy plays an important role in the pathogenesis of obesity.
In addition, PPARy is involved in glucose metabolism. TZD treatment in
patients with type 2 diabetes improves insulin resistance, hyperinsulinemia and
hyperglycemia. Furthermore, Barroso et al. reported heterozygous mutations in
the ligand-binding domain of PPARy in subjects with severe insulin resistance,
diabetes and hypertension thus providing genetic evidence for the role of this
receptor in glucose metabolism and blood pressure control in humans (Barroso
et al. 1999). Interestingly, this loss-of-funotion mutation was not associated with
obesity. Also, Ristow et al. showed that patients with gain-of-function mutation of
PPARy are severely obese but have low levels of insulin and increased sensitivity
to insulin (Ristow et al. 1998). These data suggest that excess PPARy activity
could contribute to obesity while reduced PPARy activity might elicit insulin
resistance. However, the study of animal models revealed that although PPARy
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is essential in regulating insulin sensitivity, the molecular mechanism is not well
understood (Guan & Breyer 2001).

1.4.2 PPARy and hypertension

PPARy is also involved in blood pressure regulation. However, there are
controversial data showing that PPARy activation can have hypertensive or
hypotensive effects. In a model with a generalized PPARy ablation, the mice
displayed severe lipodystrophy and insulin resistance and had surprisingly low
blood pressure (Duan et al. 2007) associated with increased vascular relaxation
and activation of the renin-angiotensin system. This is consistent with the recent
findings by Todorov et al. showing that PPARy agonist stimulates the renin gene
in Calu-6 cells in culture (Todorov et al. 2007) suggesting that in same cells
PPARy leads to activation of the renin-angiotensin II system with relevance to
blood pressure regulation. On the other hand, a study by Barroso et al. showed
that patients with a dominant-negative mutation in PPARy have extreme
hypertension, severe insulin resistance and diabetes (Barroso et al. 1999). This
serves as a proof of concept evidence for the role of this receptor in human
metabolism and suggests a beneficial role for PPARy activation in blood pressure
reduction. Consistent with these data, TZDs, have been shown to lower blood
pressure in hypertensive fatty Zucker rats (Yoshioka et al. 1993, Buckingham et
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al. 1998), obese diabetic rats (Yoshimoto et al. 1997), diet-induced hypertensive
rats (Buchanan et al. 1995, Kaufman et al. 1995, Uchida et al. 1997, Dobrian et
al. 2004), obese insulin-resistant mice (Verreth et al. 2004), obese insulinresistant humans (Nolan et al. 1994), and non-diabetic patients with arterial
hypertension (Fullert et al. 2002). The mechanism by which blood pressure falls
is not known, but in insulin-resistant animals, the blood pressure reduction may
be at least partly due to increased insulin sensitivity (Uchida et al. 1997,
Yoshimoto et al. 1997). Direct vascular effects of PPARy may also play a role as
PPARy is expressed in endothelium and vascular muscle cells (Marx etal. 1999,
Law et al. 2000). Furthermore, PPARy activation possibly modulates release of
endothelial vasoactive factors such as endothelin-1, prostacyclin, and nitric oxide
(Ruan etal. 2008) and in this way indirectly affects blood pressure regulation.
Recent data from Dobrian et al. support this by showing that treatment with TZDs
prevented hypertension in Spraque-Dawley rats on high fat diet, reduced
oxidative stress and increased renal formation of NO (Dobrian etal. 2004).
Potentially, PPARy may also directly reduce vascular tone by downregulating
angiotensin II receptor 1 or by attenuation of sympathetic overactivity (Ruan et al.
2008). In summary, most of the data identify hypotensive role of PPARy
activation which can be attributed to multiple mechanisms.
The propensity for TZDs to cause fluid retention and pulmonary and
peripheral edema has emerged as the most common, serious adverse drug
reaction associated with these compounds (Dobrian 2006). The causes of edema
and fluid retention with the use of TZDs are not known and are likely
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multifactorial. However, increased renal sodium retention probably plays a role.
This together with TZDs blood pressure lowering effect points to the direct role of
PPARy in regulating sodium and water reabsorption. Moreover, PPARy and RXR
have been found constitutively expressed in the inner medullary collecting ducts,
proximal tubules, distal tubules, thick ascending limb of the loop of the Henle,
glomerulus, and renal medullary microvascular endothelial cells in rats (Braissant
etal. 1996, Yang etal. 1999, Nicholas etal. 2001), rabbits and humans (Guan et
al. 1997, Guan & Breyer 2001) further suggesting their likely role in sodium and
water reabsorption. Yang et al. demonstrated that PPARy activation resulted in
fluid retention and increased levels of nitric oxide but did not affect GFR or renal
filtration fraction (RFF) in conscious rats indicating that the PPARy effect on
volume expansion was not related to changes in renal hemodynamics (Yang et
al. 2003). Furthermore, a study by Zanchi and coworkers provided evidence that
chronic treatment with a PPARy agonist had no effect on the systemic and renal
hemodynamic responses to salt in noninsulin-resistant, healthy, male volunteers.
However, it reduced urinary sodium excretion and lithium clearance, suggesting
increased sodium reabsorption at the proximal tubule and also significantly
increased plasma renin activity. Body weights increased with pioglitazone
treatment in most subjects (Zanchi etal. 2004). But not all data available support
the above mentioned studies. Song et al. reported that three-day treatment with
rosiglitazone produced reduction in creatinine clearance, an indirect measure of
glomerular filtration rate, and also a reduction in sodium excretion and at the
same time it lowered mean arterial pressure in normal Sprague-Dawley rats
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(Song et al. 2004). Those discrepancies could be most likely attributed to
different techniques used for GFR measurement or other experimental protocols.
Moreover, duration of the treatments could also play a role in the final outcome of
PPARy activation.
Nevertheless, besides effecting hemodynamic parameters of the kidney,
PPARy may directly act on sodium transporters leading to reduction in blood
pressure and/or fluid retention. Acute, 3 day treatment with rosiglitazone
increased whole kidney protein abundance of the a-1 subunit of Na,K-ATPase,
the bumetanide-sensitive Na-K-2CI cotransporter (NKCC2), NHE3, the
aquaporins 2 and 3, and endothelial nitric-oxide synthase (Song, J. et al. 2004)
implying that blood pressure reduction observed with PPARy agonists may occur
at the level of the proximal tubule and the thick ascending limb of the loop of
Henle. Further studies are needed to explain what mechanism leads to TZDs
blood pressure lowering effect and whether it involves direct modulation of the
sodium transporters.

1.5 Nitric Oxide

In the kidney, nitric oxide (NO) plays an important role in the control of
renal hemodynamics (Romero et al. 1992), mediation of pressure natriuresis
(Majid et al. 1993), blunting of tubuloglomerular feedback (Wilcox 1998),
inhibition of tubular sodium reabsorption (Ortiz & Garvin 2002), and modulation of
renal sympathetic nerve activity (Eppel et al. 2003). The net effect of NO in the

kidney is to promote natriuresis and diuresis (Lahera etal. 1991). Several
investigators have shown that chronic inhibition of NO production by NO
synthase inhibitors such as A^-monomethyl-L-arginine acetate or A^-nitro-Larginine methyl ester (L-NAME) produces arterial hypertension in animals (Arnal
etal. 1992, Ribeiro etal. 1992, Navarro etal. 1994, Fernandez-Rivas etal.
1995), a fall in glomerular filtration rate and an increase in filtration fraction
(Ribeiro et al. 1992). The decreased NO production is associated with
hypertension, ischemic heart disease, insulin resistance, and atherosclerotic
disease (Moss etal. 2004, Zavaroni etal. 2004). NO is formed during oxidation
of L-arginine to L-citrullin by the action of the enzyme NO synthase (NOS). There
are three NOS isoforms designated as constitutive neuronal NOS (nNOS, NOS
I), inducible NOS (iNOS, NOS II) and constitutive endothelial NOS (eNOS, NOS
III) (Stuehr 1999).
While expression of all three isoforms was reported in the kidney, the most
consistent documented sites of constitutive NOS expression in the kidney are the
macula densa for nNOS expression (Wilcox 1998) and the renal vasculature for
the expression of eNOS (Bachmann et al. 1995). It is controversial whether the
proximal tubule produces NO under basal conditions. However, the proximal
tubule constitutively expresses iNOS mRNA (Ahn et al. 1994). In addition to
iNOS, eNOS mRNA was also detected by RT-PCR in some of the rat proximal
tubule segments (Ujiie et al. 1994). NOS activity was detected in isolated rat
proximal tubules, primary cultures of rat or human proximal tubule cells, and
proximal tubule cell lines (McLay etal. 1994, Yu etal. 1994, Guzman etal.

1995). In contrast, no studies have shown the presence of NOS proteins in the
proximal tubule under basal conditions, which makes questionable whether the
proximal tubule is able to produce NO constitutively. However, recent study
provided evidence that in diabetic rats 3-5 wk after streptozotocin injection eNOS
and nNOS expression in proximal tubules increases (Baines & Ho 2002).
Moreover, Jarry et al. described the presence of nNOS in most tubules of the
human nephron including proximal tubule by several different approaches such
as immunohistochemistry, RT-PCR analysis, western blotting, and measurement
of NOS activity (Jarry et al. 2003). In addition, it was noted that epithelial cells
expressing nNOS also express soluble guanylyl cyclase, indicating that these
cells possess the machinery for an autocrine/paracrine effect of nitric oxide. Why
the earlier studies were not able to demonstrate the presence of NO protein in
proximal tubule using the same techniques is hard to explain. However, whether
or not there is a significant level of NOS protein expression in the normal kidney
under physiological conditions, evidence suggests that the proximal tubule is
constantly exposed to NO that might include NO from non-proximal tubule
sources such as the vasculature or other nephron segments (Amorena & Castro
1997, Unas & Repine 1999).

1.5.1 Functions of NO in the kidney

Synthesis of NO appears to play a substantial role in mediating pressureinduced diuretic and natriuretic responses in the kidney (Majid et al. 1993). In

anesthetized dogs intrarenal infusion of a NOS inhibitor blunted the diuretic and
natriuretic responses to the increases in renal perfusion pressure (RPP) without
altering renal blood flow (RBF) or GFR. This resulted in higher blood pressure
that was prevented by the infusion of the NO synthesis precursor L-arginine
(Salom etal. 1992). Furthermore, with the elevation of renal arterial pressure a
significant increase in urinary excretion of NO metabolites was observed and
there was a positive correlation between changes in NO metabolites excretion
rate and changes in RPP or urinary sodium excretion (UnaV) (Suzuki etal. 1992,
Majid et al. 1995) prompting the authors to suggest that during acute changes in
RPP, intrarenal changes in NO production rate may be responsible for the
changes in sodium excretion. Finally, changes in renal tissue NO activities were
assessed directly using an NO-selective microelectrode inserted into the cortical
tissue of anesthetized dogs and it was demonstrated that reductions of renal
arterial pressure lead to decreases in tissue NO activity, urinary nitrate/nitrite
excretion, and urinary sodium excretion (Majid etal. 1998). The mechanisms by
which RPP effects renal production of NO are not entirely known however the
shear stress is a likely candidate. Likewise, how increased NO in the kidney
promotes natriuresis and diuresis is not well understood but a direct effect on
tubular transport seems to play an important role. More recently, a study by Jin et
al. showed that renal interstitial cGMP, formed as a result of stimulation of
soluble guanylyl cyclase (sGC) activity by NO, induced natriuresis via protein
kinase G without changes in renal blood flow or GFR (Jin et al. 2001).
Furthermore, the same group demonstrated that pressure-natriuresis was

mediated by activation of the cGMP/PKG pathway in renal proximal tubule cells
(Jin et al. 2004). In addition, there is evidence that export of cGMP from its renal
synthesizing cells into the extracellular renal interstitial compartment was
necessary for NO-induced natriuresis. This effect was accompanied by no
change in GFR and an increase in fractional excretion of sodium and lithium
suggesting a major role for renal proximal tubule cells in this type of natriuresis
(Ahmed et al. 2007).
Many in vitro and in vivo studies have demonstrated that NO induces
natriuresis by directly inhibiting nephron transport especially at the level of
proximal tubule (Lahera et al. 1991, Jin et al. 2004, Ahmed et al. 2007). For
example, McKee observed that in the kidney NO through generation of cGMP
and stimulation of PKG inhibited Na,K-ATPase (McKee etal. 1994). Guzman et
al. have shown that in mouse proximal tubule epithelial cells Na,K-ATPase
activity decreased after NO production was induced by LPS/IFN gamma; this
inhibition of Na,K-ATPase activity was prevented by simultaneous incubation with
N omega-nitro L-arginine and markedly blunted by removal of L-arginine from the
medium. The NO donors sodium nitroprusside and SIN-1 also inhibited Na,KATPase activity to a similar extent as LPS/IFN gamma (Guzman et al. 1995).
Linas and Repine reported that NO produced by endothelial cells, caused a
decrease in sodium transport and inhibition of Na,K-ATPase as well as an
increase in cGMP levels in primary cultures of rat proximal tubule cells (Linas &
Repine 1999).

In addition to a decrease in Na,K-ATPase activity, several studies have
shown that NO decreases activity of NHE3. Roczniak et al. have shown that NO
stimulated soluble guanylyl cyclase in rabbit proximal tubule and caused
inhibition of Na+/H+ exchange which was at least partly mediated by the
generation of cGMP (Roczniak & Burns 1996). Furthermore, following chronic
treatment with L-NAME in Sprague-Dawley rats, the renal expression of NHE3 as
well as expression and activity of Na,K-ATPase were increased (Kim et al. 2006)
suggesting an inhibitory effect of NO on the transporters. As in previously cited
studies, L-NAME treatment also significantly increased blood pressure and
decreased fractional excretion of sodium with no effect on GFR. Finally, Coon et
al. reported that in rabbit intestinal villus cell brush border membrane inhibition of
constitutively expressed NOS with L-N(G)-nitroarginine methylester (L-NAME)
stimulated Na+/H+ exchange while a selective inhibitor of inducible NOS, did not
affect Na+/H+ exchange. These findings indicate that under physiological
conditions constitutive NO most likely maintains an inhibitory tone on NHE3
expression (Coon et al. 2007). Although there are also studies that indicate an
opposite effect for the NO (De Nicola et al. 1992) most of the data confirms that
in the proximal tubule NO inhibits activity of NHE3 and Na,K-ATPase (Roczniak
& Burns 1996, Stoos & Garvin 1997, Ortiz & Garvin 2002).
The other mechanism by which NO can regulate proximal tubule
reabsorption appears to involve modulation of the effects of the sympathetic
nervous system in the kidney. It has been reported that renal denervation
prevented a decrease in proximal tubule sodium reabsorption caused by NOS

inhibition (Gabbai et al. 1995) and at the same time NOS inhibition significantly
enhanced the vasoconstrictor responses to sympathetic nerve stimulation (Reid
& Rand 1992). However, Khraibi demonstrated that the natriuretic effect of NO
production inhibition in Okamoto spontaneously hypertensive rats was changed
by kidney denervation, while in Wistar-Kyoto rats it was independent of renal
innervation (Khraibi 1995) suggesting different effects depending on the animal
model used. Moreover, a study by Wu found that while NO has a direct inhibitory
effect on proximal tubular reabsorption of sodium its presence is also required for
the stimulatory effect of renal sympathetic nerves on proximal sodium transport
(Wu & Johns 2002).
Yet another mechanism by which NO can modulate proximal tubule
transport is its interaction with angiotensin II. Several studies suggested that NO
might be a direct modulator of ACE activity (Higashi et al. 1995, Takemoto ef al.
1997), may regulate angiotensin II receptors in vitro through a cGMPindependent mechanism (Cahill ef al. 1995), and an exogenous NO donor was
able to abolish the stimulatory effect of angiotensin II on proximal tubule transport
(Eitleefa/. 1998).
There is a general consensus that hypertension is associated with
impaired endothelium dependent vasodilation due to reduced NO signaling
(Schiffrin & Touyz 2004). Endothelial dysfunction may result from reduced
generation of NO due to diminished expression or activation of endothelial NO
synthase or an increase in oxidative stress that reduces bioavailability of NO
(Schiffrin & Touyz 2004). High levels of superoxide anions, which rapidly react

with NO to form highly toxic peroxynitrite anion is the mechanism leading to
reduced NO bioavailability (Beckman & Koppenol 1996). Dobrian etal. reported
that in obese hypertensive animals on high fat diet there was a reduction in
urinary NO metabolites while expression of eNOS and nNOS were increased in
the renal cortex and medulla of those animals (Dobrian etal. 2001, 2004)
implying that in obesity-induced hypertension NO bioavailability is reduced most
likely due to increased oxidative stress. Decreased renal cortical nitric oxide
production was observed in the kidney of obese Zucker rats (Erdely et al. 2004)
and a recent study in obese young humans showed a negative correlation
between BMI and NO metabolites and a positive correlation between arginine
and BMI suggesting increased NO production but reduced NO bioavailability
(Gruber et al. 2008).
However, another important mechanism which regulates the biological
activity of NO in the kidney is the sensitivity of NO signalling. For example, Ortiz
demonstrated that even though a high salt diet did not change NO production, it
increased sensitivity of the thick ascending limb to NO with regard to sodium
reabsorption (Ortiz et al. 2003).
In summary, obesity induced hypertension is extremely common in the
general population especially with the increase in number of overweight and
obese people. As in all other forms of hypertension, it is associated with the
impairment of pressure-natriuresis. However, the exact mechanisms leading to
fluid retention are not known but some suggest that direct change in tubular
reabsorption might be a cause. We propose that in obesity, activities of the
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sodium transporters at the proximal tubule level are increased leading to
increased sodium reabsorption. Therefore, we determined the responses of
obese and lean rats fed a high fat diet to changes in renal perfusion pressure and
analyzed the expression, activity and localization of the tubular transporters
NHE3 and Na,K-ATPase.
Moreover, as PPARy is a transcription factor involved in obesity and hypertension
we examined the role of PPARy activation in hypertension related to obesity with
regard to proximal tubule sodium transport, by chronically treating our obese and
lean rats with a PPARy agonist. To determine the direct involvement of PPARy
during the course of agonist treatment we studied modifications of NHE3 and
Na,K-ATPase expression in cultured proximal tubule cells.
As NO might play an important role in regulating pressure natriuresis in
the kidney and its availability seems to be altered in obese animals and humans,
we wanted to determine its role in hypertension induced by obesity by chronically
blocking its production in vivo. Moreover, since this molecule appears to affect
some other pathways in blood pressure regulation such as the renin-angiotensin
system, leptin, and insulin which are all activated in obesity, we further studied its
role on the sodium transporters in vitro.

SECTION 2
SPECIFIC AIMS

Specific Aim #1
Theoretical and experimental studies have shown that in all forms of
hypertension, including obesity hypertension, there is an abnormality of kidney
function characterized by a hypertensive shift in renal pressure natriuresis. When
obesity is induced by feeding a high fat diet, there is marked sodium retention
and expansion of extracellular fluid volume. Moreover, sodium retention and
altered pressure natriuresis appears to be caused mainly by increased tubular
sodium reabsorption.
Hypothesis: Development of hypertension in diet-induced obesity is due
to the increase in Na+ reabsorption by means of changes in activity of
sodium transporters at the level of the proximal tubule.
Aim 1: Determine mechanism of sodium handling in obese hypertensive (OP)
and lean normotensive (OR) rats on high fat diet.
Aim 1.A. Establish the renal hemodynamic parameters in OP, OR rats.
Aim 1.B. Determine the abundance, activity and localization of proximal tubule
sodium transporters-Na,K-ATPase and NHE3.
Experiments: In the first part of the study, Sprague-Dawley rats were put on the
high fat diet and systolic blood pressure (SBP) was measured by tail cuff method
at weeks 8 and 12 on the diet in obese and lean animals. Results were in

accordance to previous data to show that OP rats had high blood pressure while
OR rats were normotensive.
After 12 weeks on the diet, renal function was assessed in OP and OR
rats during surgical procedures in which animals were challenged with a change
in renal perfusion pressure. Experiments were designed to determine whether
there is a difference in sodium excretion between the groups and which nephron
segment is defective with regard to sodium reabsorption. At the end of the
experiment, fat content in obese and lean rats was measured while body weights
were recorded weekly for the duration of the study.
Next, protein expression of proximal sodium transporters- Na,K-ATPase
and NHE3 was examined by western blotting in basolateral membrane (BLM)
and brush border membrane vesicles (BBMV) preparation of kidney cortex,
respectively. In subsequent experiments activity of above transporters was
assessed in fresh BLM and BBMV fractions from obese and lean rats.
Immunohistochemistry was employed on paraffin-embedded, and formalin fixed
kidney cortexes from OP and OR rats to determine localization of NHE3 within
the villus membrane.

Specific Aim #2
Peroxisome Proliferator-Activated Receptor y (PPARy) modulates
transcription of genes involved both in obesity and hypertension (leptin,
angiotensin II). PPAR y is expressed both in the adipose tissue and kidney. Two
heterozygous mutations in the PPAR y ligand binding domain of the gene cause

severe insulin resistance and hypertension in humans. Treatment with PPAR y
ligands lowers blood pressure in both humans and rodent models.
Hypothesis: PPARy activation lowers blood pressure by altering activity of
sodium transporters Na,K-ATPase and NHE3 and thereby controlling
tubular Na+ reabsorption.
Aim 2.A. Investigate the effects of in vivo PPARy activation on blood pressure,
renal hemodynamics, and expression, localization and activity of proximal tubule
sodium transporters in obese and lean rats.
Aim 2.B. Determine whether PPARy ligands exert their action on sodium
transporters dependent or independent of PPARy using primary cultures of
human renal proximal tubule epithelial cells (RPTEC).
Experiments: In this aim OP and OR rats were treated with 0.1% (w/w)
pioglitazone (PPARy agonist) for 4 weeks from week 8 to week 12 during dietary
regimen. The effect of PPARy activation on the systolic blood pressure (SBP)
was determined. SBP was measured in obese and lean animals by the tail cuff
method as described in Aim #1, at week 8, before starting the treatments, and at
week 12, after treatment completion, on the day of the surgery. Body weights and
food intake were measured weekly. Before starting treatment and after its
completion, rats from all experimental groups were placed in metabolic cages for
24 hour urine collection and the assessment of water intake. Urine was analyzed
for Na+ content.
In the second part of the study, glomerular filtration rate, urinary sodium
excretion, fractional excretion of sodium and lithium were analyzed. Rats were
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anesthetized and catheters were implanted in the left carotid artery for the
measurement of mean arterial pressure and blood sampling, in the left jugular
vein for fluid infusions (saline solutions with inulin and lithium chloride), and in the
bladder for urine collection.
Separate groups of animals were used for the following part of the study
where we examined by western blotting protein expression of Na,K-ATPase and
NHE3 in baso-lateral membranes and brush border membrane vesicles,
respectively, isolated from renal cortexes. The same preparations were also used
for activity measurements of the above transporters.
Finally, we estimated the effect of pioglitazone treatment on NHE3
distribution in the renal proximal tubule in obese and lean rats as described in
Aim#1.
In vitro experiments were designed to demonstrate the effect of
pharmacological and molecular stimulation and inhibition of PPARy on Na,KATPase and NHE3 expression using primary culture of renal proximal tubule
epithelial cells (RPTEC). At first, cells were incubated with PPARy agonists and
antagonists for 4 hours and expression of sodium transporters were measured by
western blotting. Those experiments confirmed that PPARy stimulation
decreases and inhibition increases protein abundance of Na,K-ATPase and
NHE3.
Afterwards, using the nucleofection technique RPTEC were transiently
transfected with full length human PPARy to overexpress PPARy or with small
interfering RNA technique to silence the latter, followed by 12 hours of

pioglitazone treatment. Altogether, in vitro experiments suggested that
pioglitazone effect on Na+ transporters requires activation of PPARy.

Specific Aim #3
NO stimulates soluble guanylyl cyclase in rabbit proximal tubule and
causes inhibition of activity of Na,K-ATPase and Na+/H+ exchange which is at
least partly mediated by generation of cGMP. In carotid arteries of obese rats
levels of cGMP are enhanced. Previous studies demonstrate that feeding rats
and dogs with moderately high fat diet results in higher levels of renin activity in
obese animals compared with lean animals, higher levels of leptin in animals as
well as obese humans and that those changes are paralleled by changes in
insulin levels.
Hypothesis: The tonic inhibition on sodium transporters in the absence of
NO is achieved in obesity by increased levels of Angiotensin II, Insulin or
Leptin. These hormones act to maintain low activity of sodium transporters
in obesity via an increase in cGMP production.
Aim 3.A. To investigate the effects of chronic in vivo inhibition of nitric oxide (NO)
production on blood pressure, renal hemodynamics, and expression, localization
and activity of proximal tubule sodium transporters in obese and lean rats.
Aim 3.B. To determine whether angiotensin II, insulin, or leptin modulate the
expression of Na,K-ATPase and NHE3 in RPTEC in vitro by utilizing cGMP as a
messenger.

Experiments: Sprague-Dawley rats were put on the high fat diet for 12 weeks and
treated with nitric oxide synthase inhibitor-L-NAME (NG-nitro-L-arginine methyl
ester) between weeks 8-12. Rats were placed in metabolic cages before and
after the treatment for 24-hour urine collection and the assessment of water
intake.
After 12 weeks on the diet, renal function was assessed in OP and OR
rats treated or not with L-NAME, during acute manipulation of renal perfusion
pressure. Rats were anesthetized and catheters were placed in the trachea,
jugular vein and in the left carotid artery for mean arterial pressure (MAP)
measurement. A catheter was also implanted in the left femoral artery and in the
bladder. MAP was measured and recorded continuously during the procedure.
Blood and urine were analyzed for electrolytes, lithium, and inulin. As a result we
obtained pressure-natriuresis and diuresis curves for obese and lean animals
with or without chronic NO inhibition. Body weights were recorded weekly for the
duration of the study while fat content was measured at the conclusion of the
procedure.
Protein expression and activity of Na,K-ATPase and NHE3 in obese and
lean rats with or without L-NAME treatment were analyzed as described in Aim
#1.
Also, immunohistochemistry was employed to provide information on
effect of L-NAME on NHE3 distribution as described previously in Aim #1.
In vitro experiments were performed using primary cultures of human
renal proximal tubule epithelial cells (RPTEC). At first, ability of cells to produce

intra- and extracellular cGMP in response to various NO donor concentrations at
different time points was assessed. It was followed by the measurements of the
effect of ODQ (inhibitor of soluble guanylyl cyclase) and probenecid (an organic
anion transporter). Those experiments proved that RPTEC are capable of
producing cGMP in response to an NO donor in a concentration-dependent
manner.
Next, we evaluated the capability of angiotensin II (All), insulin and leptin,
to affect production of cGMP in the presence or absence of NO donor s-nitroacetylpenicillamine (SNAP) and have chosen concentrations of hormones which
significantly increased cGMP in the presence of SNAP in RPTEC for further
study.
Finally, we measured protein expression of Na,K-ATPase and NHE3 by
western blotting in membrane fractions of RPTEC stimulated with All, insulin or
leptin together with SNAP for 6, 12 and 24 hours. Since these data were not
conclusive, phosphorylation levels of Ser16 and 552 for Na,K-ATPase and
NHE3, respectively were assessed in membrane fractions of RPTEC treated with
All/insulin and an NO donor. From this study we concluded that there is
interaction between NO and insulin which influence phosphorylation of Na,KATPase and NHE3, probably leading to changes in activity of both transporters.
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SECTION 3
STUDIES FOR SPECIFIC AIM #1

3.1 Materials and Methods for Specific Aim #1

Animals
All procedures involving animals were approved by the Institutional Animal
Care and Use Committee of Eastern Virginia Medical School. Male 3-month old
Sprague-Dawley rats (Charles River, Wilmington, MA), weighting -300 g were
housed individually in a humidity- and temperature-controlled room with a 12 hr
dark-light cycle and allowed ad libitum access to water and food throughout the
experiment. Rats were fed either a moderately high fat diet (MHF; ~ 32% kcal as
fat; Research Diets, New Brunswick, NJ) or low fat (~11.8% kcal as fat) calorie
matched control diet (controls) for 8 weeks. Between weeks 6 and 7 they were
assigned, based on the difference in the body weight (BW) gains to an obesityprone (OP) and an obesity-resistant (OR) group as described previously (Dobrian
et al. 2001) (Fig. 3). All the OP rats had body weights higher that the heaviest
control rat and all the OR rats had body weights equal or lower than the heaviest
control. The control animals were not used later in any of the experimental
protocols. Separate groups, fed and treated exactly the same way, were used for
physiological measurements and for preparation of membrane fractions, brush
border membrane vesicles, and any subsequent experiments involving those
preparations.
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Sprague-Dawley male rats, ~3 month old (-300 g)
fed for 8-12 weeks with:

Moderately high fat diet (MHF)
32.4 kcal% fat; 29% sucrose, 0.8% NaCI
OBESITY-RESISTANT

Normotension

OBESITY- PRONE

Hypertension

Weight gain

Figure 3 Rat model of diet-induced obesity and hypertension.
Male, 3 months old Sprague-Dawley rats were put on moderately high fat diet
and stayed on this diet for 12-16 weeks. They diverged into two statistically
different populations according to their body weights and were assigned to
obesity-resistant (OR) and obesity-prone (OP) groups between weeks 6th and 7th.
After being on the diet for 8-10 weeks OR rats were normotensive while OP rats
developed high blood pressure.
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Surgical procedure for acute pressure natriuresis experiments
The surgical procedure was performed as previously described (Khraibi
2000). On the day of the acute experiment, rats were anesthetized with Inactin
(100 mg kg"1), and catheters were placed in the trachea (PE-240) and left jugular
vein (PE-50) for intravenous infusion of 0.75 ml per 100 g body wf 1 h"1 of saline
with 6 mM lithium chloride (LiCI) and 0.75 ml per 100 g body wt"1 h"1 of a solution
of 3% inulin and 6.25% bovine albumin in saline (which also contained 6 mM
LiCI). A PE-50 catheter was implanted in the left carotid artery for mean arterial
pressure (MAP) measurement and blood withdrawal. A PE-50 catheter was
implanted in the left femoral artery for the measurement of renal perfusion
pressure (RPP). A PE-90 catheter with a flared tip was placed in the bladder for
urine collection. An adjustable clamp was placed around the abdominal aorta
above both renal arteries and was used to control RPP. The rats were allowed
1 h to recover after completion of the surgical procedures. Then RPP was
controlled at a lower level (-100 mmHg) by tightening the clamp around the aorta
and reducing renal perfusion pressure. After 10 minutes a clearance period of
30 min was started; MAP was measured and recorded continuously. At the end of
this period, - 1 ml of blood was withdrawn from the left carotid artery for plasma
electrolytes, lithium, and inulin measurements. Urine was collected for 30 min. At
the conclusion of the clearance period the aortic clamp was loosened to allow
renal perfusion pressure to increase and then tightened again at the higher level
(-140 mmHg). After 10 minutes the second clearance period started during
which MAP was measured and recorded continuously. And again at the end of

this period, ~1 ml of blood was withdrawn from the left carotid artery for plasma
electrolytes, lithium, and inulin measurements. Urine was collected continuously
for 30 min. All rats were killed by an Inactin overdose (50 mg; 0.5 ml of a solution
of 100 mg ml"1 of Inactin in saline) at the end of the experiment while still under
deep anesthesia.
To avoid any manipulation of the kidneys, different groups of animals
were used for basolateral membrane and brush border membrane vesicle
fractions. At the completion of the diet protocol the rats were anesthetized with
Inactin (100 mg kg"1), kidneys were removed without any further handling,
epididymal and perirenal fat were removed and frozen in liquid nitrogen, and
finally rats were killed by an Inactin overdose as mentioned above.

Physiological parameters
Systolic blood pressure was assessed by tail-cuff method using Visitech
Blood Pressure Analysis System (BP-2000-R; Visitech Systems, Apex, NC) on
previously trained, conscious animals from groups used for physiological
measurements. The average of 3-5 readings was recorded for each animal.
Glomerular filtration rate (GFR) was calculated from the clearance of inulin, and
inulin concentrations was measured by the anthrone method (Khraibi etal. 1989,
Khraibi & Knox 1989). Lithium concentrations in plasma and urine were
measured using flame photometry (model 943, Instrumentation Laboratory,
Lexington, MA), phosphate by the method of Chen (Chen & Jorgensen 1956) and
sodium concentration in plasma and urine were measured using EasyLyte Na/K

analyzer( Medica, Bedfrod, MA). Fractional excretions of sodium and, lithium
were calculated as the ratio between their urinary excretion and the glomerular
filtration rate. Urinary sodium excretion was expressed as the rate of sodium
excretion per urine volume.

Baso-lateral membrane (BLM) and brush border membrane vesicle
(BBMV) preparations
The kidneys were rapidly isolated after the last Inactin injection and
placed on ice in the appropriate homogenizing buffers. Their capsules were
removed; cortexes dissected out and then cut out into small pieces. One kidney
was processed for baso-lateral membrane (BLM) preparation and the other for
brush border membrane vesicles (BBMV) preparation.
For BLM preparation modified protocol from V. Scalera (Scalera etal.
1980) was used. Pieces of cortex were placed into 15 ml of the homogenizing
buffer (sucrose buffer) which contained 10 mM Tris-HCI, 0.25 M sucrose, and
0.5 M phenylmethanesulphonyl fluoride (PMSF) at pH 7.6 and homogenized on
ice with Polytron homogenizer at 20 000 rpm for 60-90 seconds. The crude
homogenate was centrifuged at 3 000 g for 15 minutes to remove whole cells,
and nuclei. The supernatant was then centrifuged at 30 000 gfor 30 minutes
and the fluffy, upper layer of the pellet was resuspended again in sucrose
buffer, homogenized with Teflon glass homogenizer for 20 strokes and
centrifuged at 30 000 g for 30 minutes. The pellet was resuspended in buffer
that had 5 mM HEPES, 100 mM KCL, and 100 mM mannitol final concentration

at pH 7.2 (mannitol buffer) and centnfuged at 30 000 g for 30 minutes. The final
pellet was dissolved in a small volume of mannitol buffer and the protein
concentration for each lysate was determined on this freshly prepared sample
by using a BCA protein assay kit (Pierce Chemical) with BSA as a standard. On
the same day part of the lysate was used for Na,K-ATPase activity
measurements and the rest was frozen at -80 °C for future western blotting.
For brush border membrane vesicles (BBMV) preparation protocol from
J. Biber was used based on a different reactivity of the brush-border membrane
compared to other cellular membranes with divalent cations, such as Mg2+
(Biber et al. 2007). Pieces of cortex were homogenized in the buffer which
contained 12 mM Tris base, 5 mM EGTA, 300 mM D-mannitol, and 0.1 mM
PMSF pH 7.1 (buffer A) using a Polytron homogenizer (~20 000 rpm) for 90 sec,
on ice. Ice-cold water was then added to this crude homogenate and mixed
with it, followed by addition of magnesium chloride (MgCb) and subsequent
incubation on ice for 15 min. Then homogenate was centrifuged at 3 000 g for
15 min and supernatant transferred to a new tube and centrifuged at 30 000 g
for 30 minutes at 4 °C. The resulting pellet was resuspended in 1 ml of buffer
containing 6 mM Tris base, 2.5 mM EGTA and 150 mM D-mannitol pH 7.1
(buffer B, which was prepared by diluting buffer A 1:1 with distilled water) by
using a 27-gauge needle attached to a 1cc syringe. Then buffer B was added to
final volume of 35 ml followed by addition of MgCI2 and subsequent incubation
on ice for 15 minutes. Next, the homogenate was centrifuged at

3 000 g for 15 minutes and the supernatant transferred into a clean tube and
spun at 30 000 g for 30 minutes at 4 °C. The resulting pellet was resuspended
in 1 ml of buffer B by using a 27-gauge needle attached to a 1cc syringe
aspirating 5-7 times and buffer B was added to a final volume of 35 ml. The
suspension was centrifuged for 30 minutes at 30 000 g and pellet consisting of
brush border membrane vesicles was resuspended in 1 ml of buffer B. Protein
for each lysate was determined in freshly prepared samples by using a BCA
protein assay kit (Pierce Chemical) with BSA as a standard. NHE3 activity
measurements were performed in the same day and the remainder of the
lysate was frozen at -80 °C and used for western blotting.

Western Blotting on BLM and BBMV fractions
Na,K-ATPase and NHE3 protein expression were assessed in BLM and
BBMV, respectively. The samples were diluted with a 1/5 vol of Laemmli buffer
(62.5 mmol/L Tris-HCI, pH 6.8, 2% [wt/vol] SDS, 5% R-mercaptoethanol, 10%
[vol/vol] glycerol, and 0.001% bromophenol blue) and equal amounts of
proteins (10-20 |ug per lane) were subjected to SDS-polyacrylamide (7.5%) gel
electrophoresis and blotted onto PVDF membranes. The membranes were
treated with Odyssey Blocking solution diluted 1:1 with phosphate-buffered
saline (PBS) to block nonspecific binding sites, for 1 hour RT, and incubated
with either monoclonal anti-NHE3 antibody (1:500 dilution, Novus Biologicals,
Littleton, CO), monoclonal anti-Na,K-ATPase antibody (Upstate , Lake Placid,
NY,1:10 000 dilution), or monoclonal Villin (1:1 000 dilution, Sigma-Aldrich,

Saint Louis, MO ) overnight. Villin served as loading control for NHE3, loading
of Na,K-ATPase was assessed by Ponceau red staining. Antigen detection was
performed using appropriate secondary antibodies conjugated to fluorescent
tag (IRDye 680 and IRDye 800) at 1:15 000 dilution for 45 minutes at RT.
Membranes were scanned using the Odyssey Infrared Imaging System (Li-Cor
Biosciences, Lincoln, NE). Semi-quantitative analyses of the specific bands
were performed using Li-Cor Odyssey software. Results were expressed as
relative fluorescence units (RFU).

Activity of Na.K-ATPase in BLM fractions from renal cortex
Na,K-ATPase activity was assayed by measuring the amount of
inorganic phosphate (Pj) liberated from ATP during incubation with the fresh
membrane fraction of renal cortex at 37 °C in the assay buffer. The assay
buffer contained 120 mM NaCI, 20 mM KCI, 6.0 mM EGTA Na2, 7.5 mM MgCI2,
50 mM imidazole-HCI, 30 mM Tris-HCI (pH 7.5) and 50 \i\ of tissue fraction.
Reaction was started with addition of 4 mM of Na2ATP (Sigma-Aldrich, Saint
Louis, MO), carried out for 15 minutes at 37 °C, and after that stopped by
putting samples on ice and completed by adding 35 \i\ of ice-cold 72%
trichloroacetic acid (TCA) solution (TCA, Sigma-Aldrich, Saint Louis, MO). Then
samples were centrifuged at 5 800 g for 5 minutes and the supernatant used
for further assay. To determine ouabain insensitive Na.K-ATPase activity, the
same mixture as above was incubated with 5 mM ouabain (Sigma-Aldrich,
Saint Louis, MO) dissolved directly into assay buffer, and final Na.K-ATPase

activity was calculated as the difference between the activities assayed in the
absence of ouabain (total activity) and in the presence of 5 mM ouabain. Pj
concentration was measured by the method of Chen (Chen et al. 1956). To 200
|jj of the sample diluted 1:10 1.6 ml of working reagent was added and
incubated for 90 minutes at 37 °C. Working reagent was prepared fresh daily by
addition of 5 ml of 8 N H 2 S0 4 , 5 ml of 2.5% ammonium molybdate and 5 ml of
10% ascorbic acid added to 35 ml of water. After incubation absorbance was
read at 820 nm. To correct for spontaneous ATP breakdown, the absorbance of
the blank sample prepared as described above but with water instead of
supernatant from the membrane fraction was read and subtracted from the
absorbance of the test sample. The activity was expressed as mmol of Pj
hydrolyzed by 1mg of protein during 1 minute of incubation time (mmol min"1
mg "1 of protein). Each sample was assayed in duplicate.

Measurement of NHE3 activity in BBMV from renal cortex
BBMV were labeled with cell-permeable AM ester of the polar fluorescein
derivative BCECF (Molecular Probes Inc., Eugene, OR) by incubation in a
solution of BCECF-AM for 30 min in a buffer without Na+ at pH 7.2. A sample
containing 200 |j,g of protein was used for each measurement. The labeled
sample was mixed with a buffer containing 150 mM NaCI, pH 9.2, using a stopflow kinetic device (KinTek SF 2001, KinTek Corporation, Austin, TX); the
change in pH response to a sodium load was recorded every 0.6 seconds for 1
minute for each preparation. To normalize for the potential differences in sample

protein the unlabeled samples were also measured in the same conditions and
the readings were subtracted from the labeled samples. Dual-excitation ratio of
440/490 nm was used to transform the changes in fluorescence into changes in
intracellular pH, according to the Henderson-Hasselbalch equation. The pKa of
the indicator was determined by measuring the changes in fluorescence in
response to different values of extracellular pH. That was done by mixing the
labeled sample with buffers of known pH preincubated with nigericin (SigmaAldrich, Saint Louis, MO) - K+/H+ ionophore, which causes equilibration of
intracellular and extracellular pH in the presence of a depolarizing concentration
of extracellular K+. The activity of NHE3 was calculated from the power of the first
exponential curve and expressed as a rate of intracellular pH recovery vs. time in
response to an extracellular sodium load. The specificity of the reaction for NHE3
was tested in several arbitrary samples in which 100 |aM of 5-(N-Ethyl-Nisopropyl) amiloride (Sigma-Aldrich, Saint Louis, MO) was added to the
membrane preparation 15 minutes before the beginning of the fluorescence
recordings. At this concentration, the amiloride derivative is expected to inhibit
virtually all NHE1 and NHE2 activity, with only minimal inhibition (-10%) of NHE3
activity.

Immunohistochemistry
Formalin-fixed, paraffin-embedded kidney sections (4 urn) were
incubated at 55 °C for 1hr, deparaffinized, rinsed in water and processed for
antigen retrieval with Dako Target Retrieval Solution (Dako Corporation,

Carpinteria, CA) for a total of 15 minutes. Then sections were blocked with 5%
normal goat serum and 1% BSA in PBS for 1 hr at room temperature and
simultaneously labeled with polyclonal NHE3 antibody (Catalog number
AB3085, Lot: 23101099; Chemicon International, 1:200 dilution) and
monoclonal Villin antibody (Catalog number 0258, Lot: 17; Immunotech,
Chicago, IL; 1:50 dilution ) in blocking solution , overnight, at 4 °C.
Subsequently, sections were incubated with a mix of fluorophore-conjugated
secondary antibodies-Alexa Fluor488 goat anti-rabbit for NHE3, 1:500 dilution;
AlexaFluor594 goat anti-mouse for villin, 1:500 dilution (Molecular Probes, Inc.,
Eugene, OR) - for 45 min, at room temperature, followed by 1% Sudan black to
block tissue autofluorescence. After final washes and mounting with
VectaShield (VectaShield Mounting Medium, Vector Labs, Burlingame, CA)
images were visualized and recorded by confocal fluorescence microscopy
using a Zeiss LSM 510 laser scanning microscope (Carl Zeiss Microscopy,
Germany). Some sections in which the primary antibodies were omitted were
used as negative controls. Each tissue section was excited with two lasers,
Argon (488 nm), and HeNel (543 nm) and scanned pixel by pixel using frame
mode with line averaging. Emission signals were collected by using the 505550 nm band pass and 560 nm long pass filters and quantified using a
photomultiplier tube and the LSM5 software. The composite image consisted of
green staining for NHE3, red staining for villin, and yellow staining for
colocalization of the two. For each slide 6-10 z-stacks were taken from different
areas of the tissue. Each z-stack contained from 12 to 20 XY images recorded

at intervals of 1 arbitrary unit apart with a zoom of 2X on a 40X oil immersion
objective. Image analysis was performed using MetaMorph software vs.6.3
(Molecular Devices, Downingtown, PA).

Image analysis and data collection
Metamorph software separated each composite image into two images,
one for each laser. Regions of interest were drawn around tubules which were
round in shape and had an opened lumen. For each image a manual threshold
was set to subtract background from true signal. The green fluorescent signal
(NHE3 staining) as well as the overlapping of the green (NHE3) over the red
(villin) fluorescent signals on each plane of the Z-stack were used in the final
computation. A number of 12-20 planes were analyzed for each individual
tubule. Colocalization was expressed as the percentage of the sum of green
fluorescence overlapping the red fluorescence to the sum of green
fluorescence only, in all the planes selected from an individual z-stack and was
recorded using an Excel spreadsheet. Six to ten tubules were analyzed for
each animal, 3-4 animals were analyzed for each experimental group, and the
final percentage for each group was expressed as mean ± SD.

Statistical analysis
Results are presented as mean ± standard error of mean (SEM) or
standard deviation (SD), as indicated for each experiment unless stated
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otherwise. Statistical analysis was performed using Student's t test for paired
and unpaired data. The null hypothesis was rejected for a p-value<0.05.
3.2 Results for Specific Aim #1

Body Weights, Fat content and Systolic Blood Pressure
When fed moderately high fat diet (MHF) normal male Sprague-Dawley
(SD) rats spontaneously diverge into two groups: obesity-prone (OP) and
obesity-resistant (OR) as previously described (Dobrian et al. 2001).
Retrospectively, in our study SD rats segregated into distinct populations of
obese and lean rats after being fed with MHF for 4 weeks and attained a
significance in their body weights starting at week 6 (Fig. 4a). This difference was
maintained until the end of the experiment at week 12. OP group was on average
12% heavier than OR group at week 6 and continuously obese animals were
weighting more than lean until week 12 when OP rats weighted on average 22%
more than OR rats ( 737.8 ± 15.4 g vs. 604.9 ± 14.8 g).
Those differences were paralleled by higher content of epididymal fat in
OP rats compared to OR rats, 22.93 + 1.33 g vs. 15.8 ± 1.64 g (p<0.01) but not
reflected by differences in perirenal fat pads, 27.98 ± 4.49 g vs. 16.65 ± 2.03 g
where it failed by a small margin to attain significant difference (p=0.06) (Fig. 4b).
This could be explained by the small number of animals in the groups at the time
of the surgeries (n = 4). Overall, total fat (sum of perirenal and epididymal fat)
content was 56.85% higher in obese rats compare to lean rats, 50.90 ± 5.32 g vs.
32.45 ± 3.43 g (Fig. 4b) and statistically significant.
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Figure 4 Representative graphs illustrating the typical body weights and fat
content in OP and OR rats.
Panel (a): Body weights and food intake (not shown) were measured weekly.
Starting at week 6 BWs between OP and OR groups were significantly different.
Panel (b): Weights of perirenal and epididymal fat pads were measured at the
completion of the experiments. Results are means ± SEM of n=4-5 rats/ group.
Significance was determined using unpaired Student's t-test and the null
hypothesis was rejected for a p-value< 0.05. *= significant compared to lean
counterparts.

In this study we measured systolic blood pressure (SBP) by the tail-cuff
method on previously trained rats at week 8 and week 12 of the diet. At week 8
SBP was significantly higher in obese animals than in lean (153.7 ± 3.2 mmHg
vs. 142.4 ± 2.6 mmHg) and remained higher at the completion of the study at
week 12 (158.9 ± 3.5 mmHg vs. 143.5 ± 4.2 mmHg) (Fig. 5).

Acute pressure natriuresis and diuresis in OP and OR rats
As previously described by our lab, an increase in SBP in obese animals
compared to lean rats is not reflected in 24 hour sodium excretion (Dobrian et al.
2001). 24 hour sodium excretion was not significantly different between OP and
OR groups in that study, suggesting that after 16 weeks on the diet both groups
reached steady state. However, in this study we aimed to determine differences
in pressure natriuresis and diuresis in OP and OR rats when they were
challenged with acute changes in renal perfusion pressure (RPP). Between low
(101.25-102.75 mmHg) and high (134.0-135.63 mmHg) renal perfusion
pressures (RPPs) urine flow rate in OP rats failed to achieved statistical
significance (18.75 ± 2.81JJ.I min"1 vs. 46.25 ± 16.79 |J min"1), but in the OR group
an increase in RPP was accompanied by an increase in urine flow rate (V) from
14.75 ± 1.75 \i\ min"1 to 53.25 ± 15.67 ^l min "1 (Fig. 6a). This indicates blunted
diuresis in obese rats compared to their lean counterparts. Urinary sodium
excretion (UNaV) between low and high RPP were not different in the obese
group (from 1.18 ± 0.59 (xEQ min"1 to 7.01 ± 4.87 |aEQ min"1) but once more
gained statistical significance in the lean group (from 1.03 ± 0.72
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Figure 5 Systolic blood pressures in lean and obese Sprague-Dawley rats.
SBP was assessed in previously trained rats by tail cuff method at week 8th and
12th of the diet, right before completion of the study. Obese rats had significantly
increased blood pressures compared to lean. Values are means ± SEM of n=6
rats/group with 3-5 readings for each animal. Significance was determined using
unpaired Student's t-test and the null hypothesis was rejected for a p-value<
0.05. *= significant compared to lean rats.
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9.97 ± 3.63 nEQ min"1, p-value=0.05) (Fig. 6b). The same response was
achieved when fractional excretion of sodium (FENa) was calculated: in OP rats
there was no significant change in FENa between low and high RPP (from 0.13 ±
0.05% to 0.79 ± 0.57%). However, there was an increase in FENa in OR rats
from 0.20 ± 0.14% to 1.34 ± 0.39% (Fig. 6c). The magnitude of change for UNaV
and FENa amid low and high RPP were not significantly different in obese and
lean rats. These results show that obese animals do not respond to the increase
in pressure the same way lean animals do, suggesting that their pressure
natriuresis and diuresis is altered compare to lean counterparts. However,
despite those differences in UnaV and FENa among the groups glomerular
filtration rate (GFR) remained the same: in OP rats: 5.66 ± 0.65 ml min"1 at low
RPP and 5.6 ± 0.7 ml min"1 at high RPP; in OR rats: 3.95 ± 0.66 ml min"1 at low
RPP and 4.9 ± 0.64 ml min"1 at high RPP (Fig. 6d) suggesting that autoregulatory
capability of kidneys were preserved.
Finally, fractional excretion of lithium (FELi) was determined and used as
an index of reabsorption in the proximal tubule. In the OP group a change in RPP
from 101.2 ± 0.63 mmHg to 134.2 ± 2.58 mmHg caused a change in FELi from
5.61 ± 1.74% to 13.89 ± 3.09% which failed by a small margin to attain statistical
significance (p-value=0.058) (Fig. 7). However, in the OR group an increase in
RPP from 102.7 ±1.1 mmHg to 135.6 ± 1.38 mmHg caused a significant
increase in FELi from 8.74 ± 4.09% to 19.77 ± 1.37% (Fig. 7). This result
suggests that OP's attenuated pressure natriuresis is most likely associated with
a defect at the proximal tubule level.
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Figure 6 Acute pressure natriuresis and diuresis in obese (OP) and lean (OR)
rats.
During surgical procedure an adjustable clamp was placed around aorta above
renal arteries to control renal perfusion pressure (RPP). At first RPP was set
~100 mmHg and urine collected for 30 min. At the end of this period blood was
drawn from carotid artery for plasma electrolytes, lithium and inulin
measurements. Then RPP was set ~140 mmHg and all above procedures were
repeated. Panel (a): Effect of RPP on urine flow in OP and OR rats. At high RPP
lean rats had an increase in urine flow rate, obese animals had impaired diuresis.
Panel (b): Renal perfusion pressure effect on urinary sodium excretion (UNaV) in
obese and lean animals. Increasing RPP caused a significant increase in sodium
excretion rate in OR group but not in OP. Panel (c): Fractional excretion of
sodium (FENa) at low and high RPP in OP and OR groups. While lean rats had
significantly higher FENa at higher RPP obese rats demonstrated no change
manifesting impaired natriuresis. Panel (d): Relations between renal perfusion
pressure and glomerular filtration rate (GFR), calculated as the rate of inulin
clearance, in OP and OR rats. Both groups showed well preserved
autoregulatory kidney function. Results are expressed as means ± SEM of n = 45 rats/ group. Significance was determined using paired or unpaired Student's ttest and the null hypothesis was rejected for a p-value< 0.05. *= significant
compared to low RPP in the same group of animals.
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Figure 7 Fractional excretion of lithium (FELi) at low and high RPP in obese and
lean Sprague-Dawley rats.
During surgical intervention rats were infused with lithium and after the
experiment lithium concentrations in urine and plasma were assessed. FELi was
calculated as the ratio between its urinary excretion and the amount filtered at
low and high RPP and it was used as a marker for the proximal tubule function.
High RPP significantly increased excretion of lithium in OR group but not in OP
rats. Results are expressed as means ± SEM of n = 4-5 rats/ group. Significance
was determined using paired Student's t-test for data within the group or
unpaired t-test was used for group comparison. The null hypothesis was rejected
for a p-value< 0.05. *= significant compared to low RPP in the same group of
animals.
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Expression, activity and localization of proximal tubule transporters: NHE3
and Na.K-ATPase
In a separate and similar experiment using different groups of rats we
measured protein expression, activity and localization of quantitatively the most
important transporter on the apical side of proximal tubule -the Na/H exchanger
type 3 and on basolateral side, the Na.K-ATPase.
The protein expression of Na.K-ATPase assessed by western blotting in a
membrane fraction enriched in baso-lateral membrane (BLM) was significantly
higher in obese rats when compared to lean rats 54.39 ± 3.25 RFU vs. 30.69 ±
0.69 RFU, respectively (Fig. 8a and 8b). The membranes were stained with
Ponceau Red to insure equal loading of the gel. Na.K-ATPase activity measured
as a release of inorganic phosphate in the fresh preparations of BLM was not
different between the groups (0.27 ± 0.04 mmolPj mg"1 min"1 vs. 0.37 ± 0.04
mmol Pi mg"1 min"1) (Fig. 9). This latter result could most probably be explained
by impurity of the preparations and contaminations with other membranes; as
well as the fact that in this ouabain-sensitive ATPase fractions the inhibition by
ouabain was 30% and 37% for OP and OR groups respectively (data not shown).
Again this suggests that our preparations were impure and contained other
pumps insensitive to ouabain like H+,K+-ATPase from proximal tubule or cortical
segment of collecting tubules. In addition, although Na.K-ATPase is an
oligomeric protein, we measured expression levels of the a-subunit only, which
may not directly correlate with the activity of the pump.
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Figure 8 Na,K-ATPase protein expression in fractions of baso-lateral
membranes (BLM) from OP and OR rats kidneys.
For this set of experiments different groups of animals were used to avoid any
manipulations of kidney before harvesting. Those animals were kept at the same
conditions, fed the same diet for the same amount of time as animals used for
physiological measurements. Panel (a): Graph representation of Na,K-ATPase
abundance, measured in arbitrary units, represented as means ± SEM of n = 6
rats/group. Blots were probed with Na,K-ATPase oc1-subunit specific antibody.
Semi-quantitative densitometry analyses were done by using Odyssey Infrared
Imaging System software. Significance was determined using unpaired Student's
t-test and the null hypothesis was rejected for a p-value< 0.05. *= significant
compared to lean rats. Panel (b): Immunoblots of BLM samples from OP and OR
rats. Each lane represents a sample from an individual rat. Equal protein loading
was ensured by staining each membrane with Ponceau red.
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Figure 9 Na,K-ATPase activity in fractions of baso-lateral membranes (BLM)
from OP and OR rats kidneys.
Na,K-ATPase activity was expressed as a mmol of inorganic phosphate (Pi)
liberated per mg of protein per minute and performed on freshly prepared basolateral membrane (BLM) fractions. It was calculated as the difference between
activities assayed in the absence of ouabain (total) activity and in the presence of
5 mM ouabain. Values are means ± SEM from 6 rats per group. Each sample
was assayed in duplicate and background was subtracted from the mean. There
was no significant difference between the groups. Significance was determined
using unpaired Student's t-test and the null hypothesis was rejected for a pvalue< 0.05. *= significant compared to lean rats.

The protein expression of NHE3, the other transporter of interest was
measured in brush border membrane vesicles (BBMV). Villin was used as a
loading control. NHE3 expression was significantly higher in obese compared to
lean rats (0.56 ± 0.04 RFU vs. 0.35 ± 0.06 RFU) (Fig. 10a and 10b). This was
paralleled by higher activity of this transporter in OP animals then in OR rats
(0.414 ± 0.06 ApH At"1 vs. 0.306 ± 0.09 ApH At"1) measured in fresh BBMV
fractions as the rate of pH recovery in response to an external sodium load (Fig.
11). Randomly chosen samples were incubated with 100 (iM 5-(N-ethyl-Nisopropyl) amiloride (EIPA) to insure that activity measured was of NHE3 since
NHE1 isoform is 100 times more sensitive to inhibition by EIPA than NHE3
isoform. In our BBMV preparations NHE activity was resistant to EIPA (data not
shown) suggesting that it contain mostly NHE3 isoform.
NHE3 is one of the most regulated transport proteins and its stimulation
and inhibition are at least partially due to changes in trafficking. In the apical
membrane of proximal tubule cells it exists in two pools: in the microvilli where it
appears to be active and in the intervillus spaces where it appears to be less
active or inactive (Biemesderfer et al. 2001). Using immunohistochemistry and
fluorescent microscopy we have measured localization of NHE3 transporter with
regard to villin which is localized in the microvilli of the brush border of the
epithelial cells. The highest overlapping of the two suggests that more NHE3 is in
the active form. Representative fluorescent pictures from OP and OR groups are
shown in the Fig. 12a. There was a significantly higher colocalization of villin
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Figure 10 Na/H exchanger protein abundance in fractions of brush border
membrane vesicles (BBMV) from OP and OR rats kidneys.
For this set of experiments different groups of animals were used to avoid any
manipulations of kidney prior to harvesting. Animals were kept at the same
conditions, on the same diet for the same time interval as the ones used for
physiological measurements. Panel (a): Semi-quantitative densitometry
analyses, measured in relative fluorescent units, represented as mean ± SEM of
n = 6 rats/group. Blots were probed with anti-NHE3 and anti-villin antibodies.
Semi-quantitative densitometry analyses were done by using Odyssey Infrared
Imaging System (Li-Cor) software. Significance was determined using unpaired
Student's t-test and the null hypothesis was rejected for a p-value< 0.05. *=
significant compared to lean group. Relative abundance of NHE3 was increased
in OP group compared to OR group. Panel (b): Immunoblots of BBMV samples
from OP and OR rats. For each blot, each lane was loaded with equal amount of
protein from brush border membrane vesicles (BBMV) from a different rat. Equal
protein loading was ensured by probing duplicates of each membrane with antivillin antibody, and density of NHE3 bands was normalized to that of villin bands.
Proteins were detected with Odyssey Infrared Imaging System (Li-Cor).
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Figure 11 NHE3 activity in fractions of brush border membrane vesicles (BBMV)
from OP and OR rats kidneys.
Na/H exchanger activity was measured in freshly obtained BBMVs. from OP and
OR rats and it is expressed as a change in pH over time. Na+/H+ exchange
activity was determined as the rate of Na+-dependent intracellular pH recovery
assessed using BCECF-AM in the presence and absence of external sodium.
Some samples were incubated with NHE1 inhibitor amiloride to test the
specificity of the reaction. NHE3 activity was greater in OP rats then in OR rats.
Values are means ± SEM from 6 rats per group. Significance was determined
using unpaired Student's t-test and the null hypothesis was rejected for a pvalue< 0.05. *= significant compared to lean counterparts.

(red) and NHE3 (green) in obese animals when compared to lean (21.5 ± 4.4%
vs. 9.1 ± 3.7%) (Fig. 12b). This suggests that localization of NHE3 transporter as
well as its protein levels could contribute to the higher activity measured in OP
rats.

3.3 Discussion for Aim #1

In our study we aimed at understanding the mechanism responsible for
the weight-related increase in blood pressure in a rat model of diet-induced
obesity. We have used a moderately high fat diet containing 32% kcal fat which
mimics the fat content in the Western type of human diet. Similarly to the human
population, not all animals fed with this diet become obese. Additionally, our
experimental model has many characteristics of obese humans (Kopelman 2000,
Hall 2003) including hyperinsulinemia (Levin & Keesey 1998), hyperleptinemia
(Levin et al. 2003), increased renin activity and high blood pressure (Dobrian et
al. 2000).
After 12 weeks of high fat feeding obese rats weighted significantly more
than lean rats. Body weight in the OP group was on average 17% higher than in
the OR group. Associated with this increase in BW was a 10% increase in
systolic blood pressure in the obese compared to lean rats. According to a study
by Guyton (Guyton 1990) all forms of hypertension are linked to the impairment
in pressure natriuresis. We also report that pressure natriuresis and diuresis are
attenuated in obese compared to lean rats. In obesity induced hypertension,
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Figure 12 Confocal immunofluorescence analysis of NHE3 distribution in obese
(OP) and lean (OR) Sprague-Dawley rats.
4 micron sections of paraffin embedded kidneys were double labeled with
polyclonal NHE3 and monoclonal anti-villin antibodies followed by the
corresponding anti-rabbit and anti-mouse secondary antibodies (AlexaFluor 488green, AlexaFluo594- red). Panel (a): Representative images of cortical tubules
from obese and lean animals double stained with NHE3 and villin. In OP group a
larger fraction of NHE3 is localized at the apical brush border, illustrated by
colocalization with villin (yellow). Panel (b): Semi-quantitative analysis of NHE3
and villin colocalization in kidney section from OP and OR animals. 6-10 z-stack
images were taken with laser scanning confocal microscope from each animal (n
= 3 rats per group). Images were analyzed using Metamorph software and
colocalization was expressed as the percentage of the sum of the green staining
overlapping the red staining to the sum of the green fluorescence only. OP group
had higher colocalization of NHE3 and villin compared to OR group. Significance
was determined using unpaired Student's t-test and the null hypothesis was
rejected for a p-value< 0.05. *= significant compared to lean rats. Bar=
10microns.

abnormal kidney function is initially associated with increased tubular sodium
reabsorption, which leads to sodium retention and expansion of extracellular and
blood volumes (Hall 2003). This increase in sodium reabsorption results in a
rightward shift in the renal pressure-natriuresis curve and an increase in blood
pressure. As a result, an obese individual has to have a higher blood pressure
set point in order to maintain sodium and water balance. In our study, glomerular
filtration rates were not different between anesthetized obese and lean animals
under basal conditions or following an increase in renal perfusion pressure,
suggesting that GFR is well autoregulated between renal perfusion pressure
(RPP) values of 100 and 135 mmHg in both groups. These findings indicate that
the difference in the sodium excretory responses to high RPP between obese
and lean rats are most likely caused by abnormalities in renal tubular
reabsorption of sodium. Although fractional excretion of lithium was similar
between the two rat groups, there was a difference in response to an acute
increase in RPP between lean and obese animals suggesting that the defect in
sodium reabsorption may be at the level of the proximal tubule.
In our study we intended to define the cellular mechanisms which are
responsible for sodium retention seen in obese rats. Sodium is reabsorbed from
the proximal tubule across the apical membrane via sodium-hydrogen exchanger
type 3 (NHE3), and actively pumped out of the cell by the basolateral sodium
pump, Na,K-ATPase, which generates the gradient for Na+ entry across the
apical membrane. Protein expression of Na,K-ATPase and NHE3 were studied
by immunoblots after preparation of baso-lateral membrane fractions (BLM) and

brush border vesicle membrane (BBMV), respectively. Protein expression and
activity of the transporters in BLM and BBMV were measured and the subcellular
distribution of NHE3 was studied by immunohistochemistry. We reported that
expression of Na,K-ATPase was 77% higher in OP than the OR group but its
activity was the same between the groups. However, the activity of Na,K-ATPase
was reported to correlate to the number of pump units (Ewart & Klip 1995) and
this suggests that in general Na,K-ATPase was more active in obese rats. This
is in agreement with the study by Bickel et al. (Bickel et al. 2001) in which the
increase in the abundance of Na,K-ATPase was reported in the kidneys of
obese, hypertensive, hyperinsulinemic Zucker rats evaluated by semiquantitative
immunoblotting. Not all reports on Na,K-ATPase abundance in obesity are in
agreement, as a reduction of Na,K-ATPase activity was reported in liver and
kidneys of obese animals (Bray & Yukimura 1978, York et al. 1978) and humans
(Klimes etal. 1982). However, the different results most likely reflect cell-specific
regulation of Na,K-ATPAse in liver, renal or blood tissue. Also, a number of
studies indicate no change in Na,K-ATPase activity in obese humans (Simat et
al. 1983, Klimes et al. 1984).
It is known that Na,K-ATPase is an oligomeric protein composed of a a
subunit, a p subunit and a FXYD protein (y subunit). Expression of the catalytic
subunit a, the one which hydrolyzes ATP and transports the cations is most
commonly measured and was also evaluated in our study. However, recent
findings suggest that |3 subunits and FXYD proteins essentially contribute to the
various physiological roles of Na,K-ATPase in different tissues and can modulate
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its activity in a tissue-specific way (Geering 2008). It is not clear whether changes
in expression and activity of the a subunit are paralleled by changes in the p and
FXYD subunits and how they can affect the overall activity and expression of the
transporter. Moreover, Na,K-ATPase is irregularly distributed along the whole
length of the nephron and we can not exclude the fact that beside proximal
tubules our membrane preparations could as well include other nephron
segments such as the thick ascending limb of Henle's loop, distal convoluted
tubule, and connecting tubule.
Beside the protein abundance, phosphorylation and subcellular
distribution play a major part in the regulation of Na,K-ATPase enzyme activity.
The catalytic a subunit of Na,K-ATPase can be phosphorylated by PKA at the Cterminus at Ser943 (Feschenko & Sweadner 1995), as well as by PKC at the Nterminal sites: Ser11, Ser18 and Ser23 (Logvinenko etal. 1996). Phosphorylation
is generally associated with altered enzyme activity (Lai et al. 2000, Bertuccio et
al. 2007), though phosphorylation status of Na,K-ATPase was not assessed at
this point in our study. Previous studies demonstrated that in the proximal tubule
the effect of angiotensin II on Na,K-ATPase is mediated by PKC (Rangel et al.
2002). The mechanism of regulation of Na,K-ATPase by insulin in the kidney is
largely unknown. It has been shown that PKC may play a role in the insulinmediated activation of Na,K-ATPase in cultured rat skeletal muscle cells
(Sampson etal. 1994). Sweeney and Klip have shown that in 3T3-L1 fibroblasts
phosphatidylinositol 3-kinase and PKC-zeta appear to be involved in the
signaling pathway of insulin effect on Na,K-ATPase activity (Sweeney et al.

1998). However, there are also data showing that stimulation of Na,K-ATPase
activity by insulin in the proximal tubule is likely mediated by phosphorylation of
TyriO (Feraille ef a/. 1999).
In addition, redistribution of a transporter between the plasma membrane
and cytosolic compartments is another mechanism by which its activity could be
regulated (Periyasamy et al. 2005). There is some evidence that trafficking can
be associated with phosphorylation of Na,K-ATPase (Chibalin etal. 1999,
Efendiev etal. 2003). These are all important regulatory mechanisms that
deserve further investigation.
The other transporter of interest to us was sodium/hydrogen exchanger
type 3 (NHE3) found in the kidneys almost exclusively in the apical side of the
epithelium in the proximal tubule segment. We reported that obese rats had 60%
higher expression of NHE3 when compared to lean rats (0.56 ± 0.04 RFU vs.
0.35 ± 0.06 RFU) and this was paralleled by 35% higher activity of the
transporter in the OP group (0.414 ± 0.06 ApH At"1 vs. 0.306 ± 0.09 ApH At"1).
Also, we found a higher degree abundance of NHE3 in the villus tip in OP vs. OR
group.
The role of NHE3 in hypertension is of potential importance. NHE3 has
been studied in various models of obesity and hypertension but the data which
links NHE3 and high blood pressure is not conclusive. In agreement with our
study there are reports of increased activity of exchanger in spontaneously
hypertensive rats (SHR) and Milan hypertensive rats (MHR) compared to their
normotensive controls of the same age (Morduchowicz etal. 1989, Parenti etal.

1992, Hayashi et al. 1997). These results were supported by other studies in
which both activity and abundance of Na/H exchanger was determined in freshly
isolated or cultured proximal tubule cells and in renal cortical tubules from the
spontaneously hypertensive rat (SHR) and WKY rats before and after the
development of hypertension (Kelly et al. 1997, LaPointe et al. 2002). In contrast,
there is as well evidence of decreased NHE3 activity or no change in NHE3
activity and protein expression in primary cultured renal cells from spontaneously
hypertensive rats (Orlov et al. 1991), in induced acute or chronic hypertension in
Sprague-Dawley and spontaneously hypertensive rats, respectively (Yip et al.
1998, Zhang etal. 1998, Magyar et al. 2000), in hypertensive Dahl salt-sensitive
rats on high-salt diet (Kobayashi et al. 2004) and in obese Zucker rats (Bickel et
al. 2002). The reason for the discrepancy is unclear, although the background on
which hypertension develops could modulate the final outcome of exchanger
activity as much as the high blood pressure itself (Kobayashi et al. 2004).
Furthermore, since NHE3 activity is the resultant of several factors besides
protein abundance, such as interaction with NHE regulatory factors (NHERF),
NHE3 phosphorylation, membrane trafficking and changes in turnover rate, any
above mentioned changes can determine NHE3 activity. There is evidence for
redistribution of proximal tubule NHE3 from the apical microvilli to the
intermicrovillar region, as determined by both subcellular fractionation and
confocal microscopy (Zhang etal. 1998, Yang etal. 2002). Interestingly, the
distribution was observed with both acute and chronic hypertension (Yip et al.
1998) and was associated with decreased proximal tubule sodium transport

(Zhang et al. 1996, 1998). In our study we have observed significantly higher
colocalization of NHE3 with villin in obese vs. lean groups (21.46 ± 4.38% vs.
9.10 ± 3.67%) and we concluded that in OP rats more NHE3 is distributed in the
physiologically active membrane pool compared to the OR rats.
In summary, in our study we demonstrated possible cellular mechanisms
responsible for the changes seen in hypertension related to obesity.
Approximately half of SD rats fed high fat diet became obese and had high blood
pressure while the rest stayed lean and normotensive. That was well correlated
with higher protein expression and activity of NHE3 and higher overall activity of
Na,K-ATPase in the renal proximal tubule. The mechanisms which contribute to
those changes are multifactorial and can include phosphorylation of the
transporters, activation/inhibition of their regulatory factors or transporters
redistribution between different membrane pools. We provided evidence of
differences in NHE3 abundance, activity and membrane distribution between
lean and obese rats which could contribute to the increased sodium retention
seen during acute pressure-induced natriuresis and diuresis.
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SECTION 4
STUDIES FOR SPECIFIC AIM #2

4.1 Materials and Methods for Specific Aim #2

Animals
The animal husbandry and separation into groups was done as
described in methods for specific Aim #1. The OP and OR groups were
randomly divided into sub-groups {n = 6): 1) no treatment, diet only: NT-OP/NTOR and 2) treatment with 0.1% (w/w) pioglitazone (Takeda Pharmaceuticals,
Lincolnshire, IL): PIO-OP/PIO-OR. The rats were kept on respective
diet/treatments for 4 additional weeks (Fig. 13). Pioglitazone was incorporated
into the food pellets. Body weights and food intake were measured weekly as
mentioned in section 4. Before and after the treatment rats were put into the
metabolic cages and urine was collected for 24 hours for sodium
measurements. Separate groups, fed and treated exactly the same way, were
used for preparation of membrane fractions, brush border membrane vesicles,
and any subsequent experiments involving those preparations.

Surgical procedure
The surgical procedure was performed as previously described (Khraibi et
al. 2002). On the day of the acute experiment, rats were anesthetized with Inactin
(100 mg kg"1), and catheters were placed in the trachea (PE-240) and
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Figure 13 Research design for specific Aim #2.
Male, 3 months old Sprague-Dawley rats were started on moderately high fat diet
(MHF) a week after arrival to the facility. At week 5, halfway through the diet, rats
were trained for the tail-cuff blood pressure measurements by the blood pressure
analysis system (BP-2000-R; Visitech Systems; Apex, NC). Blood pressure was
measured at week 8, before starting the treatments, and at week 12, after
treatment completion on the day of the surgery. Average of 3-5 readings were
taken for each animal and recorded by the automated software. Before and after
treatment, rats from all groups were placed in metabolic cages for 24-hour urine
collection. Non-treated groups OP and OR were placed in metabolic cages only
once, right before surgeries. Water intake and urine volume was recorded and
urine was analyzed for Na+ content. Starting with week 8th of the diet each
group: OP and OR was further divided into 2 subgroups and was treated for
additional 4 weeks with: 0.1% (w/w) pioglitazone incorporated in the food pellets
or left untreated (diet only). After 4 weeks of treatments, and total of 12 weeks of
the diet acute measurements of renal function were performed during surgical
procedure.

left jugular vein (PE-50) for intravenous infusion of 0.75 ml per 100 g body wt h
of saline with 6 mM lithium chloride (LiCI) and 0.75 ml per 100 g body wt"1 h"1 of a
solution of 3% inulin and 6.25% bovine albumin in saline (with 6 mM LiCI). A PE50 catheter was implanted in the left carotid artery for mean arterial pressure
(MAP) measurement and blood withdrawal. PE-90 catheter with a flared tip was
placed in the bladder for urine collection. The rats were allowed 1 hrto recover
after completion of the surgical procedures. Then, a clearance period of 30 min
was started; MAP was measured and recorded continuously. At the end of this
period, ~1 ml of blood was withdrawn from the left carotid artery for plasma
electrolytes, lithium, and inulin measurements. Urine was collected for 30 min. All
rats were killed by an Inactin overdose (50 mg; 0.5 ml of a solution of 100 mg ml"1
of Inactin in saline) at the end of the experiment while still under deep
anesthesia.
To avoid any manipulations of the kidneys different groups of animals were
used for membrane and brush border membrane vesicle fractions. At the
completion of the treatments rats were anesthetized with Inactin (100 mg kg"1),
kidneys were removed without any further handling and then rats were killed by
an Inactin overdose as mentioned above.

Physiological parameters
All physiological parameters were assessed, measured and calculated
as described in the Material and Methods section for Aim #1.

Baso-lateral membrane (BLM) and brush border membrane vesicles
(BBMV) preparations
BLM and BBMV fractions of renal cortexes from nontreated animals and
rats treated with pioglitazone were prepared using the same protocols as
described in the Material and Methods paragraph for Aim #1.

Western Blotting on BLM and BBMV preparations
Na,K-ATPase and NHE3 protein expression were assessed by western
blotting as described in the Material and Methods paragraph for Aim #1.

Activity of Na.K-ATPase and NHE3
Na,K-ATPase activity was measured in freshly obtained BLM
preparation and NHE3 activity was measured in freshly obtained BBMV fraction
as previously described in the Material and Methods paragraph for Aim #1.

Immunocytochemistry, image analysis and data collection
Colocalization of NHE3 (green) and Villin (red) were evaluated on
paraffin-embedded sections of kidney from untreated and treated animals;
images were recorded by confocal fluorescent microscopy and overlapping of
both colors were analyzed by MetaMorph software as described in the Material
and Methods paragraph for Aim #1.

Cell culture and treatments
Human renal proximal tubule epithelial cells (RPTEC) (primary cells) were
purchased from Lonza, Inc (Walkersville, MD). Cells were grown in the media
recommended by the supplier-REBM, containing 5% fetal bovine serum. RPTEC
were seeded at density of 3.3 x 105per 100 mm plate and 2.5 x 105-1 x 106 per
well on 6-well plates for transfection purposes, grown to ~80% confluence and
used between passages 3 and 6 in all experiments. They were kept in serumfree medium 24 hr before experiments. Quiescent cells were treated with various
PPARy agonists: pioglitazone (50 |aM), rosiglitazone (100 mM), and PGJ2 (2 ^M)
or PPARy antagonists BADGE (100 fiM), and GW (2 y.M) for 4 hrs, harvested
and total homogenate or membrane fractions were prepared to assess protein
expression of Na,K-ATPase and NHE3. The protein concentration for each
lysate was determined by using a BCA protein assay kit (Pierce Chemical) with
BSA as a standard. PPARy agonists and antagonists were purchased from
Cayman Chemicals (Ann Arbor, Ml). Transiently transfected cells (to either
overexpress or silence PPARy) were seeded in 6-well plates and incubated for
12 hours, at 37 °C, in transfection media with serum, followed by additional 24
hour incubation in media without serum. Afterwards, the cells were incubated for
12 additional hours in fresh serum free medium supplemented with either
pioglitazone (50 \iM) or PGJ2 (2 (iM), both PPARy agonists, and subsequently
harvested and processed for appropriate assays.

Plasmid preparation
GeneHogs strain of E.coli (GeneStorm clone ID # RG001382, Invitrogen
Carlsbad, CA) was streaked from a glycerol stock onto a freshly prepared agar
plate containing Zeocin as a selective antibiotic and placed at 37 °C. After 24 hrs
2-3 single colonies were picked from the plate and inoculated into 2 ml of LB
medium again containing Zeocin and grown for 8 hours at 37 °C with vigorous
shaking (250 rpm). 500 jal of the starter culture was then diluted into 150 ml of LB
medium and further grown with vigorous shaking (~300 rpm) to saturation (-1216 hours). The bacterial cells were then harvested by centrifugation at 6 000 g
for 15 min at 4 °C in Beckman JA-25 centrifuge and cDNA was isolated from
plasmid according to MidiPrep kit instructions (Qiagen, Valencia, CA). In the last
step DNA was eluted in DNAase free water and the purity of plasmid was
checked by measurements of the A260:A280 ratio. The integrity of plasmid was
verified by Bgl II restriction enzyme digestion and visualized on 0.8% agarose
gel.

Transient transfection and PPARy overexpression
Full length PPAR-y cloned in pcDNA3.1/GS vector already transformed in
GeneHogs strain of E.coli (GeneStorm clone ID # RG001382) was purchased
from Invitrogen (Carlsbad, CA). Transfection was done by Amaxa's Nucleofector
technology following the basic nucleofection protocol for primary mammalian
epithelial cells (Amaxa Biosystems, Gaithersburg, MD). After transfection, cells
were left undisturbed at 37 °C for 36 hrs. Afterwards, the transfection medium

was replaced with the media supplemented with pioglitazone for 12 hrs. Control
cells were transfected with empty vector in identical conditions. The efficiency of
the transfection was verified by fluorescent microscopy of cells transfected with
pcDNA3.1/GFP.

Transient transfection and small interfering RNA (siRNA) technique
One day prior to transfection, RPTEC were plated in REBM into 6-well
plates, at density of 2.5 x 105 cells/well. For transfection with X-tremeGene
siRNA Transfection Reagent (Roche Applied Science, Indianapolis, IN)
expression vector and either a specific siRNA duplex or a control siRNA was
diluted in a serum-free medium. In parallel, X-tremeGene siRNA Transfection
Reagent (Roche Appied Science, Indianapolis, IN) was added to serum-free
REBM, and the resulting mixture was combined immediately with the diluted
nucleic acids. After 20 minutes incubation at room temperature the solution was
added to the cells. Without further medium change the cells were assessed for
viability by microscopic inspection. Next day additional media with serum was
added to each well. Subsequently cells were washed and incubated for 12 hr
with PPARy ligands, then lysed in the homogenizing buffer. siRNA (sense and
antisense) were designed to target a common sequence in both PPAR-y1 and y2
isoforms. The following sequences were used for PPAR-y1, 2:
sense siRNA: 5'-GACUACAUUGGCUGGACCUTT-3';
antisense siRNA- 5'AGGUCCAGCCAAUGUAGUCTT-3';

control sense: 5'-GACUACAUUGGCUGGACCUTT-3'; control antisense:
5'AGGUCCAGCCAAUGUAGUCTT-3'.The efficiency of the transfection was
verified by fluorescent microscopy of cells transfected with Cy3 luciferase-labeled
oligonucleotides.

Protein preparation from RPTEC and Western blotting
Na,K-ATPase and NHE3 protein expression was assessed in total
homogenates and in membrane fractions of RPTEC. The latter was prepared
using Compartmental Protein Extraction Kit (Chemicon, Billerica, MA)
according to the protocol from the manufacturer. Cell pellets were homogenized
in RIPA buffer without detergents, with 5% sorbitol, 1mM PMSF, 1mM NaF,
1mM Na 3 V0 4 final concentration, Protease Inhibitor Cocktail (Sigma Aldrich,
Saint Louis, MO) at 1:1 000 dilution. Protein concentration for each lysate was
determined using a BCA protein assay kit (Pierce Chemical) with BSA as a
standard. The general western blot protocol was described in Materials and
Methods paragraph for specific Aim #1. For RPTEC the following antibodies
were used: polyclonal anti-NHE3 (Chemicon, Billerica, MA, 12 jxg ml"1) and
monoclonal Na,K-ATPase (Upstate , Lake Placid, NY,1:10 000 dilution).
Polyclonal anti-oc-tubulin antibody (Abeam, Cambridge, MA, 1:500 dilution) or
monoclonal anti-a- tubulin (Sigma, Saint Louis, MO, 1:1 000 dilution) served as
a loading control. Antigen detection was performed using appropriate
fluorescent secondary antibodies (IRDye 680 and IRDye 800, Li-Cor
Biosciences, Lincoln, NE) at 1:15 000 dilution for 45 minutes at RT. Membranes

100
were scanned using Odyssey Infrared Imaging System (Li-Cor Biosciences,
Lincoln, NE). Semi-quantitative analyses of the specific bands were performed
using Li-Cor Odyssey software. Results were expressed as relative
fluorescence units (RFU). For some blots, secondary HRP-antibodies were
used at 1:7 500 dilution (Amersham, Piscataway, NJ, USA) and the antigenantibody complexes were detected using enhanced chemiluminescence (ECL,
Amersham, Piscat away, NJ, USA). The films were scanned and the intensity of
the bands was measured by densitometry using SigmaGel software (Jandel
Scientific).

Statistical analysis
Results are presented as mean ± standard error of mean (SEM) of the
indicated number of experiments unless stated otherwise. Statistical analysis
was performed using Student's t-test for unpaired data (treatment versus
control), or by analysis of variance (ANOVA) and Holm-Sidak modification for
multiple group comparisons, as appropriate using InStat software (San Diego,
CA). The null hypothesis was rejected for a p-value<0.05.

4.2 Results for Specific Aim #2

In vivo experiments
Physiological parameters
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The summary of the effect of 4 weeks of pioglitazone treatment on various
physiological parameters in obese and lean rats is presented in Table 1 and
Table 2. OP rats had significantly higher body weights (BW) than OR rats.
Chronic treatment with pioglitazone significantly increased body weights in the
obese group by ~10%, had no effect on body weights in the lean group and thus
made the difference in BWs between treated OP and OR animals significant
(Tablel). Those changes were paralleled by a significant increase in total
visceral fat after treatment with pioglitazone in obese rats with no effect in lean
rats (Tablel). Furthermore, average food intake (Table 1) during the 4 weeks of
treatment was significantly increased in the pioglitazone treated OP group and
was significantly higher compared to the treated OR group. Treatment did not
have an effect on food intake in lean animals. Systolic blood pressure (SBP) was
significantly higher in obese animals compared to lean; pioglitazone treatment
lowered SBP in OP groups from 158.9 ± 3.5 mmHg to 140.3 ± 8.9 mmHg and
had no significant effect in the OR rats (Table 1). Since it is known that sustaining
a hypertensive state requires an increase in the blood volume which is achieved
by sodium and water retention we have estimated chronic sodium excretion in all
groups of animals placed in metabolic cages. Urine sodium excretion (UNaV)
over the period of 24 hours was not different between obese and lean rats. Also,
pioglitazone treatment did not significantly change 24 hours UNaV in OP and OR
groups (Table 1). In addition, there was no significant difference in water intake
and urine volume over 24 hours in obese and lean rats non-treated or treated
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Table 1 Final measurements of the body weights (BW) and total fat, food and
water intake, systolic blood pressure (SBP) and chronic urinary sodium excretion
in obese (OP) and lean (OR) rats with or without pioglitazone treatment.

OP

PIO OP

OR

PIO OR

(n = 6)

(n = 6)

(n = 6)

(n = 6)

BW(g)

639.7±26.6

702.5±22.4 *

563.6±4.2 f

566.6119.6 §

Average food intake
(g/week) over 4 weeks of
Pio treatment

157.1+3.0

172.1 ±7.0

137.2±4.0 f

129.4110.0 §

Total visceral fat (g)

27±3.6

42.7±4.5 *

26.4±4.4

21.612.5 §

SBP (mmHg)

158.9±3.5

140.3+8.9 *

143.5±4.2 f

149.716.9

Urine Na+ (mmol 24 h"1)

2.12±0.27

2.7510.23

2.0310.10

2.2710.19

Water intake (ml 24 h"1)

20.83±2.01

22.50±4.43

22.5011.83

22.5011.12

Urine volume (ml 24 h"1)

11.67±1.86

14.50±2.35

12.5411.28

12.1710.84

Body weights represent averages for each group from the last week of the diet
before sacrifice. Food intake represents average over the 4 weeks of treatment.
Significance remained the same when data of food intake was calculated over
the entire period of the study. Total visceral fat represents sum of epididymal and
retropritoneal fat. Systolic blood pressure corresponds to final readings of the
experiment. Values for urine sodium, water intake and urine volume were
obtained from metabolic cages over 24 hours period. Values are mean ± SEM
from n = 6 rats/group. Significance was determined using one-way ANOVA with
Holm-Sidak modification for multiple group comparisons and null hypothesis was
rejected for a p-value <0.05. *=significant compared to non-treated; f=significant
compared to OP; §= significant compared to PIO-OP.
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with pioglitazone (Table 1). The lack of difference in sodium excretion could most
probably be explained by the fact that after being fed with high fat diet for 8
weeks high blood pressure was already established in obese groups and those
animals were in sodium balance; additional 4 weeks of treatment did not change
that (Hall 2003). Next, we examined natriuresis and diuresis in obese and lean
rats after acute saline loading (Table 2). No significant difference was found in
glomerular filtration rate (GFR), urine flow (V) and fractional excretion of sodium
(FENa) between four experimental groups. However, acute measurements
showed sodium retention in OR group treated with pioglitazone compared to OP
group (14.8 ± 3.2 ^Eq min"1 vs. 2.9 ± 1.2 f^Eq min"1) with no effect on sodium
excretion (UNaV) in non-treated groups. Fractional lithium excretion (FELi) which
assesses proximal tubule function was not different between OP and OR rats
after saline loading and was comparable after pioglitazone treatment. The limited
natriuretic and diuretic response to acute volume expansion in our study could be
explained by relatively fixed GFR in our experimental groups and different extend
of volume expansion between obese and lean rats. Together, these data suggest
that pioglitazone has different effects in obese and lean rats with respect to
sodium reabsorption and regulation of blood pressure. Next, we examined the
expression, activity and localization of the renal proximal tubule sodium
transporters. This part of the study was conducted in different set of animals
subjected to identical dietary and treatment protocols.
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Table 2 Renal parameters measured during surgical procedure in obese (OP)
and lean (OR) rats with or without pioglitazone treatment: glomerular filtration
rate (GFR) and urinary sodium excretion (UNaV), fractional excretion of sodium
(FENa), fractional excretion of lithium (FELi) and urine volume (V).

OP

PIOOP

OR

PIOOR

(n = 6)

(/I = 6)

(n = 5)

(n = 5)

GFR (ml min"1)

4.08±0.7

5.75±0.8

3.4510.4

3.2310.8

UNaV (nEq min"1)

9.9±2.3

14.813.2

8.311.6

2.911.2 §

FENa (%)

2.611.3

1.910.4

1.810.4

0.610.2

FELi (%)

41.9±16.2

25.415.1

2714.4

14.713.9

V (nl min-1)

71.3±13.1

81.3114.0

56.717.0

28.2116.4

Anesthetized rats were infused with lithium and inulin, urine was collected and
blood withdrawn. Glomerular filtration rate was calculated from the clearance of
inulin. Urinary sodium excretion was measured as the rate of sodium excretion
per volume of urine per time unit. Fractional excretion of sodium and lithium was
calculated as the ratio between the amount excreted in the urine versus the
amount reabsorbed by the kidney. Values presented are mean ± SEM from n =
5-6 rats/group. Significance was determined using one-way ANOVA with HolmSidak modification and null hypothesis was rejected for a p-value <0.05. §=
significant compared to PIO-OP.
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Activity, protein expression and localization of sodium transporters
In this part of the study we investigated some of the mechanisms which
were responsible for blood pressure lowering effect of pioglitazone in obese but
not lean rats on high fat diet. As described in results paragraph of Aim #1 Na,KATPase and NHE3 are two proximal sodium transporters of interest to us. Their
activity, as well as activity of any transporter, is the resultant of several factors
including protein abundance, modifications of the function of single units of
transporter and/or localization. We have measured protein expression of the a 1 subunit of Na,K-ATPase by western blotting in baso-lateral enriched membrane
(BLM) preparations from renal cortex (Fig. 14). Pioglitazone treatment
significantly increased Na,K-ATPase expression by 2 1 % in OP group from 54.4
± 3.2 RFU to 68.3 ± 3.3 RFU and by 46% in OR group from 30.7 ± 0.7 RFU to
56.1 ± 1.7 RFU. The activity of Na,K-ATPase was also measured in BLM, on the
day of preparation ( Fig. 15). The 4 week treatment with pioglitazone almost
doubled the activity of the pump in obese animals (0.27 ± 0.04 vs. 0.52 ± 0.04
mmol Pi mg"1 min"1) while had a tendency to an increase in lean rats (0.37 ± 0.04
vs. 0.47 ± 0.04 mmol Pj mg"1 min"1) although did not attain significance (p-value=
0.113).
Next, we examined NHE3 protein levels in brush border membrane
vesicles (BBMV) prepared from renal cortex of obese and lean rats with or
without pioglitazone treatment by western blotting (Fig. 16). Villin served as
loading control. NHE3 expression was dramatically reduced by treatment in both
groups: in OP from 0.56 ± 0.04 to 0.07 ± 0.007 RFU and in OR from 0.36 ± 0.05
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Figure 14 Na,K-ATPase protein expression measured in baso-lateral-enriched
membranes isolated from renal cortex of obese (OP) and lean (OR) rats with
(PIO) or without pioglitazone treatment (NT).
Panel (a): Graph representation of Na,K-ATPase abundance, measured in
arbitrary units, represented as means ± SEM of n = 6 rats/group. Blots were
probed with Na.K-ATPase a1 subunit specific antibody. Semi-quantitative
densitometry analyses were done by using Odyssey Infrared Imaging System
software. Significance was determined using one-way ANOVA and the null
hypothesis was rejected for a p-value< 0.05. *=significant compared to nontreated; t=significant compared to OP; §= significant compared to PIO-OP. Panel
(b): Immunoblots of BLM samples from non-treated and treated OP and OR rats.
Each lane represents a sample from an individual rat. Equal protein loading was
ensured by staining each membrane with Ponceau red.
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Figure 15 Effect of pioglitazone on Na,K-ATPase activity assessed in basolateral membranes prepared from renal cortexes of obese (OP) and lean (OR)
animals.
Na,K-ATPase activity expressed as mmol of inorganic phosphate liberated per
mg of protein per minute performed on freshly prepared baso lateral membrane
(BLM) fractions. Na,K-ATPase activity was calculated as the difference between
activities assayed in the absence of ouabain (total) activity and in the presence of
5 mM ouabain. Values are means ± SEM from 6 rats per group. Each sample
was assayed in duplicate and background was subtracted from the mean.
Pioglitazone treatment significantly increased activity of the pump in obese rats
with no effect in lean group. Significance was determined using one-way ANOVA
and the null hypothesis was rejected for a p-value< 0.05.
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Figure 16 Na/H exchanger (NHE3) protein abundance after pioglitazone
treatment in obese (OP) and lean (OR) rats.
NHE3 was assayed in brush border membrane vesicles (BBMV) fractions
prepared from renal cortex of OP and OR groups treated or not with pioglitazone.
Panel (a): Densitometric analysis of immunoblots shown below. NHE3
immunoreactivity is expressed as a ratio between NHE3 and Villin signals, in
relative fluorescent units (RFU). Results represent average ± SEM of n = 6
rat/group. Significance was determined using one-way ANOVA and the null
hypothesis was rejected for a p-value< 0.05. Pioglitazone treatment significantly
decreased NHE3 protein expression in OP and OR groups. Panel (b):
Immunoblots of BBMV samples from obese and lean rats. Equal amount of
proteins were loaded into each gel and duplicates of membranes were probed
with anti-villin antibody which served as a loading control. Antigen-antibody
complexes were detected with Odyssey Infrared Imaging System (Li-Cor).
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Figure 17 Na+/H+ antiporter activity in obese and lean rats non-treated (NT) or
treated with pioglitazone (PIO).
Brush border membrane vesicles (BBMV) prepared from renal cortex were
preloaded with pH indicator BCECF-AM in Na+-free buffer, pH 7.2 and then
mixed with the buffer solution containing 150 mmol I"1 NaCI, pH 9.2 for
determination of pH recovery as described in methods paragraph for Aim #1.
Equal amounts of protein were labeled and readings for unlabeled samples were
subtracted from final values. NHE3 activity was expressed as a change in pH
over time. Values are means ± SEM from 6 rats per group. Significance was
determined using one-way ANOVA and the null hypothesis was rejected for a pvalue< 0.05. Pioglitazone treatment significantly reduced activity of the
exchanger in OP but not in OR group.
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to 0.06 ± 0.015 RFU. To determine if reduced protein abundance was
accompanied by modifications of sodium hydrogen exchanger activity, we
measured the latter in freshly isolated BBMVs. and expressed it as the rate of pH
recovery in response to extravesicular sodium load (Fig. 17). In the obese group,
pioglitazone treatment significantly reduced activity of NHE3 from 0.46 ± 0.13 to
0.22 ± 0.09 ApH At"1, which corresponds well with the protein change whereas in
lean group pioglitazone had no significant effect on the activity of the transporter.
As described in result paragraph for Aim #1 to insure that the activity measured
was specific for NHE3, randomly chosen samples of BBMV were incubated with
100 \xM of 5-(N-Ethyl-N-isopropyl) amiloride (EIPA) since it inhibits NHE1 isoform
of the transporter (data not shown). This incubation resulted in less than 10%
inhibition in the rate of fluorescence. To ensure the specificity of the NHE3
activity assay, randomly chosen samples of BBMV were incubated with a higher
concentration of EIPA (500 j^M), which was expected to block all NHE related
activity. The inhibition found in our experiments was more than 95% in all
assayed samples (data not shown). Next, we tested if localization of NHE3 plays
a role in overall activity of the exchanger since it is possible that redistribution of
NHE3 out of the apical microvilli is correlated with inhibition of the transporters.
For this purpose we employed immunohistochemistry techniques and acquired
images with confocal microscopy. Fig. 18a represents typical images from all four
experimental groups. Sections of kidneys were simultaneously stained with
NHE3 and villin where the latter was used as a marker of the top of the villi.
Therefore, the greater the overlaying of colors the closer NHE3 was to the top of
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Figure 18 Confocal immunofluorescence analysis of NHE3 distribution in obese
and lean rats with or without pioglitazone treatment.
4 micron sections of paraffin embedded kidneys were double stained with
polyclonal NHE3 antibody and monoclonal anti-villin antibody followed by the
corresponding anti-rabbit (AlexaFluor488-green) and anti-mouse (AlexaFluor594red) secondary antibodies. Panel (a): Representative images of cortical tubules
from all experimental groups double stained with NHE3 (A, D, G, J) and villin (B,
E, H, and K). Overlapping (C, F, I and L) of NHE3 and Villin appears yellow.
Treament with pioglitazone seemed to change this colocalization but not
significantly. Panel (b): Semi-quantitative analysis of NHE3 and villin
colocalization in kidney section. 6-10 z-stack images were taken with laser
scanning confocal microscope from each animal (n = 3 rats per group). Images
were analyzed using Metamorph software and colocalization was expressed as
the percentage of the sum of the green staining overlapping the red staining to
the sum of the green fluorescence only. Pioglitazone treatment did not produce
significant NHE3 redistribution. Significance was determined using one-way
ANOVA and the null hypothesis was rejected for a p-value< 0.05. Bar=
10microns.
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apical brush border microvilli. Pioglitazone treatment did not have an effect on
NHE3 localization in obese rats. However, in the OR group, it increased
colocalization from 9.1 ±2.1 to 14.6 ± 1.3% with borderline significance (pvalue=0.09) (Fig. 18b). Therefore we concluded that since changes in protein
expression of both transporters are paralleled to a certain extent by changes in
activity, pioglitazone must exert its effect at least partially at the genomic level,
although there are other factors which can influence general activity of
transporters in vivo.

In vitro experiments
For our in vitro study we used primary cultures of human renal
proximal tubule epithelial cells (RPTEC) and examined the effect of PPARy
modulation on NHE3 and Na,K-ATPase using pharmacological and molecular
approach. Protein expression of both transporters was assessed by western
blotting in cells treated with PPARy antagonists (GW9682 and BADGE) and
PPARy agonists (PGJ2 and rosiglitazone). Rosiglitazone (Avandia) is a highaffinity ligand for PPARy and belongs to the same group of anti-diabetic
thiazolidinediones (TZD) as pioglitazone. 15-deoxy-A 12, 14-prostaglandin J2
(PGJ2) is a natural PPARy ligand. Activation of PPARy by PGJ2 and
rosiglitazone caused a significant reduction in protein expression of Na,KATPase compared to control (C: 0.68 ± 0.04 vs. PGJ2: 0.34 ± 0.1 vs. Rosi: 0.42
± 0.07 arbitrary units) while PPARy antagonists: GW9682 and BADGE increased
it by 70% and 30% respectively (Fig. 19). Activation and inhibition of PPARy had
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Figure 19 Effect of PPARy activation or inhibition on Na,K -ATPase protein
expression in human renal proximal tubule epithelial cells (RPTEC).
RPTEC were incubated for 4 hours with PPARy antagonists (GW9682 and
BADGE) or PPARy natural or synthetic ligands, PGJ2 and rosiglitazone,
respectively. Top: Semi-quantitative analysis of western blots from membrane
fractions of RPTEC. Results are expressed as a ratio of Na.K-ATPase to tubulin
signal in arbitrary units and represent means ± SD from of 3-5 experiments.
Significance was determined using one-way ANOVA and null hypothesis was
rejected for a p-value <0.05. *=significant compared to control. PPARy inhibition
increased protein expression of Na.K-ATPase while PPARy activation reduced it.
Bottom: Representative western blots for Na,K-ATPase and tubulin. Equal
amounts of protein were loaded into the SDS-PAGE gel and probed with a
monoclonal antibody against Na,K-ATPase oc1 subunit. Immunoreactive bands
were visualized, after incubation with appropriate secondary antibody, using
enhanced chemiluminescence. Then membranes were stripped and
immunoblotted with anti-tubulin antibody as a protein loading control.
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Figure 20 NHE3 protein expression in membrane fractions of human renal
proximal tubule epithelial cells (RPTEC) treated with PPARy agonist and
antagonists.
RPTEC were incubated for 4 hours with PPARy antagonists (GW9682 and
bisphenol A diglycidyl ether-BADGE) or the PPARy natural or synthetic ligands,
PGJ2 and rosiglitazone, respectively. Top: Semi-quantitative analysis of western
blots from membrane fractions of RPTEC. Results are expressed as a ratio of
NHE3 to tubulin signal in arbitrary units and represent means ± SEM from of 3-5
experiments. Significance was determined using one-way ANOVA and null
hypothesis was rejected for a p-value <0.05. *=significant compared to control.
PPARy inhibition increased the abundance of NHE3 while PPARy activation
reduced it. Bottom: Representative immunoblots for NHE3 and tubulin. Equal
amounts of protein were loaded into the SDS-PAGE gel and probed with a
monoclonal antibody against NHE3. Immunoreactive bands were visualized, after
incubation with appropriate secondary antibody, using enhanced
chemiluminescence. Then membranes were stripped and immunoblotted with
anti-tubulin antibody as a protein loading control.
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the same effect on NHE3 protein expression namely: GW9682 and Badge
increased it from 0.76 ± 0.02 to 1.4 ± 0.07 arbitrary units (GW9682) and 1.27 ±
0.07 arbitrary units (Badge) while PGJ2 and rosiglitazone reduced it to 0.39 ±
0.08 and 0.51 ± 0.01 arbitrary units, respectively (Fig. 20). Those results suggest
that PPARy can effect protein expression of both sodium transporters in cultured
renal proximal tubule epithelial cells.
To differentiate if the effects of agonists and antagonists are PPARy
dependent or independent we transiently over-expressed PPARy using human
full-length PPARy cDNA, containing the V5 tag, cloned into a mammalian
expression vector. The efficiency of transfection was verified in cells transfected
with the same vector containing the green fluorescent protein gene and was
-55% (Fig. 21). Since PPARy is a phosphoprotein whose activity is regulated by
phosphorylation in addition to ligand binding (Chana etal. 2004), the levels of
phosphorylated form of PPARy were evaluated in transfected cells which
expressed more phosphorylated PPARy under basal conditions and upon
pioglitazone treatment (Fig. 21).
To further test the involvement of PPARy in response to pharmacological
manipulation we used the small interfering RNA method. The efficiency of the
transfection was verified by fluorescent microscopy of cells transfected with Cy3
luciferase-labeled oligonucleotides and was > 90%. Maximal inhibition of mRNA
has been achieved after 24-48 hours whereas minimal protein levels were
measured 48 to 72 hr after transfection. Based upon these data we performed
the experiments 36 hours post-transfection, with an additional 12 hours of
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Figure 21 Efficiency of transient transfection for primary renal proximal tubule
epithelial cells (RPTEC) by nucleofection method.
36 hours after cells were transfected with plasmid expressing green fluorescent
protein (GFP) (pcDNA3.1/GFP) the efficiency of transfection was verified by
microscopy. Top panel: Microscopic images of transfected cells taken with phase
contrast (left) and fluorescence optics (right). On average, the efficiency of
transfection was ~55%. The overexpressed PPARy, which contains a C-terminal
peptide encoding the V5 epitope, was detected by western blot using a anti-V5HRP antibody (shown on far right). Bottom panel: Representative immunoblot of
transfected and non-transfected RPTEC in basal conditions and with pioglitazone
treatment probed with antibody against the phosphorylated form of PPARy.
Transfected cells expressed more phosphorylated PPARy under both conditions.
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Figure 22 Efficiency of transient transfection with small interfering RNA (siRNA)
for primary renal proximal tubule epithelial cells (RPTEC) using X-tremeGene
siRNA Transfection Reagent.
Top panel: Representative results of transfection efficiency 24 hr after
transfection of RPTEC with Cy3-Luciferase siRNA. The efficiency of the
transfection was > 90%. Middle panel: Representative RT-PCR showing
expression of PPARy mRNA at 24, 48, 72 hours in RPTEC transfected (T) or
non-transfected (NT) with siRNA (left). Transfection was most effective between
24 and 48 hours. Representative western blotting of protein expression of PPARy
at 24, 48, 72 and 96 hours post-transfection in cells non-transfected (NT),
transfected (T) or transfected with scrambled oligonucleotides (TS) (right). The
lowest protein expression was detected between 48-72 hours. Bottom panel:
Representative western blotting of transfected and non-transfected RPTEC in
basal conditions and with pioglitazone treatment probed with anti-phospho
PPARy. Expression of pPPARy was virtually undetectable in RPTEC transfected
with siRNA.
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pharmacological stimulation with pioglitazone (Fig. 22). Na,K-ATPase protein
expression was significantly reduced in wild type cells upon pioglitazone
treatment to 50% of the control. Overexpression of PPARy followed by
pioglitazone treatment decreased Na,K-ATPase protein by 65% while silencing of
the receptor abolished the inhibitory effect of the drug (Fig. 23). To diminish
variability of the data from different blots controls are presented as 100% and
treatment values are normalized to controls. Similar changes were estimated in
protein expression of NHE3. In wild type cells pioglitazone significantly
decreased NHE3 levels by 35%, simultaneous overexpression and activation of
PPARy caused reduction of exchanger by 54% while siRNA eliminated the effect
of PPARy activation (no change in protein levels) (Fig. 24). Together, the in vitro
data indicate that pioglitazone exerts its action on human proximal tubule sodium
transporters, Na,K-ATPase and NHE3, via PPARy activation.

4.3 Discussion for Specific Aim #2

In this study we examined the effect of chronic pioglitazone treatment on
systolic blood pressure (SBP) in obese and lean Sprague-Dawley rats on high fat
diet and began to unravel cellular and molecular mechanisms underlying the
observed effects. Pioglitazone (Actos) is an antidiabetic agent that acts primarily
by decreasing insulin resistance and is used in the management of type 2
diabetes. Together with rosiglitazone it belongs to the thiazolidinedione (TZD)
group of drugs which are high-affinity synthetic ligands for PPARy. We reported

119

• • • Control
i
1 PIO

Control

Overexpression Silencing

Figure 23 Na,K-ATPase expression levels in RPTEC following overexpression
or silencing of PPARy and pioglitazone stimulation.
Cells were transiently transfected with either a full length human PPARy cDNA
cloned in a pcDNA3.1/GS vector or with siRNA designed to target a common
sequence in both PPAR-y1 and y2 isoforms. Equal amount of protein from total
homogenates of cells were loaded into 7.5% polyacrylamide gel. Membranes
were immunoblotted with monoclonal anti Na,K-ATPase a1 subunit antibody and
detected by Odyssey Infrared Imaging System. Membranes were stripped and
reprobed with anti-tubulin which served as a loading control. Results are
expressed as a percentage of the controls of Na,K-ATPase/tubulin ratio to
minimize variability between different blots. Values are mean ± SD from 3-5
experiments performed in duplicate. Significance was determined using unpaired
two tail t-test and the null hypothesis was rejected for a p-value <0.05. *=
significant compared to control.
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Figure 24 NHE3 expression levels in RPTEC following overexpression or
silencing of PPARy and pioglitazone stimulation.
Cells were transiently transfected with either a full length human PPARy cDNA
cloned in a pcDNA3.1/GS vector or with siRNA designed to target a common
sequence in both PPAR-y1 and y2 isoforms. Equal amount of protein from total
homogenates of cells were loaded into 7.5% polyacrylamide gel. Membranes
were immunoblotted with polyclonal anti NHE3 antibody and detected by
Odyssey Infrared Imaging System. Membranes were stripped and reprobed with
anti-tubulin which served as a loading control. Results are expressed as a
percentage of the controls of NHE3/tubulin ratio to minimize variability between
different blots. Values are mean ± SD from 3-5 experiments performed in
duplicate. Significance was determined using unpaired two tail t-test and the null
hypothesis was rejected for a p-value <0.05. *= Significant compared to control.
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that 4 week pioglitazone treatment lowered SBP by ~18 mmHg in obesity-prone
(OP) rats while having no effect on blood pressure of obesity-resistant (OR) rats
on a high fat diet. To date, there is extensive evidence that PPARy agonists
reduce blood pressure in a wide range of insulin-resistant (Yoshimoto et al. 1997,
Walker et al. 1999) as well as in non-insulin-resistant animal models of
hypertension (Zhang et al. 1994), and in human studies of diabetic or nondiabetic hypertensive subjects (Ogihara etal. 1995, Fullert etal. 2002). The
effects of these PPARy agonists on blood pressure in normotensive rats and
humans are not very conclusive. Song et al. reported a decrease in blood
pressure in normal rats after treatment with rosiglitazone (Song et al. 2004) while
Tanimoto etal. reported no change in systemic blood pressure in diabetic KK/Ta
mice treated with pioglitazone for 4 or 8 weeks (Tanimoto et al. 2004). Moreover,
Zanchi and coworkers demonstrated that in healthy human subjects chronic
administration of pioglitazone did not alter blood pressure (Zanchi et al. 2004).
The discrepancy between the study by Song and our results could most likely be
explained by differences in the selection of the animal model, the diet, the length
of the treatments, or various TZDs used (rosiglitazone vs. pioglitazone).
Multiple mechanisms have been implicated in the anti-hypertensive effects
of TZDs, including an increase in insulin sensitivity (Uchida etal. 1997, Walker et
al. 1999), direct vascular effects (Diep et al. 2002, Ryan et al. 2004), modulation
of endothelial vasoactive factors (Fujiwara et al. 1998) and direct renal action
(Isshiki et al. 2000). The renal related effects of TZDs explained the fluid
retention and edema, a serious side-effect, induced sometimes by TZD treatment
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in both animals and humans (Yang et al. 2003, Zanchi etal. 2004). The present
study was undertaken to elucidate the renal mechanisms of blood pressure
lowering effects of TZDs. This could further facilitate our understanding of the
complex renal effects of TZDs. We showed that sodium excretion was similar
under chronic conditions in all the experimental groups. However, when
challenged with acute volume expansion, lean rats treated with pioglitazone
excreted significantly less sodium than obese rats. Glomerular filtration rate
(GFR) remained the same in all the groups. In accordance with our data, studies
by Yang et al. and Zanchi et al. showed no change in GFR after TZD treatment in
animal and humans, respectively (Yang et al. 2003, Zanchi et al. 2004).
Conversely, a study by Song et al. reported that acute, three-day administration
of rosiglitazone, reduced the GFR, measured indirectly as creatinine clearance,
(Song et al. 2004). It remains to be reconciled whether or not this discrepancy is
related to the methods used to estimate GFR or differences in other experimental
protocols such as the length of the treatment, the choice of the animal model or
dietary regimen.
Our study demonstrated that in an animal model of obesity-induced
hypertension pioglitazone lowers blood pressure without effecting renal
parameters or sodium excretion while in normotensive lean rats it caused no
difference in blood pressure even as it lead to sodium retention with no change in
GFR. As we did not observe an alteration in renal hemodynamic parameters
following treatment with pioglitazone we proceeded to evaluate the ability of
TZDs to directly influence tubular reabsorption. We focused our work on the
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proximal tubule since we showed in the previous aim that in our model of dietinduced hypertension the blunted pressure natriuresis and diuresis was mediated
by increased sodium reabsorption in this segment of the nephron.
We evaluated expression, activity and distribution of two sodium
transporters: Na,K-ATPase and Na+/H+ exchanger type 3 (NHE3) in obese and
lean Sprague-Dawley rats chronically treated with pioglitazone. We reported that
Na,K-ATPase protein expression was increased by pioglitazone in obese and
lean rats while its activity was stimulated only in the OP group. This is difficult to
reconcile with the observed reduction in blood pressure in obese rats treated with
pioglitazone and a lack of changes in sodium excretion in this group. The reason
for this is not clear but our less than pure basolateral membrane preparations
could be one probable cause. Renal cortex is enriched in proximal tubules but it
also contains other nephron segments such as the thick ascending limb of
Henle's loop, distal convoluted tubule, and connecting tubule. All these segments
express Na,K-ATPase in the epithelial cell basolateral membranes and may also
contain other pumps which are ouabain sensitive such as H+,K+-ATPase
(Beltowski & Wojcicka 2002). A contamination with intracellular membranes
although unlikely, remains a possibility. A lower than expected ouabain
inhibitable activity was found consistently in our membrane preparations. In OR
rats treated with pioglitazone, an increase in Na,K-ATPase abundance correlated
well with reported stimulation of sodium reabsorption in these animals but did not
explain the lack of difference in their blood pressure after the treatment. The
discordant data between activity and expression of Na,K-ATPase in this group
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could be attributed to a redistribution of enzyme subunits to intracellular
organelles (early endosomes) during Na,K-ATPase inhibition as suggested by
Chibalin etal. in opposum kidney (OK) cells (Chibalin etal. 1998).
Another regulatory mechanism for Na,K-ATPase activity involves the
cytoplasmic sodium concentration (Soltoff & Mandel 1984) and the levels of
circulating hormones such as dopamine (Meister & Aperia 1993) and insulin
(Sweeney & Klip 1998). There are reports showing defects of dopamine
receptors (D1) in proximal tubules of spontaneously hypertensive rats (SHR)
(Kinoshita, S. etal. 1989) which lead to blunted pressure natriuresis (Felder etal.
1990). Similarly, dopamine was unable to inhibit the activity of Na,K-ATPase and
NHE3 in proximal tubules of obese Zucker rats (Hussain etal. 1999). Umrani and
co-workers reported that PPARy activation restores renal dopamine receptor
function in obese Zucker rats by lowering plasma insulin levels (Umrani etal.
2002). Although we did not measure dopamine receptors in our model, it is
probable that the same effect was achieved in our study. In addition to dopamine,
insulin exerts both short and long-term effects on Na,K-ATPase. Nevertheless, in
diabetic experimental models, effects of PPARy activation are rather
controversial. An increase in whole kidney and cortical Na,K-ATPase activity was
reported by Ng etal. in streptozotocin-induced diabetic rats (Ng etal. 1993) and
by Bickel et al. in obese Zucker rats at 2 and 4 months of age (Ng et al. 1993,
Bickel etal. 2001); no change in cortical Na,K-ATPase expression was found in
6-month old obese Zucker rats (Bickel et al. 2002). Furthermore, Song et al.
have demonstrated that a 3 day treatment with a PPARy agonist increased the
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renal abundance of Na,K-ATPase in normal Sprague-Dawley rats (Song etal.
2004). Riazi et al. reported that 12 week treatment with rosiglitazone also
increased the whole kidney expression of Na,K-ATPase in obese Zucker rats
(Riazi etal. 2006) whereas Umrani etal. showed that4 week rosiglitazone
treatment of obese Zucker rats attenuated the increased Na,K-ATPase activity
(Umrani etal. 2002). In OP rats Dobrian etal. reported increased levels of
insulin (Dobrian et al. 2004). This may account for differential regulation of Na,KATPase in different animal models. Moreover, the disagreement between
different studies indicate that not only insulin but additional factors such as age
and other hormones interacting together can influence Na,K-ATPase activity.
Although TZDs effectively attenuate insulin resistance in hyperinsulinemic states
they do not affect sodium transporters in an unequivocal way. This suggests that
the effects of PPARy stimulation on sodium transporters is dependent on the
length of treatment, animal model used (normal versus obese versus lean treated
high fat diet), the metabolic milieu of the animal, or type of TZD used.
We also examined the effect of PPARy activation on the apical
sodium/hydrogen exchanger type 3 (NHE3). NHE3 is one of the most regulated
transport proteins. It can be modulated by changes in expression, alterations in
intrinsic activity without changes in NHE3 protein abundance (Soleimani etal.
1995), phosphorylation status (Moe 1999), changes in trafficking (Biemesderfer
et al. 2001), and presence or absence of its regulatory factors (NHERF) (Yun et
al. 1997). Pioglitazone treatment decreased NHE3 protein expression in lean rats
without a reduction in the activity of the transporter. We also found a
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redistribution of NHE3 towards the top of the villus in the lean rats, which may
account for the lack in activity change despite a reduction in protein abundance.
In the obese rats we did not find a change in NHE3 membrane distribution and a
reduction in both protein abundance and activity. These results suggest that both
abundance and distribution of NHE3 are important for activity of the transporter.
The results for both OP and OR groups correlate well with changes in sodium
reabsorption reported in this Aim. However, this data further implies that ability to
respond to TZDs can vary depending on the metabolic state of the subject (lean
versus obese). Based on the reports by Hall (Hall 2003) and the results from this
and the previous aims we may conclude that obese rats present with the
expansion of extracellular fluid volume and most likely can not retain much fluid
when challenged with acute saline loading. On the other hand, lean rats treated
with pioglitazone react to acute volume expansion with the disproportionate
expansion of the extracellular space which finally leads to fluid retention. Further
studies are needed to address these observations.
In obese rats treated with pioglitazone, reduction in expression and activity
of NHE3 at the proximal tubule level could explain a drop in systolic blood
pressure. On the other hand, the lack of changes in sodium excretion in this
group could possibly be justified by an upregulation of other transporters in this
or other nephron segments. These transporters include, among others, the
sodium phosphate cotransporter subtype II (NaPi-2), at proximal tubule level and
the amiloride-sensitive sodium channel (ENaC) in the collecting duct (Knepper
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2002). Circumstantial evidence provided by this study suggests that stimulation
of NaPi-2 and ENaC represents a potential alternative.
Since our animal model of diet-induced obesity makes difficult the in vivo
assessment of a direct effect of TZDs on PPARy activation, we examined the
latter in vitro in human renal proximal tubule epithelial cells (RPTEC). We
modulated PPARy pharmacologically or by gene overexpression or silencing.
Protein expression of Na,K-ATPase was decreased upon activation of PPARy by
the natural and synthetic ligands PGJ2 and rosiglitazone, respectively and was
increased by PPARy inhibitors GW9682 and BADGE. Moreover, overexpression
of the receptor followed by its activation led to reduction in Na,K-ATPase protein
expression. This effect of pioglitazone was abolished in cells transfected with
siRNA for PPARy, providing evidence that pioglitazone requires the expression of
peroxisome proliferator-activated receptor gamma in order to reduce Na,KATPase protein expression.
There are a few proposed mechanisms through which PPARy activators
can negatively regulate expression of other genes. The transcriptional
suppression of Na,K-ATPase could be due to a direct binding of activated PPARy
to the PPAR-response element in the gene promoter, as previously described for
the sex hormone-binding globulin gene (Selva & Hammond 2009) and for TZDs
inhibition of B3-adrenergic receptors (Bakopanos & Silva 2000). Alternatively,
inhibitory effects might occur independent of a PPAR binding site by a physical
interaction with other transcription factors in a process called trans-repression.
For instance, sumoylation of PPARy ligand-binding domain leads to prevention of
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the ubiquitylation machinery that normally mediates the signal-dependent
removal of corepressor complexes required for gene activation as was noted for
inducible nitric oxide synthase (iNOS) (Pascual etal. 2005). The trans-repression
mechanism is indirectly supported by the lack of PPRE element in the promoter
of human a1-subunit Na.K-ATPase (mapped data supplied by NCBI
ID:NM_000701.6) as determined using Genomatix Matlnspector software
(Genomatix Software Inc., Ann Arbor, Ml).
Nevertheless, it was surprising that the effects of PPARy activation on
sodium transporters expression in vivo and in vitro were contradictory. We
observed an increase in Na.K-ATPase expression in the former experiments and
a reduction in the latter after treatment with pioglitazone. This discrepancy could
most likely be clarified by the fact that very different preparations were used for
these experiments. As already discussed, baso-lateral fractions prepared from
the rat kidney were not very pure and could contain some other segments of
nephron as well as some intracellular membranes. On the other hand, for our in
vitro measurements we used a pure preparation of renal proximal tubule
epithelial cells. Furthermore, the metabolic milieu in vivo may have important
influences on the transporters modulation as previously discussed. Finally, it is
very likely that in our in vivo model of diet-induced obesity and in vitro cell culture
model PPARy expression and activity levels are different.
Similarly, we conducted in vitro experiments to investigate whether
pioglitazone modulates NHE3 expression via a PPARy related mechanism. The
effects measured for Na.K-ATPase were mirrored by the results obtained for
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NHE3. Protein expression of NHE3 was decreased upon activation of PPARy by
the natural or synthetic ligands PGJ2 and rosiglitazone, respectively and was
increased by PPARy inhibition by GW9682 and BADGE. Stimulation of PPARy in
cells overexpressing the receptor led to a reduction in NHE3 abundance while
having no effect in cells transfected with PPARy siRNA. Thus, we concluded that
pioglitazone requires the presence of peroxisome proliferator-activated receptor
gamma in order to exert its inhibitory effect on NHE3 protein expression. Studies
by Oliver et al. showed that troglitazone inhibited NHE3 activity in proximal
tubule-like LLC-PK1 cells (Oliver et al. 2005). Also, de Dios et al. showed that
acute exposure to troglitazone but not rosiglitazone, inhibits Na/H exchange
activity in cultured bovine endothelial cells (de Dios etal. 2001).
As discussed before for Na,K-ATPase, inhibition of NHE3 gene
transcription by activated PPARy can take place by binding to peroxisome
proliferator responsive element (PPRE) in the gene promoter (Selva & Hammond
2009) or by trans-repression mechanisms (Pascual et al. 2005). Since human
NHE3 does not contain a putative PPRE sequence in the promoter based on
software analysis of the promoter sequence (Genomatix Software Inc., Ann
Arbor, Ml) it is unlikely to have a direct NHE3 transcriptional effect. However, in
the rat NHE3 promoter (GeneBank # S833406) a putative PPRE sequence is
reported (Genomatix Matlnspector software; Genomatix Software Inc., Ann
Arbor, Ml) suggesting a possible direct transcriptional regulation of NHE3 gene
and implying that the PPARy signaling pathway may be species-specific.
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In addition, some of the pleiotropic actions of PPARy synthetic ligands on
cellular function may involve pathways other than the classical PPARy mediated
pathway (Rangwala & Lazar. 2004). These involve Mitogen Activated Protein
Kinase Kinase (MEKK) (Takeda. etal. 2001) and mitochondrial AMPK (AMPactivated protein kinase) activation (Feinstein etal. 2005). Turturro etal.
demonstrated an inhibitory effect of troglitazone on NHE3 activity in proximal
tubule-like LLC-PK1 cells and proposed that physiological responses to TZDs
may reflect the interaction of more than one pathway (Turturro et al. 2007). This
opens the possibility that in RPTEC PPARy activation may use different
pathways to exert effects on NHE3 expression and activity. However, further
studies are warranted to examine the involvement of these different pathways.
In summary, the in vitro study demonstrated that pioglitazone can inhibit
protein abundance of Na,K-ATPase and NHE3 by directly activating PPARy. In
vivo the reduction in blood pressure in obese animals was correlated with
reduced NHE3 activity due, at least partially, to a reduction in protein expression
without significant changes in transporter trafficking. Besides, pioglitazone
stimulated basolateral Na,K-ATPase in the renal tubules. Also, blood pressure of
lean rats was not changed following chronic pioglitazone treatment but sodium
reabsorption was significantly increased.
Clearly, further in vivo studies are needed to determine the expression
and activity of other sodium transporters along nephron length in obese and lean
rats fed a high fat diet to complement our understanding of physiological
processes underlying their diverse responses to PPARy activation.
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SECTION 5
STUDIES FOR SPECIFIC AIM #3

5.1 Materials and Methods for Specific Aim #3

Animals
The animal husbandry and separation into groups was done as described
in methods for specific Aim #1. After 8 weeks on the diet the OP and OR groups
were randomly divided into 2 sub-groups (each with n of 6): 1) no treatment, diet
only: NT-OP/NT-OR and 2) treatment with 1.2 mg kg"1day"1 NG-nitro-L-arginine
methyl esther (L-NAME, Sigma-Aldrich, Saint Louis, MO) in drinking water for 4
additional weeks (L-OP/L-OR). This dose of L-NAME has been reported not to
increase mean arterial pressure (Cadnapaphornchai etal. 2001). Body weights
and food intake were measured weekly as mentioned in section 4, water intake
was determined every other day during treatment with L-NAME (Fig. 25). For
part of the study in which the effects of L-NAME on pressure natriuresis were
evaluated, different groups of rats were used than for studies involving regualtion
of sodium transporters. However, both groups followed the same dietary and
treatment protocols.

Surgical procedure for acute pressure natriuresis experiments
The surgical procedure was modified from Khraibi etal. (Khraibi 2000)
and performed as previously described in the Material and Methods part of
specific Aim #1.
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Figure 25 Research design for specific aim #3A.
Male, 3 months old Sprague-Dawley rats were started on moderately high fat diet
(MHF) a week after arrival to the facility. Before and after treatment, rats from all
groups were placed in metabolic cages for 24 hour urine collection. Non-treated
groups OP and OR were placed in metabolic cages only once, right before
surgeries. Water intake and urine volume was recorded and urine was analyzed
for Na+ content. Starting with week 8th of the diet each group: OP and OR was
further divided into 2 subgroups and was treated for additional 4 weeks with: 1.2
mg"1 kg"1 L-NAME in drinking water or left untreated (diet only). After 4 weeks of
treatments, and total of 12 weeks of the diet, acute measurements of renal
function were performed during surgical procedure.
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Physiological parameters
All physiological parameters were assessed, measured and calculated
as described in the Material and Methods section for Aim #1.

Baso-lateral membrane (BLM) and brush border membrane vesicles
(BBMV) preparations
BLM and BBMV fractions of renal cortexes from nontreated animals and
rats treated with pioglitazone were prepared using the same protocols as
described in the Material and Methods paragraph for Aim #1.

Western Blotting on BLM and BBMV preparations
Na,K-ATPase and NHE3 protein expression were assessed by western
blotting as described in the Material and Methods paragraph for Aim #1.

Activity of Na.K-ATPase and NHE3
Na,K-ATPase activity was measured in freshly obtained BLM
preparations and NHE3 activity was measured in freshly obtained BBMV
fractions as previously described in the Material and Methods paragraph for
Aim #1.

Immunocvtochemistry, image analysis and data collection
Colocalization of NHE3 (green) and villin (red) were evaluated on paraffinembedded sections of kidney from untreated and treated animals; images were
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recorded by confocal fluorescent microscopy and overlapping of both colors were
analyzed by MetaMorph software as described in the Material and Methods
paragraph for Aim #1.

Nitrite/nitrate Measurement
Total nitrite/nitrate levels were determined as a measure of NO production
in urine collected from untreated and treated animals during a 24 hr period and in
the supernatant from treated and control cells using an enzymatic kit (R&D
Systems, Minneapolis, MN). This assay determines NO concentrations based on
the enzymatic conversion of nitrate to nitrite by nitrate reductase, which is
followed by colorimetric detection of nitrite. A set of standards was assayed in
duplicates along with the samples. The background was subtracted from each
reading, and the average optical density was calculated. The values were
represented as micromole of nitrite/nitrate per milliliter.

Cell culture and treatments
The initial batch of human renal proximal tubule epithelial cells (RPTEC)
was purchased from Lonza, Inc (Walkersville, MD) and was grown in the media
recommended by the supplier-REBM, containing 5% fetal bovine serum. RPTEC
were always used between passage 3 and 6. They were seeded at a density of
3.3 x 105per 100 mm plate for western blotting and grown to ~80% confluence
before the start of the experiments. For measurements of cGMP cells were
seeded at 1 x 105 cells per well on 12-well plates 48 hours before experiments.
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Cells were kept in serum and insulin-free medium 24 hrs before experiments. At
first, RPTEC were treated with NO donor S-nitro-acetylpenicillamine (SNAP,
Cayman Chemical, Ann Arbor, Ml) at various concentrations (10"4 M, 10"5 M, 10"6
M) for 5 min, 30 min and 2 hrs in the presence of 1 mM 3-lsobutyl-1methylxanthine (IBMX, Sigma, Saint Louis, MO). In the next step of the study,
cells were preincubated with 1 mM IBMX and incubated with SNAP (10"5 M) and
oxadiazolo-quinoxaline (ODQ, 10"4M, Sigma, Saint Louis, MO), a guanylyl
cyclase inhibitor or Probenecid (10"4M, Sigma, Saint Louis, MO) which blocks an
organic anion transporter (OAT). Next, RPTEC were preincubated withl mM
IBMX and incubated with different concentrations of Angiotensin II (10"6M, 10"7
M, 10"8M)( Sigma-Aldrich, Saint Louis, MO), Leptin (15 ng ml"1, 30 ng ml"1, 45 ng
ml"1 and 60 ng ml"1) (Calbiochem, San Diego, CA) and Insulin (10"7M, 10"8M, 10"
9

M)( Sigma-Aldrich, Saint Louis, MO ) for 2 hrs in the presence or absence of

SNAP (10"6 M). Finally, cells preincubated with 1 mM IBMX were treated with the
selected concentrations of Angiotensin II (10"8M), Insulin (10"9M), Leptin (45 ng
ml"1) with or without SNAP (10"5 M) in the absence or presence of Probenecid
(lO^M).

cGMP measurements
cGMP measurements were performed using a commercially available
competitive enzyme immunoassay (EIA) kit (Cayman Chemical, Ann Arbor)
following the instructions by the manufacturer. Levels of cGMP were initially
assessed in the supernatant and cell lysates in the presence of 1 mM of IBMX

136
under basal conditions and upon treatments with different concentrations of
SNAP at various time points. In the next step, levels of cGMP were assessed in
the cells preincubated with 1 mM IBMX and incubated with SNAP (10"5M) and
ODQ (10"4M) or Probenecid (10 4 M). Also, cGMP levels were tested in the
supernatant and cell lysates of the cells preincubated withl mM IBMX and
incubated with different concentrations of angiotensin II, leptin, and insulin for 2
hrs in the presence or absence of SNAP (10"6 M). Afterwards cGMP levels were
tested in supernatant or cell lysates preincubated with 1mM IBMX and incubated
with angiotensin II (10"8M), insulin (10"9M), leptin (45 ng ml"1) with or without
SNAP (10"5 M) in the absence or presence of Probenecid (10"4 M). cGMP
measurements were performed in the medium and cell lysates to test extra- and
intracellular levels of cGMP, respectively. Medium from the wells were aspirated
and cells were extracted according to the protocol provided and both
preparations were stored at -80 °C for further tests. All samples were acetylated,
diluted, and sampled in duplicates.

Protein preparation from RPTEC and Western blotting
Na,K-ATPase and NHE3 protein expression was assessed in membrane
fractions of RPTEC which were prepared using Compartmental Protein
Extraction Kit (Chemicon, Billerica, MA) according to the protocol from
manufacturer. For assessing levels of phosphorylated forms of sodium
transporters, membrane fractions were prepared during different steps of
centrifugation. Cell pellets were homogenized in RIPA buffer without
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detergents, with 5% sorbitol, 1 mM PMSF, 1 mM NaF, 1 mM Na 3 V0 4 final
concentration, Protease Inhibitor Cocktail (Sigma Aldrich, Saint Louis, MO) at
1:1 000 dilution and additionally 1:100 dilution of Phosphatase Inhibitor
Cocktail (Sigma Aldrich, Saint Louis, MO) for phosphoantibodies. After
incubation on ice, samples were centrifuged at 4 800 rpm for 10 min.
Supernatants were transferred and centrifuged again at 38 000 rpm for 90 min.
Pellets produced were reconstituted in RIPA buffer as described above. Protein
concentrations for each lysate were determined by using a BCA protein assay
kit (Pierce Chemical) with BSA as a standard. Western blot protocol was
followed as described in Materials and Methods paragraph for specific Aim #1
with the exception of some antibodies used. The following antibodies were
used: polyclonal anti-NHE3 (Chemicon, Billerica, MA, 12 \xg ml"1), monoclonal
antibody against phosphoNHE3 [Ser 552] (Novus Biologicals, Littleton, CO; 12
jxg ml"1), monoclonal Na,K-ATPase (Upstate , Lake Placid, NY,1:10 000
dilution) and polyclonal phospho Na,K-ATPase [Ser 16] (Cell Signaling
Technology, Danvers, MA; 1:500 dilution). Antigen detection was performed
using appropriate secondary antibodies conjugated to fluorescent tag (IRDye
680 and IRDye 800) at 1:15 000 dilution for 45 minutes at RT. Membranes
were scanned using the Odyssey Infrared Imaging System (Li-Cor Biosciences,
Lincoln, NE). Membranes probed with phospho antibodies were scanned and
then stripped with Western Re-probe Buffer (Geno Technology, Inc, St. Louis,
MO) according to the protocol provided and incubated with antibodies
.recognizing total form of transporters. Semi-quantitative analyses of the specific
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bands were performed using Li-Cor Odyssey software. Results were expressed
as the ratio of membrane to cytosolic fractions or phospho to total form in
relative fluorescence units (RFU).

Statistical analysis
Results are presented as mean ± standard error of mean (SEM) of the
indicated number of experiments unless stated otherwise. Statistical analysis
was performed using Student's t test and non-parametric test for unpaired data
(treatment versus control), or by analysis of variance (ANOVA) and Holm-Sidak
or Student-Newman-Keuls post-hoc for multiple group comparisons, as
appropriate using InStat software (San Diego, CA). The null hypothesis was
rejected for a p-value<0.05.

5.2 Results for Specific Aim # 3

In vivo experiments
Physiological parameters
After 12 weeks of the moderately high fat diet (MHF) final body weights
(BWs) of obese rats nontreated or treated with 1.2 mg"1 kg"1 day"1 L-NAME for 4
weeks were significantly higher then lean rats ( OP-781.0 ± 33.4 g vs. OR-633.5
± 2.8 g; L-OP-821.0 ± 10.6 g vs. L-OR-658.0 ± 13.6 g)(Fig. 26a). As in earlier
studies, obesity prone rats weighted significantly more than obesity resistant rats
and treatment with L-NAME did not affect BWs. Total fat content remained 45%
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Figure 26 Final measurements of the body weights (BW) and total fat in obese
(OP) and lean (OR) rats with or without L-NAME treatment.
Body weights represent averages for each group from the last week of the diet
before sacrifice. Total visceral fat represents sum of epididymal and
retroperitoneal fat. Values are mean ± SEM from n = 6 rats/group. Significance
was determined using one-way ANOVA with Holm-Sidak modification for multiple
group comparisons and null hypothesis was rejected for a p-value <0.05. Obese
rats treated or not were significantly heavier then corresponding group of lean
rats and those differences were paralleled by changes observed in the amount of
total fat.

higher in the OP group treated with L-NAME compared to the OR group and
paralleled changes observed in BWs (54.6 ± 2.5 g vs. 37.6 ± 2.2 g) (Fig. 26b). At
the end of the dietary protocol, during the surgical procedure, mean arterial
pressure (MAP) was measured (Fig. 27) and we found no significant differences
in MAP between the experimental groups.
To ensure equal effectiveness of L-NAME treatment, metabolites of nitric
oxide (NO) nitrate and nitrite were assessed in urine collected for 24 hours in
metabolic cages. Levels of NOx in urine were not different between OP and OR
groups (6.95 ± 1.0 |amol ml"1 vs. 6.61 ±1.1 ^mol ml"1, respectively). Treatment
with L-NAME caused a decrease in NO production to 4.2 ± 0.3 |j.mol ml"1 in
obese rats and to 3.7 ± 0.4 (xmol ml"1 in lean rats but failed to gain significance by
an extremely small margin (p=0.052) in the former (Fig. 28). Daily water intake
from 8th to 12th week of the diet was used to assess the L-NAME dose received
since the drug was delivered in drinking water. Average daily water intake was
increased in the OP group compared to the OR group: 42.3 ± 2.0 ml day"1 vs.
35.8 ± 1.6 ml day"1 (data not shown) suggesting that L-NAME levels were
comparable between the groups when adjusted for differences in body weights.

Acute pressure natriuresis and diuresis in OP and OR rats treated with LNAME
During the surgical procedure, animals from all experimental groups were
challenged with an increase in renal perfusion pressure (RPP). At low RPP there
were no differences in urine flow rate (V) between treated and nontreated obese
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Figure 27 Mean arterial pressure (MAP) in OP and OR groups non-treated or
treated with nitric oxide synthase inhibitor (L-NAME).
MAP was measured and recorded continuously during surgical procedure. LNAME was administered in drinking water at dose which is known not to induce
hypertension. There was no difference in MAP between the study groups. Values
are mean ± SEM from n = 6 rats/group. Significance was determined using oneway ANOVA with Holm-Sidak modification for multiple group comparisons and
null hypothesis was rejected for a p-value <0.05.
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Figure 28 Final measurements of urinary nitrate and nitrite (NOx) levels in OP
and OR rats with or without L-NAME treatment.
Metabolites of nitric oxide were measured in urine collected over a period of 24
hours by using an enzymatic method and stored at -80 °C until used for an
assay. Each sample was diluted in order to produce values within the dynamic
range of the test and then assayed in duplicates. Background was subtracted
from the average measurements and concentrations normalized to 24 hr urine.
Values represent mean ± SEM from n = 6 rats/group. Significance was
determined using one-way ANOVA with Student-Newman-Keuls method for
multiple group comparisons and null hypothesis was rejected for a p-value <0.05.

and lean rats. In OR rats treated with L-NAME, elevation in RPP provoked a
significantly lowered increase in urine flow rate (V) compared to nontreated
animals (OR: 53.25 ± 15.7 [i\ ml"1, L-OR: 23.5 ±4.1 |LLI ml"1) while having no
significant effect on V in OP rats (Fig. 29a). This result suggests that L-NAME
treatment reduced the diuretic response in lean rats whereas obese rats did not
respond to NO inhibition in the same manner.
There were no differences in glomerular filtration rate (GFR) among the
study groups with or without NOS inhibition at either low or high RPP suggesting
that L-NAME treatment did not impair autoregulatory function of the kidney in the
interval of RPP employed in the experiment (Fig. 29b).
Pressure natriuresis was assessed by urinary sodium excretion (UNaV)
and fractional excretion of sodium (FENa) at two different RPP. Treatment with LNAME caused a significant reduction in UNaV in OR group at higher RPP from
9.97 ± 3.63 nEq min"1 to 1.13 ± 0.45 |aEq min"1 and did not change urinary
sodium excretion in OP group (Fig. 30a). Change in FENa showed the same
pattern: at high RPP lean rats treated with L-NAME had a significant decline in
fractional excretion of sodium compared to their nontreated counterparts from
1.34 ± 0.39% in the latter to 0.27 ± 0.09% in the former while there was no
change in FENa in the obese group (Fig. 30b). The above results indicate that LNAME treatment while uniformly reducing NO production in both groups modifies
pressure diuresis and natriuresis significantly only in the OR group.
Finally, we measured fractional excretion of lithium (FELi) in response to
low and high RPP as a method of assessing proximal tubule function. The
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Figure 29 Relations between renal perfusion pressure (RPP) and urine flow (a)
and glomerular filtration rate (b) in obese (OP) and lean (OR) rats with or without
chronic inhibition of NOS.
During surgical procedure an adjustable clamp was placed around aorta above
renal arteries to control renal perfusion pressure (RPP). At first RPP was set
~100 mmHg and urine collected for 30 min. At the end of this period blood was
drawn from carotid artery for plasma electrolytes, lithium and inulin
measurements. Then RPP was set -140 mmHg and all above procedures were
repeated. L-NAME treatment reduced response of lean rats to high RPP while
having no effect on obese rats. Glomerular filtration rate, calculated as the rate of
inulin clearance remained the same in non-treated and treated OP and OR rats
suggesting that inhibition of NO production did not impair autoregulatory kidney
function. Results are expressed as means ± SEM of n = 4-5 rats/ group.
Significance was determined using one-way ANOVA with Student-NewmanKeuls method for multiple group comparisons and the null hypothesis was
rejected for a p-value< 0.05. *= significant compared to L-NAME treated at a
similar perfusion pressure. §= significant compared to low RPP in the same
group of animals.
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Figure 30 Pressure-natriuresis in obese and lean Sprague-Dawley rats treated
or not with L-NAME.
In acute settings, as described in material and methods paragraph for Aim #1
and also in the previous figure, animals were challenged with the change in RPP
from 98-105 mmHg to 128-145 mmHg. Panel (a): Relation between RPP and
urinary sodium excretion (UNaV). When compared with that in non-treated lean
rats, L-NAME treated OR animals excreted less sodium. Panel (b): Relation
between RPP and fractional excretion of sodium. The changes mirrored those
mentioned previously: L-NAME treated lean rats excreted less sodium than their
non-treated counterparts. Results are expressed as means ± SEM of n = 4-5
rats/ group. Significance was determined using one-way ANOVA with StudentNewman-Keuls method for multiple group comparisons and the null hypothesis
was rejected for a p-value< 0.05. *= significant compared to L-NAME treated at a
similar perfusion pressure. §= significant compared to low RPP in the same
group of animals.

146
increase in the FELi in response to an elevation in RPP was reduced in the OR
group treated with L-NAME compared to the untreated group from 19.8 ± 1.4% to
13.5 ± 5.4% while FELi did not change in the OP group treated with L-NAME vs.
the untreated control (Fig. 31). This result suggests that inhibition of NO
production impairs natriuresis and diuresis in the OR rats at least partially
through a proximal tubule related mechanism. Moreover, in our previous aims we
focused our efforts on this segment of the nephron. Therefore, we again
examined the expression, activity and localization of two of proximal tubule
transporters: Na,K-ATPase and NHE3 in the separate set of experiments as
described in the methods.

Activity, protein expression and localization of Na.K-ATPase and NHE3 in
OP and OR rats treated with L-NAME for 4 weeks
Activity of any transporter is the interplay of several factors which could
act alone or in combination and include protein expression, membrane trafficking,
interaction with regulatory factors or substrate affinity.
In this aim we started to investigate some of the mechanisms that could
lead to changes in natriuresis and diuresis in obese and lean rats chronically
treated with nitric oxide synthase (NOS) inhibitor L-NAME observed in first part of
the study. Protein expression of basolateral transporter Na.K-ATPase was
measured by western blotting in basolateral membrane preparations (BLM) from
renal cortex. The membranes were stained with Ponceau Red to insure equal
loading of the gels. L-NAME treatment significantly elevated protein abundance
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Figure 31 Fractional excretion of lithium (FELi) at low and high RPP in obese
and lean Sprague-Dawley rats with or without chronic NO depletion.
During surgical intervention rats were infused with lithium and after the
experiment lithium concentrations in urine and plasma were measured. FELi was
calculated as the ratio between its urinary excretion and the amount filtered and it
was used as a marker for the proximal tubule function. NO depletion produced a
reduction in response to high RPP in OR group but not in OP rats. Results are
expressed as means ± SEM of n = 4-5 rats/ group. Significance was determined
using one-way ANOVA with Student-Newman-Keuls method for multiple group
comparisons and the null hypothesis was rejected for a p-value< 0.05. *=
significant compared to L-NAME treated at a similar perfusion pressure. §=
significant compared to low RPP in the same group of animals. # = borderline
significance (0.05<p-value<0.07) compared to the low perfusion pressure.
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of Na,K-ATPase from 30.69 ± 0.69 RFU to 40.24 ± 2.43 RFU in lean rats and did
not affect Na,K-ATPase expression in the OP group (Fig. 32). Induction of Na,KATPase protein expression could at least partially explain the decrease in
urinary sodium excretion and fractional excretion of sodium observed after
chronic administration of L-NAME in obesity resistant rats by association with
pump activity. However, those changes were not reflected in our estimation of
Na,K-ATPase activity measured as a release of inorganic phosphate from
freshly prepared BLM. There was no difference in Na,K-ATPase activity between
treated and nontreated groups of obese and lean animals (Fig. 33). This
discrepancy between expression and activity could most probably be explained
by different mechanisms of Na,K-ATPase activity regulation in normal and
hyperinsulinemic states deprived of NO. Lack of correlation between activity and
pressure diuresis and natriuresis in the lean group could be clarified by the
approach used during basolateral membrane preparation and in a consequence
partial contamination of basolateral membranes by apical membranes or different
nephron segments. Moreover, ouabain-sensitive Na+,K+-pump activity accounted
for about 38 and 36% of total activity of BLM fractions from obese and lean rats
treated with L-NAME (data not shown), respectively; again suggesting that our
preparations were impure and contained other pumps insensitive to ouabain like
H\K+-ATPase from proximal tubule or cortical segments of collecting tubules.
Next, we determined protein expression of the sodium/hydrogen
exchanger type 3 (NHE3) by western blotting in brush border membrane vesicles
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Figure 32 Na,K-ATPase protein expression measured in baso-lateral-enriched
membranes isolated from renal cortex of obese (OP) and lean (OR) rats with or
without L-NAME treatment.
Panel (a): Graph representation of Na,K-ATPase abundance, measured in
arbitrary units, represented as means ± SEM of n = 6 rats/group. Blots were
probed with Na,K-ATPase a1 subunit specific antibody. Semi-quantitative
densitometry analyses were done by using Odyssey Infrared Imaging System
software. Significance was determined using one-way ANOVA and the null
hypothesis was rejected for a p-value< 0.05. Panel (b): Immunoblots of BLM
samples from non-treated and treated OP and OR rats. Each lane represents a
sample from an individual rat. Equal protein loading was ensured by staining
each membrane with Ponceau red. Treatment with L-NAME significantly reduced
expression of basolateral sodium pump in OP and OR rats.
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Figure 33 Effect of L-NAME on Na,K-ATPase activity assessed in baso-lateral
membranes prepared from renal cortexes of obese(OP) and lean (OR) animals.
Na,K-ATPase activity expressed as mmol of inorganic phosphate liberated per
mg of protein per minute performed on freshly prepared basolateral membrane
(BLM) enriched fractions. Na,K-ATPase activity was calculated as the difference
between activities assayed in the absence of ouabain (total) activity and in the
presence of 5 mM ouabain. Values are means ± SEM from 6 rats per group.
Each sample was assayed in duplicate and background was subtracted from the
mean. There was no difference in activities between study groups. Significance
was determined using one-way ANOVA and the null hypothesis was rejected for
a p-value< 0.05.
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(BBMV) from renal cortex. Villin was used as a loading control. The purity of
BBMV was estimated by measuring activity of leucine aminopeptidase N (LAP)
for each sample and comparing it to activity of LAP in the initial homogenate.
According to the protocol from Biber et al. (Biber et al. 2007) an average 18fold
enrichment achieved for all samples provided us with high purity for brush
border membrane vesicles. L-NAME treatment significantly increased expression
of NHE3 in both groups: lean and obese compared to non-treated controls by
-36% and 42%, respectively (Fig. 34). Activity of NHE3 calculated in freshly
obtained BBMV fractions corresponded only partially to the protein
measurements. In obese rats reduction of NO did not change activity of the
exchanger while in lean rats the 42% increase in protein levels was reflected in
~53% increase in activity of NHE3 (Fig. 35). As described earlier in the results
paragraph of Aim #2, sensitivity and specificity of the NHE3 activity assay was
assessed by incubation of randomly chosen samples with various concentrations
of 5-(N-Ethyl-N-isopropyl) amiloride. We concluded that the assay was specific
and sensitive for the NHE3 isoform.
Since changes observed in natriuresis and diuresis could most probably
be elucidated by modifications in abundance and activity of NHE3 in lean rats
treated with L-NAME but not in L-NAME treated obese rats, we pursued another
mechanism of NHE3 activity regulation- membrane trafficking.
As described before, we used immumohistochemistry and image visualization
techniques to quantify localization of NHE3 with regard to villin. Villin was used
as a marker for the microvillus membrane, therefore the higher the degree of
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Figure 34 Na/H exchanger (NHE3) protein abundance after L-NAME treatment
in obese (OP) and lean (OR) rats.
NHE3 was assayed in brush border membrane vesicles (BBMV) fractions
prepared from renal cortex of OP and OR groups treated or not with L-NAME.
Top panel: Densitometric analysis of immunoblots shown below. NHE3
immunoreactivity is expressed as a ratio between NHE3 and Villin signals, in
relative fluorescent units (RFU). Results represent average ± SEM of n=6
rat/group. Significance was determined using one-way ANOVA and the null
hypothesis was rejected for a p-value< 0.05. L-NAME treatment significantly
increased NHE3 protein expression in OP and OR groups. Bottom panel:
Immunoblots of BBMV samples from obese and lean rats. Equal amount of
proteins were loaded into each gel and duplicates of membranes were probed
with anti-villin antibody which served as a loading control. Antigen-antibody
complexes were detected with Odyssey Infrared Imaging System (Li-Cor).
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Figure 35 Na+/H+ antiporter activity in obese and lean rats non-treated (NT) or
treated with L-NAME.
Brush border membrane vesicles (BBMV) prepared from renal cortex were
preloaded with pH indicator BCECF-AM in Na+-free buffer, pH 7.2 and then
mixed with the buffer solution containing 150 mmol I"1 NaCI, pH 9.2 for
determination of pH recovery as described in methods paragraph for Aim #1.
Equal amounts of protein were labeled and readings for unlabeled samples were
subtracted from final values. NHE3 activity was expressed as a change in pH
over time. Values are means ± SEM from 6 rats per group. Significance was
determined using one-way ANOVA and the null hypothesis was rejected for a pvalue< 0.05. L-NAME treatment significantly elevated activity of exchanger in OR
group while did not effect OP group.
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colocalization between villin and NHE3, the more abundant is the transporter in
the microvillus membrane (Fig. 36a). NO depletion had no effect on NHE3
distribution in the OP group (21.46 ± 4.38% vs. 23.29 ± 10.47%) though it
significantly increased colocalization of NHE3 with villin in the OR group from 9.1
± 3.67% to 20.50 ± 5.9% (Fig. 36b). As a result, alterations in NHE3 distribution
may account for an increase in exchanger activity together with an increase in
NHE3 protein expression in lean groups treated with nitric oxide synthase
inhibitor.
In conclusion, similar depletion of NO in obese and lean animals lead to
impairment in pressure natriuresis and diuresis supported by an increase in
activity and expression of NHE3 and its redistribution to the tip of the villus in
concert with elevation of Na,K-ATPase in obesity resistant rats only.
Based on these results the following questions arose: 1) Why did obese and lean
groups react differently to NO inhibition? 2) Are lean rats more sensitive to NO
deprivation or are obese rats more resistant to it? 3) How can those differences
be explained? 4) Does the metabolic state influence the effects of NO on sodium
transport in the proximal tubule in vivo?
As this study did not provide definite information regarding the direct
effects of NO on sodium transport in the proximal tubule in vivo, it seemed almost
imperative to try to explain some of our questions using an in vitro system which
is devoid of any other influences beside those imposed in the experiment.
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Figure 36 Changes in NHE3 distribution in obese and lean rats after chronic
treatment with L-NAME.
4 micron sections of paraffin embedded kidneys were double stained with
polyclonal NHE3 antibody and with monoclonal anti-villin antibody followed by
the corresponding anti-rabbit (AlexaFluor488-green) and anti-mouse
(AlexaFluor594- red) secondary antibodies. Panel (a): Representative images of
cortical tubules from all experimental groups stained simultaneously with NHE3
(A, B, C, D) and villin (E, F, G, and H). Overlapping (I, J, K and L) of NHE3 and
Villin appears yellow. Chronic L-NAME administration caused NHE3
redistribution in lean rats and did not have an effect in the obese group. Panel
(b): Semi-quantitative analysis of NHE3 and villin colocalization in kidney section.
6-10 z-stack images were taken with laser scanning confocal microscope from
each animal (n = 3 rats per group). Images were analyzed using Metamorph
software and colocalization was expressed as the percentage of the sum of the
green staining overlapping the red staining to the sum of the green fluorescence
only. Significance was determined using one-way ANOVA and the null
hypothesis was rejected for a p-value< 0.05. *= significant compared to nontreated group, f = significant compared to OP rats. Bar = 10microns.
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In vitro experiments

cGMP levels, role of oxadiazolo-quinoxaline (ODQ) and probenecid in
human renal proximal tubule epithelial cells (RPTEC) model
Since it is controversial whether renal proximal tubules cells produce NO
under basal conditions, we determined the capability of primary cultures of
RPTEC to generate guanosine cyclic 3', 5' monophosphate (cGMP) in response
to direct stimulation of soluble guanylyl cyclase by the NO donor: S-nitroso-A/acetylpenicillamine (SNAP) (Fig. 37). In a concentration- and time-dependent
manner SNAP caused significant stimulation of intracellular and extracellular
cGMP. After 5 minutes of SNAP incubation intracellular cGMP production
increased from a basal value of 0.14 ± 0.07 to 12.77 ± 4.5 pmol ml"1 at 10~5 M
SNAP and to 104.32 ± 19.6 pmol ml"1, at 10"4 M SNAP, while extracellular cGMP
concentration did not change significantly at this time point (data not shown).
After 30 minutes at a 10"6 M SNAP concentration, intracellular levels of cGMP
remained elevated and extracellular levels began to increase from 0.03 ± 0.01
pmol ml"1 to 1.63 ± 0.24 pmol ml"1 (Fig. 38a). At the same time point, a
concentration of 10"5 M SNAP significantly increased intracellular levels of cGMP
from 0.15 ± 0.08 to 30.27 ± 10.9 pmol ml"1. However, extracellular levels of
cGMP did not reach statistical significance (from 0.03 ± 0.01 to 31.01 ± 20.94
pmol ml"1), most probably due to the large variance and small number of
experiments (Fig. 38a). As demonstrated in Fig. 38b, after 2 hours SNAP
increased intracellular cGMP production and also extracellular cGMP levels in
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Figure 37 Schematic of experimental design for Aim # 3B.
As it is controversial whether renal proximal tubule epithelial cells (RPTEC)
contain nitric oxide synthase (NOS), enzyme responsible for Nitric Oxide (NO)
production, RPTEC were exposed to (NO) donor-SNAP (S-nitro-N-acetyl-DLpenicillamine) and intracellular and extracellular levels of cGMP (cyclic
guanosine monophosphate) were measured. cGMP synthesis is catalyzed by
guanylate cyclase (GC). Membrane-bound GC is activated by peptide hormones
while soluble GC (sGC) is typically activated by NO to stimulate cGMP synthesis.
ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one), highly selective, irreversible,
inhibitor of soluble guanylyl cyclase was used to test whether SNAP modifies
levels of cGMP through its action on sGC. To investigate whether presence of
cGMP in extracellular milieu is necessary for its action we used probenecid to
block organic anion transporter through which cGMP is exported from the cell.
The ultimate goal of this experiment was to measure protein expression of
sodium transporters in RPTEC: apical sodium/hydrogen exchanger type 3
(NHE3) and basolateral Na,K-ATPase pump.
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Figure 38 The effects of SNAP incubation on intracellular and extracellular
cGMP levels in human renal proximal tubule epithelial cells (RPTEC) for 30 min
(Panel a) and 2 hrs (Panel b).
Cells were seeded at 100 000 cells/well density in 12-well plates and kept in
serum-free medium 24 hr before the experiments. RPTEC were incubated for 30
min or 2 hours with no SNAP (control) or with 10"6, 10"5 and 10"4 M SNAP in the
presence of 1 mM IBMX (isobutylmethylxanthine), a non-specific inhibitor of
phosphodiesterases. The concentration of cGMP was quantified in cell lysates
(intracellular) and in the medium (extracellular) using a commercially available
EIA kit. The samples were acetylated and tested in duplicates. Dilutions were
performed to insure that samples were in the range of the linear response.
Values are mean ± SEM from 3 experiments performed in duplicates.
Significance was determined using unpaired two tail t-test and the null hypothesis
was rejected for a p-value <0.05. *= Significant compared to control for
intracellular levels, f = Significant compared to controls for extracellular levels of
cGMP. SNAP significantly in concentration-dependent manner increased cGMP
levels intra- and extracellular.
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a concentration-dependent manner. Based on those results we chose the 2 hour
time point with a 10"6 M SNAP concentration to test the effects of different
hormones.
To determine if the effect of SNAP was mediated by soluble guanylyl
cyclase (sGC) we used a highly specific inhibitor of sGC, 1-H-[1,2,4] oxadiazolo [4,2-alpha] quinoxalin-1-one (ODQ, lO^M). For those experiments we
intentionally employed a higher concentration of SNAP then in previous
experiments to show that ODQ and probenecid are capable of blocking cGMP
generated by higher SNAP concentrations. ODQ significantly abolished the
increase in intracellular and extracellular cGMP levels produced by SNAP (10"5
M) after 5 min (only intracellular; data not shown) and 30 minutes incubation (Fig.
39a). After 2 hours, the extracellular level of cGMP was significantly reduced,
while intracellular cGMP levels were reduced with borderline significance (pvalue=0.09) compared to levels of intracellular cGMP achieved after incubation
with SNAP only. However, intra- and extracellular levels of cGMP measured in
samples incubated with SNAP and ODQ for 2 hrs were not significantly different
then control values of cGMP (without SNAP) (Fig. 39b).
In the next series of experiments we tested the ability of probenecid to
prevent the export of cGMP in the extracellular compartment. As demonstrated in
Fig. 39c, after 30 minutes probenecid (10~4 M) did not prevent the export of cGMP
from the cells. After 2 hours, probenecid significantly decreased extracellular
cGMP accumulation close to control levels from 79.4 ± 33.08 pmol ml"1 to 0.74 ±
0.33 pmol m"1 in the presence of SNAP (10"5 M)(Fig. 39d).
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Figure 39 The effects of ODQ (a, b) and probenecid (c and d) on intracellular
and extracellular cGMP responses to SNAP in RPTEC.
Cells were seeded at 100 000 cells/well density in 12-well plates and kept in
serum-free medium 24 hr before the experiments. Panel (a) and (b): Effects of
ODQ on intracellular cGMP following incubation with SNAP for 30 minutes (Panel
a) or 2hrs (Panel b). To test whether the effect of SNAP was mediated by
formation of cGMP, RPTEC were incubated without SNAP (control) or with SNAP
at 10"5 M and with simultaneously with ODQ (10"4 M) plus SNAP at 10"5 M for 30
min or 2 hours in the presence of 1mM IBMX. ODQ significantly reduced
intracellular cGMP levels after 30 minutes and 2 hours. Panel (c) and (d): Effects
of probenecid on extracellular cGMP following incubation with SNAP for 30
minutes (Panel c) or 2 hrs (Panel d). Cells were incubated with probenecid and
SNAP for 30 minutes or 2 hours. After 2 hr probenecid significantly abolished
extracellular cGMP accumulation. Concentration of cGMP was quantified in cell
lysates (intracellular) and in the medium (extracellular) using a competitive
enzyme immunoassay. Samples were acetylated and dilutions performed to
insure linearity of response. Values are mean ± SEM from 3 experiments
performed in duplicates. Significance was determined using unpaired two tail ttest and non-parametric test and the null hypothesis was rejected for a p-value
<0.05. *= Significant compared to control for intracellular levels. | = Significant
compared to controls for extracellular levels of cGMP. #= Significant compared to
SNAP treatment. §= Borderline significance (0.05<p-value<0.09) compared to
SNAP treatment.
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Accumulation of intracellular cGMP was also observed during this time course
but it did not reach statistical significance, most probably due to large variability
between the samples. In conclusion, at 2 hrs and 10"5M SNAP concentration
probenecid almost entirely blocks cGMP export.

Effect of angiotensin II, insulin and leptin on cGMP production in the
absence or presence of NO
Angiotensin II and insulin at different concentrations significantly increased
extracellular levels of cGMP after simultaneous incubation with 10"6 M SNAP for
2 hours (Fig. 40). Leptin however did not induce cGMP production at any of the
concentrations tested in the experiment. The ability to modulate cGMP
production was tested at 3-4 concentrations for the three hormones as follows:
angiotensin II: 10"8, 10"7, and 10"6M; insulin: 10"9, 10"8, and 10"7M and leptin: 15,
30, 45 and 60 ng ml"1, either in the presence or absence of SNAP (10"6 M) for two
hours. This concentration of SNAP was chosen since as described earlier, it
produced a significant increase in the levels of intracellular and extracellular
cGMP at 30 min and 2 hrs.
In the absence of NO donor, angiotensin II, insulin or leptin had no effect
on cGMP production (data not shown). Nevertheless, in the presence of SNAP
extracellular cGMP was increased following treatments with 10"8 M angiotensin II
(Fig. 40a) or 10"9M insulin (p-value=0.05) (Fig. 40b). Leptin treatment at
45 ng ml"1 had increased cGMP production compared to control from 25.47±4.3
to 42.4±6.8 pmol ml"1 but failed to gain statistical significance (p-value=0.1)
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Figure 40 Angiotensin II, insulin and leptin effect on intra- and extracellular
cGMP production in the presence of SNAP in RPTEC.
Cells were seeded at 100 000 cells/well density in 12-well plates and kept in
serum-free and insulin-free medium 24 hr before the experiments. Panel (a):
Effect of different angiotensin II concentrations on intracellular and extracellular
cGMP production in the presence of SNAP. RPTEG were incubated
simultaneously with SNAP (10"6M) and angiotensin II (10"8, 10"7, and 10"6M) for 2
hours in the presence of 1 mM IBMX. 10~8 M All significantly increased
extracellular cGMP over the control values after 2 hours incubation. Panel (b):
Effect of different insulin concentrations on intracellular and extracellular cGMP
production in the presence of SNAP. RPTEC were incubated simultaneously with
SNAP (10"6M) and insulin (10"9, 10"8, and 10"7M) for 2 hours in the presence of
1mM IBMX. 10"9 M of Insulin significantly increased extracellular cGMP over the
control values after 2 hours incubation. Panel (c): Effect of different leptin
concentrations on intracellular and extracellular cGMP production in the
presence of SNAP. RPTEC were incubated simultaneously with SNAP (10"6 M)
and leptin (15, 30, 45 and 60 ng ml"1) for 2 hours in the presence of 1mM IBMX.
Leptin had no effect on cGMP production at any given concentration.
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(Fig. 40C). However, we decided to proceed with all the above hormones
because we considered that effect of leptin on cGMP production did not become
statistically different because of the large assay variability as mentioned earlier.

Effect of NO and angiotensin II, insulin and leptin on Na.K-ATPase and
NHE3 total protein expression
We investigated the effects of NO together with angiotensin II (All), insulin
and leptin on Na.K-ATPase and NHE3 on total protein expression in membrane
fractions of RPTEC by western blotting. Tubulin was used as a loading control.
Protein expression of both: Na.K-ATPase and NHE3 were not consistently
changed at 6, 12 and 24 hour time course by any of the above mentioned
hormone treatments concurrent with NO donor administration at 10"6 M (data not
shown) or 10"5 M (Fig. 41 and 42) compared to controls (NO donor only). For this
reason we did not pursue measurements of Na.K-ATPase and NHE3 protein
abundance at those time points, however we continued to determine expression
of phosphorylated forms of both transporters at shorter time periods. Also, we
have decided to focus our efforts on treatments with angiotensin II and insulin
only as leptin did not significantly increase cGMP production.

Effect of NO, angiotensin II, and insulin on phosporvlation status of Na,KATPase and NHE3
There is evidence that serine-threonine phosphorylation of the catalytic a-subunit
by PKA or PKC is a key event in the short-term regulation of Na.K-ATPase

164

Control
Angiotensin II 10'8M
Insulin 10'9M
Leptin 45 ng ml"1

.2

25

"35
W

0)

<n
re

Q.

6 hrs

12hrs

24hrs

-100 kDa

Na,K-ATPase
6hrs

-55 kDa ..

12hrs

24hrs
Tubulin

Figure 41 Protein levels of Na,K-ATPase cc1 subunit in RPTEC stimulated with
NO and treated with angiotensin II, insulin and leptin for 6, 12 or 24 hours.
Cells were plated on 100 mm dishes at 330 000 cells/plate density and grown
until they reached confluency; then kept in serum-free medium 24 hr before the
experiments. SNAP, 10"5 M was added to all dishes followed by no treatment
(control) or angiotensin II (10~8M), insulin (10"9M), leptin (45 ng ml"1) for 6, 12 or
24 hours. Top: Values represent a ratio between Na,K-ATPase and tubulin signal
from 1 experiment in relative fluorescent unit (RFU). Bottom: Western blots of
Na, K-ATPase and tubulin which served as a loading control. Equal amount of
proteins were loaded into SDS-PAGE gel and membrane were simultaneously
probed with a monoclonal antibody against Na,K-ATPase and a polyclonal
antibody against tubulin. Bands were visualized by Odyssey Infrared Imaging
System.
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Figure 42 Protein levels of NHE3 in RPTEC stimulated with NO and treated with
angiotensin II, insulin and leptin for 6, 12 or 24 hours measured by western
blotting.
Cells were plated on 100 mm dishes at 330 000 cells/plate density and grown
until they reached confluency; then kept in serum-free medium 24 hr before the
experiments. SNAP, 10"5 M was added to all dishes followed by no treatment
(control) or angiotensin II (10"8M), insulin (10"9M), leptin (45 ng ml"1) for 6, 12 or
24 hours. Top: Values represent a ratio between NHE3 and tubulin signal from 1
experiment in relative fluorescent unit (RFU). Bottom: Western blots of NHE3 and
tubulin which served as a loading control. Equal amount of protein were loaded
into SDS-PAGE gel and membrane were simultaneously probed with a
polyclonal antibody against NHE3 and a monoclonal antibody against tubulin.
Bands were visualized by Odyssey Infrared Imaging System.
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(Fisone et al. 1994, Belusa etal. 1997, Pedemonte etal. 1997, Chibalin etal.
1999). In contrast, phosphorylation of NHE3 is not always necessary for its acute
regulation. The most definitive studies showed that cAMP effected in vivo
phosphorylation of rat NHE3 Ser605 and Ser552 in a concentration-dependent
manner (Moe 1999). Given all the above, we investigated whether All and insulin
could change the phosphorylation status of proximal tubule transporters and if
this mechanism involves the NO pathway. RPTEC were incubated with 10"8 M
angiotensin II and 10"9M insulin in the presence or absence of 10"5M SNAP for
30 minutes. Protein phosphorylation was expressed as the ratio between protein
phosphorylated on Ser16 and Ser552 to total protein expression.
The phosphorylation status of Na,K-ATPase was increased by incubation
with angiotensin II and insulin 3fold and 5fold, respectively, compared to control
levels. Conversely, SNAP alone decreased phophorylation of Na,K-ATPase by
200fold. However, simultaneous administration of SNAP with All further elevated
phophorylation levels of Ser16 of Na,K-ATPase over the control with SNAP only
(Fig. 43). At the same time, SNAP prevented the effect achieved by insulin alone
(as percent of control: insulin, 534%; SNAP, 0.4%; insulin+SNAP, 56%) (Fig. 43).
These results suggest that phosphorylation of the a1-subunit of Na,K-ATPase at
Ser16 can be stimulated by angiotensin II and insulin independent of cGMP
production since neither angiotensin II or insulin could change cGMP production
in the absence of the NO donor. However, only insulin effect on the
phosphorylation status of Na,K-ATPase was modulated in the presence of NO
implying that insulin signaling pathway can also be influenced by the NO pathway

167

^ H Control
i
I Angiotensin II
i . i Insulin

1000.0
g?
^

500.0
300.0

&

100.0

O

sz

50.0
30.0

Q.
(0

10.0

o
.c

Q.
O
(0
(0

Q.
I-

5.0
3.0
1.0
0.5
0.3
0.1

-SNAP

+SNAP

Figure 43 Serine 16 phosphorylation of Na,K-ATPase ot1 subunit in RPTEC
treated simultaneously with NO and angiotensin II (All) or insulin.
Cells were plated on 100 mm dishes at a density of 330 000 cells/plate, grown to
near confluency and then kept in serum-free, insulin-free medium 24 hr before
the experiments. Cells were treated withIO"5 M SNAP in the absence (control) or
presence of angiotensin II (10"8M) or insulin (10"9M) for 30 min. In all conditions,
phosphodiesterase inhibitor (IBMX) was used. Values represent a ratio between
phospho- and total Na,K-ATPase signal from 1 experiment. Control without
SNAP was set to 100% and treatments were expressed relative to the control
level. Phosphorylation levels of Na,K-ATPase were greatly reduced by NO and
increased by All and insulin. NO together with All further increased
phosphorylation of Ser16 while reversed insulin response in RPTEC.
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in renal proximal tubule epithelial cells. Whether cGMP is a share messenger of
those pathways needs additional testing where ODQ compound should be used.
As demonstrated in Fig. 44, the phosphorylation level of Ser552 of Na/H
exchanger 3 was slightly elevated by angiotensin II and remained unchanged
after incubation with insulin when compared to control levels. SNAP alone
decreased phosphorylation of NHE3 by 35% and it prevented the effect of
angiotensin II (as percent of control: angiotensin II, 120%; SNAP, 65%;
angiotensin ll+SNAP, 88%). Simultaneous incubation of RPTEC with SNAP and
insulin increased posphorylation of NHE3 to 117% from 97% with insulin alone.
These results suggest that angiotensin II and insulin may not play a role in
phosphorylation of NHE3 at Ser552. Nevertheless, in the presence of NO
angiotensin II and insulin modulated the phosphorylation status of NHE3
differently, pointing to the fact that their signaling pathways could be influenced
by NO pathway in RPTEC. Further experiments are required to establish whether
cGMP plays a role.
Insulin cross-talk with NO at the level of cGMP production and the
resultant production of cGMP could in turn induce phosphorylation of the two
transporters. This may account at least in part for different levels of activity of
those transporters determined in vivo. However, further studies are required to
determine the precise mechanism(s) involved.
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Figure 44 Serine 552 phosphorylation of NHE3 in RPTEC treated
simultaneously with NO and angiotensin II (All) or insulin.
Cells were plated on 100 mm dishes at a density of 330 000 cells/plate, grown to
near confluency and then kept in serum-free, insulin-free medium 24 hr before
the experiments. Cells were treated with SNAP 10"5 M in the absence (control) or
presence of angiotensin II (10~8 M) or insulin (10"9 M) for 30 min. In all conditions
phosphodiesterase inhibitor (IBMX) was used. Values represent a ratio between
phospho- and total NHE3 signal from 1 experiment. Control without SNAP was
set to 100% and treatments were expressed relative to the control level. NO
decreased, All slightly increased and insulin did not change NHE3
phophorylation levels. In the presence of NO, All decreased and insulin
increased phosphorylation of Ser552of NHE3 in RPTEC.
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5.3 Discussion for Specific Aim # 3

In the previous Aim we described the effects of pioglitazone on sodium
transport and renal excretory function. Earlier data published by our group
showed that pioglitazone treatment resulted in an increase of NOx as well as
eNOS and nNOS expression in the kidney (Dobrian et al. 2004). Since several
studies showed that NO can modulate renal sodium handling, we further
investigated the effect of in vivo chronic NO blockade on expression and activity
of Na,K-ATPase and NHE3.
The results of our present study demonstrated that inhibition of NO
synthesis by chronic treatment with L-NAME lead to a marked attenuation of the
urine flow rate and sodium excretion in response to changes in renal perfusion
pressure in lean, but not obese, rats on a moderately high fat diet. The dose of LNAME was chosen to inhibit NO without changes in blood pressure. This
approach allowed us to determine if the changes in renal hemodynamics and
sodium excretion were related to changes in NO production and not simply a
consequence of the increase in blood pressure. Indeed, L-NAME reduced NO
production in a comparable manner in both groups while having no significant
effect on MAP. In obese rats, treatment with L-NAME did not produce any
changes in pressure natriuresis and diuresis. In contrast, in lean rats NO
inhibition reduced natriuresis and diuresis. In both groups, GFR was not affected
by the treatment and remained the same in treated and non-treated animals. In
agreement with our results from the lean animals, several studies have indicated
that inhibition of renal NO synthesis blunted the diuretic and natriuretic
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responses without altering renal blood flow or glomerular filtration rate (Salom et
al. 1992, Majid etal. 1993). Moreover, there is evidence suggesting that
excretion of urinary NO metabolites was increased with renal perfusion pressure
(Suzuki et al. 1992, Majid et al. 1995). Finally, direct measures of renal cortical
NO activity in the dog with an NO-sensitive microelectrode showed that it
decreased linearly with the reduction in renal perfusion pressure within the
autoregulatory range (Majid et al. 1998). However, these data do not explain the
differences in natriuretic responses between the lean and obese rats. In animal
models of obesity and in obese humans there are reports of elevated renal
sympathetic nerve activity (Vaz et al. 1997, Hall 2003) and activation of the reninangiotensin system (Sharma 2004). Interaction between NO and renal
sympathetic nerves is an important factor in the regulation of renal
hemodynamics and sodium homeostasis. Basal NO synthesis has been reported
to blunt the vasoconstrictive effect of sympathetic nerve stimulation in the
isolated perfused rat kidney (Reid & Rand 1992). In addition, there is also
considerable evidence concerning NO interaction with the renin-angiotensin
system. NO synthesis inhibition and angiotensin II stimulation are quite similar in
terms of regulation of vascular tone. For example, inhibition of nitric oxide
production stimulates endothelial angiotensin-converting enzyme (ACE) activity
and generation of angiotensin II (Takemoto etal. 1997, Katoh etal. 1998).
However, it is not clear the extent to which the vasoconstrictor response to NO
blockade results from withdrawal of an NO vasodilatory stimulus or is related to
the amplification of vasoconstrictor systems. Moreover, obesity is usually
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associated with expansion of extracellular fluid volume (Carroll etal. 1995, Hall et
al. 2002). Therefore, we propose that most probably lack of changes in excretion
of water and sodium in obese Sprague-Dawley rats fed a high fat diet and treated
chronically with L-NAME to inhibit NO production is a result of an imbalance
between NO and other vasoconstrictor signaling pathways which leads to their
defective mutual regulation.
Exactly how increased renal NO synthesis or inhibition of NO production
cause changes in natriuresis and diuresis are not fully understood. Since NO did
not alter renal autoregulatory function under the experimental conditions we
used, inhibition of tubular sodium transport appears to be important in our model.
In an attempt to elucidate whether overall actions of NO in the kidney can be
attributed to a direct tubular effect we analyzed the outcome of chronic L-NAME
treatment on proximal tubule transporters Na,K-ATPase and NHE3 expression
and activity. We have observed in obese rats treated with L-NAME an increase in
abundance of NHE3 but no changes in its activity. Also, we did not determine
changes in abundance and activity of Na,K-ATPase. On the other hand, after NO
inhibition in lean rats we reported an increase in protein expression of Na,KATPase without changes in its activity and an increase in NHE3 abundance and
activity, as well as redistribution of this transporter to the more active membrane
pool.
The effect of NO on tubular sodium transport varies in different segments
of the nephron. In most cases, however, NO inhibits sodium transport which is
consistent with its natriuretic and diuretic action (Ortiz & Garvin 2002). In the
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proximal tubule, which is responsible for reabsorbing 50-60% of filtered sodium
and water, the effects of NO are not fully understood. As reviewed by Ortiz and
Garvin, there are reports showing that NO inhibits proximal tubule transport,
while others suggest that NO stimulates proximal tubule transport (Ortiz & Garvin
2002). Wu et al. proposed that while NO itself has a direct inhibitory effect on
proximal tubule sodium transport, the presence of NO is necessary to ensure that
renal nerves can stimulate fluid reabsorption by the proximal tubules (Wu &
Johns 2002).
However, the direct inhibitory role of NO on proximal tubule sodium
transport seems to be due to decreased apical Na/H exchange (Roczniak &
Burns 1996) and reduced Na,K-ATPase activity (Liang & Knox 1999a) which is
in agreement with results we obtained from lean rats. The NO inhibition did not
significantly change proximal Na+ transport in obese rats. Ortiz and Stoos
proposed that effects of NO in the kidney can be modulated by changes in the
sensitivity to NO signaling (Ortiz et al. 2003). Differences in NO signaling
pathway are possible between OP and OR rats and could play a role in final
responses to NO production blockage. An interesting observation suggesting
differences in NO sensitivity between obese and lean animals was reported by
Jebelovszki et al. in coronary arterioles of rats. They reported that coronary
arteriolar dilations to acetylcholine (ACh) were preserved and not significantly
affected by NOS inhibition, whereas the dilations to NO donors were significantly
enhanced in obese rats compared to lean. In contrast, the inhibition of NO
synthesis with L-NAME decreased ACh-induced dilation in coronary arterioles
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isolated from lean animals only. In addition, the authors found that NO donorstimulated vascular cGMP immunoreactivity and cGMP levels were increased in
obese rats compared to lean rats. The authors suggested that in high fat dietinduced obesity, due to the increased soluble guanylyl cyclase activity, the NO
sensitivity of coronary arterioles was enhanced despite the impaired NO
bioavailability (Jebelovszki et al. 2008).
Besides possible variations in NO sensitivity in OP vs. OR rats, a
difference in the metabolic milieu of the obese and lean animals is another
possibility which may lead to different responses to NO depletion. It is known that
the NO signaling cascade is influenced by other systems. Previous studies
demonstrated that feeding rats and dogs a moderately high fat diet results in
higher levels of renin activity in obese animals compared with lean animals
(Dobrian etal. 2000, Henegar etal. 2001, Boustany et al. 2004). Higher levels of
leptin in animals as well as obese humans were observed in diet-induced obesity
(Hirose etal. 1998, Lauterio etal. 1999, Levin etal. 2003, Ricci & Levin 2003).
Moreover, those changes are paralleled by changes in insulin levels (Hall et al.
1998, Lauterio etal. 1999, Henegar etal. 2001, Levin etal. 2003). For example,
angiotensin II stimulated NO production via both AT1 in cultured endothelial cells
(Saito et al. 1996) and via AT2 receptors in SHR rats (Saito et al. 1996, Gohlke
et al. 1998) while it decreased NO bioavailability by stimulating superoxide
production in Wistar rats (Mollnau et al. 2002) as well as blocking NO signal
transduction in animals (Kim etal. 2001, Mollnau et al. 2002). Experimental
evidence also suggests that NO is involved in the pathogenesis of diabetes and
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insulin resistance. NADPH oxidases in the vascular wall are activated in diabetes
mellitus, leading to enhanced degradation of NO and the production of reactive
oxygen species (Guzik et al. 2002). Furthermore, uncoupling of eNOS has been
demonstrated in animal models of diabetes (Elrod etal. 2006). In the kidney,
leptin interferes with NO synthesis and this effect depends on the exposure time
to the hormone as well as its concentrations. For instance, long-term
hyperleptinemia decreased natriuresis and urinary excretion of NO metabolites
and cGMP (Beltowski et al. 2004) by increasing levels of systemic and intrarenal
oxidative stress, leading to NO deficiency (Beltowski et al. 2004). However, in an
acute setting leptin stimulated systemic NO release (Beltowski et al. 2002) while
chronic inhibition of NO synthesis impaired the acute leptin-mediated natriuretic
effect in normotensive lean rats (Villarreal etal. 2004). Interestingly, the shortterm leptin-induced natriuretic effect observed in lean rats was attenuated in
obese rats and was blunted in spontaneously hypertensive rats (SHR) (Villarreal
et al. 1998, Beltowski et al. 2002). It was suggested that while leptin may be a
potential salt-excretory factor in normal rats, in obesity and hypertension its
function may be impaired. Overall, these data imply that in hypertension induced
by obesity there are factors which could tip the already existing imbalance
between NO and systems that antagonize its action, in the favor of the latter.
Therefore, further NO inhibition in obese rats is unlikely to induce additional
significant changes.
As mentioned before, to investigate whether the differences in natriuretic
responses could be attributed to differences in sodium transport we examined
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expression and activity of Na,K-ATPase and NHE3 in obese and lean rats
treated with L-NAME. In the lean rats we reported an increase in protein
expression of Na,K-ATPase and an increase in NHE3 abundance and activity as
well as redistribution of this transporter. In obese rats we did not observe a
significant change in either Na,K-ATPase or NHE3 activities following chronic LNAME treatment. Little is known about the molecular mechanism of NHE3
regulation by NO. As described earlier, Roczniak and Burns showed that NO
stimulated soluble guanylyl cyclase in both freshly isolated proximal tubule
segments and in primary cultures of proximal tubule cells, and caused inhibition
of Na+/H+ exchange. It was concluded that this effect was at least partly mediated
by generation of cGMP (Roczniak & Burns 1996). Using the Caco-2 cell line, a
human colonic carcinoma cell line that has been used to study regulation of
electrolyte uptake by various hormones and growth factors, Gill et al. reported
that NHE3 activity was decreased through the activation of soluble guanylyl
cyclase, resulting in increased production of intracellular cGMP and activation of
protein kinase G (PKG); there was no involvement of PKC- or protein kinase A
(PKA)-mediated pathways in this process (Gill et al. 2002). Further downstream
events in the NO signaling pathway which lead to NHE3 inhibition have not been
fully deciphered although a study by Cha et al. demonstrated that cGMP
inhibition of NHE3 required NHE3 regulatory factor 2 (NHERF2). NHERF2 binds
cGMP-dependent protein kinase type II (cGKII), and then anchors this complex
to the brush border membrane (Cha et al. 2005). It was also suggested that
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cGMP could stimulate phosphorylation of NHE3 while additional signaling
molecules still need to be identified.
Na,K-ATPase is also subjected to regulation by NO and various hormones
that are increased in obesity and hypertension. Na,K-ATPase activity was found
to be inhibited by NO in an opossum kidney (OK) proximal tubule cell line (Liang
& Knox 1999a), in the mouse proximal tubule epithelial cells (Guzman etal.
1995, Seven etal. 2005)) and in guinea pig kidney (Seven etal. 2005).
Moreover, it was noted that in primary culture of rat proximal tubule cells in the
presence of an NHE3 inhibitor, NO still decreased Na,K-ATPase activity implying
that this inhibition is independent of intracellular Na+ concentration (Linas &
Repine 1999). Recently, it was reported by Shahidullah etal. that various nitric
oxide donors decreased Na,K-ATPase activity by activation of soluble guanylyl
cyclase, generation of cGMP and activation of PKG in epithelial cells from
porcine eyes (Shahidullah & Delamere 2006). Therefore, it is conceivable to
believe that a similar mechanism might be responsible for the NO effect on Na,KATPase in the kidney as well. However, whether PKG regulates Na,K-ATPase
through secondary modulators or by direct phosphorylation should be further
investigated. We propose that the lack of responses from obese animals treated
with L-NAME could be explained, as in the case of apical NHE3, by a difference
in the metabolic and hormonal milieu in the obese vs. lean rats.
Our results did not provide definitive information regarding direct effects of
NO on the activity of proximal tubule sodium transporters in vivo thus we
designed in vitro experiments on sodium reabsorption in primary cultures of
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human renal proximal tubule epithelial cells (RPTEC). We analyzed expression
of Na,K-ATPase and NHE3 in the presence of angiotensin II, insulin or leptin and
examined the role of cGMP as a potential mediator of their responses. We
demonstrated that in response to an NO donor, RPTEC stimulated cGMP
production by activation of soluble guanylyl cyclase (sGC) since the selective
sCG inhibitor, ODQ, was effective in blocking this increase. However, it is
controversial whether the proximal tubule produces NO under basal conditions.
Nevertheless, evidence suggests that the proximal tubule is constantly exposed
to NO that might include NO from nonproximal tubule sources such as the
vasculature or other nephron segments (Amorena & Castro 1997, Linas &
Repine 1999). Also, proximal tubule cells from humans contain sGC (Sasaki et
al. 2004) therefore are being able to signal through NO, regardless of the source.
Next, we reported that in the presence of an NO donor, angiotensin II and
insulin but not leptin increased cGMP levels in renal proximal tubule epithelial
cells. To our knowledge, there are no reports about the effect of insulin and leptin
on cGMP production in RPTEC. As already mentioned before, infusion of
angiotensin II into rats significantly decreased expression of both subunits of
sGC in blood vessels (Mollnau et al. 2002). Moreover, in isolated proximal
tubules Zhang and Mayeux showed that angiotensin II induced a rise in cGMP
production which was mediated by AT1 receptors (Zhang & Mayeux 1998).
As we did not observe any changes in total abundance of Na,K-ATPase
and NHE3 after 6, 12 and 24 hours incubation of RPTEC with angiotensin II and
insulin in the presence of an NO donor, we decided to determine changes in
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phosphorylation status of Na,K-ATPase and NHE3 in the same conditions but in
shorter periods of time. We reported that phosphorylation of the a1-subunit of
Na,K-ATPase at Ser16 was stimulated by angiotensin II and insulin in the
absence of NO while phosphorylation status of NHE3 at Ser552 was not
changed. However, in the presence of an NO donor only insulin affected the
phosphorylation state of Na,K-ATPase but both: angiotensin II and insulin
modulated the phosphorylation status of NHE3. As already discussed in aim # 1,
it has been shown that in the proximal tubule the oc-subunit of Na,K-ATPase can
be phosphorylated by PKA in the C-terminal at Ser943 (Feschenko & Sweadner
1995) as well as by PKC in the N-terminal at Ser11, Ser18 and Ser23
(Logvinenko etal. 1996). Modification of Na,K-ATPase by phosphorylation is
generally associated with altered enzyme activity (Bertuccio et al. 2007) and
changes in subcellular Na,K-ATPase distribution . For example, angiotensin II
stimulated Na,K-ATPase in the proximal tubule by PKC activation (Rangel et al.
2002) very rapidly, by a direct mechanism that could involve changes in
phosphorylation (Yingst etal. 2004). In the rat, angiotensin II induced the
phosphorylation of both Ser11 and Ser18of the Na,K-ATPase a-subunitby
protein kinase C beta. This resulted in the recruitment of Na,K-ATPase molecules
to the plasma membrane and an increased capacity to transport sodium ions
(Efendiev et al. 1999, 2000). However, in human type Na,K-ATPase Ser11 was
essential for the hormonal regulation of Na,K-ATPase activity and
phosphorylation of this residue either lead to stimulation or inhibition of the
enzyme with the subsequent recruitment or rectraction of Na,K-ATPase to or
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from plasma membrane, respectively (Efendiev & Pedemonte 2006). Our data
are supported by the above mentioned findings since incubation of RPTEC with
angiotensin II lead to the increase in the phosphorylation status of Ser16 of the
a1-subunit although we do not have evidence yet to indicate that this could be
translated into changes in Na,K-ATPase activity.
The mechanisms by which insulin regulates Na,K-ATPase in the kidney is
largely unknown. There are reports demonstrating that insulin can stimulate
Na,K-ATPase (Sweeney et al. 1998) by tyrosine phosphorylation in kidney
proximal tubule cells (Feraille et al. 1999). However, in the present study, we
have observed that phosphorylation of Ser16 was stimulated following the insulin
administration. To ensure that the effects of angiotensin II and insulin were in fact
achieved by activation of protein kinase C further testing with PKC inhibitors is
required.
NO was shown to inhibit Na,K-ATPase activity acting through the cGMP
pathway and by activating protein kinase C-a (Liang & Knox 1999b), however,
no phosphorylation sites were described. It is possible that as mentioned before,
Ser11, Ser18 and Ser23 are involved. Our data suggest that an NO donor
decreased the phosphorylation status of Ser16. However, in the presence of NO,
angiotensin II at a concentration which increased cGMP levels, did not change
the phosphorylation status of Ser16 of Na,K-ATPase while insulin did. To the
best of our knowledge, reports about interaction of angiotensin II and NO/cGMP
pathways in the proximal tubule and their effects on sodium transporters are
missing. Zhang and Mayeux demonstrated that angiotensin II had a biphasic
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effect on Na,K-ATPase activity in the rat proximal tubule and that activation of
NOS opposed the stimulatory effects of angiotensin II on Na,K-ATPase activity
(Zhang & Mayeux 2001). Also, there are no reports on simultaneous effects of
NO and insulin on Na,K-ATPase and NHE3. To better understand the influence
of the NO/cGMP signaling cascade on angiotensin II and insulin pathways
additional studies are needed.
NHE3 is subjected to both short- and long-term regulation. Long-term
regulation is associated with an increase in protein abundance, whereas shortterm regulation is associated with transporter trafficking as well as posttranslational modifications of the proteins. We examined one of the acute
regulatory mechanisms of NHE3 in vitro. NHE3 was phosphorylated in intact
tissue or in cell culture models by PKA and PKC (Wiederkehr et al. 1999, Zhao et
al. 1999). While an increase in NHE3-phosphorylation was paralleled, in general,
by a decrease in NHE3 activity (Fan et al. 1999, Zhao et al. 1999), PKC
activation lead to either stimulation or inhibition of NHE3 activity (Wiederkehr et
al. 1999). The result was dependent on the system used and suggested that
phosphorylation of NHE3 per se is necessary but not sufficient to regulate
activity. The study by Zhao et al. demonstrated that Ser552 and Ser605 are
involved in PKA-inhibition of NHE3 (Zhao et al. 1999). Kocinsky and coworkers
showed that phosphorylation of NHE3 at serines 552 and 605 by PKA did not
alter NHE3 activity in vivo. Furthermore, in a proximal tubule cell model PKA
activation reduced NHE3 activity in a time-dependent manner (Kocinsky et al.
2007). The authors implied that the lack of direct association between NHE3
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phosphorylation and NHE3 activity demonstrates that NHE3 phosphorylation at
serines 552 and 605 per se does not directly inhibit transport. Nonetheless, we
assessed the phosphorylation state of NHE3 Ser552 RPTEC after stimulation
with angiotensin II and insulin in the presence or absence of NO. In the absence
of an NO donor, neither angiotensin II nor insulin modulated Ser552
phosphorylation of NHE3. Angiotensin II is known to stimulate NHE3 by its action
on AT1 receptors through pathways that are dependent on phospholipase C,
metabolism of arachidonic acid, phosphatidyl inositol 3 kinase and Akt in human
intestinal epithelial Caco2BBE cells (Musch etal. 2009). Studies by Becker etal.
revealed that angiotensin II stimulated NHE3 activity in the proximal tubule, but
the stimulatory response was markedly greater in obese Zucker than in lean
Zucker rats; in addition, angiotensin II caused greater inhibition in cAMP
accumulation in the proximal tubule of obese compared to lean rats (Becker et al.
2003). Some in vivo results suggested that angiotensin II stimulated Na+/H+
exchange in the proximal tubule by a depression in intracellular cAMP (Liu &
Cogan 1989). Although, no correlations have been made to the phosphorylation
of NHE3 at Ser552, it is tempting to suggest that angiotensin II may stimulate
NHE3 by reducing cAMP levels and by further decreasing the phosphorylation
status of NHE3 at the Ser552 residue.
How insulin signals NHE3 stimulation is not known. In opossum kidney
(OK) cells, insulin increased NHE3 activity in a time- and concentrationdependent manner (Klisic et al. 2002). While the chronic effect of insulin on
NHE3 appeared to proceed through the phosphatidylinositol 3-kinase-serum- and
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glucocorticoid-dependent kinase 1 pathway, the signaling cascade for the acute
effect is not known; in addition, in clear contradistinction to hormones coupled to
protein kinase A, insulin acutely alters NHE3 activity without changes in its
phosphorylation (Fuster et al. 2007).
Our data suggest that in the presence of an NO donor, signaling cascades
of angiotensin II and insulin may be altered and differently modulate Ser552
phosphorylation of NHE3. Further studies are necessary to evaluate whether
those changes are cGMP dependent by using a soluble guanylyl cyclase
inhibitor, such as ODQ. Moreover, it is imperative to measure how the
phosphorylation status of Na,K-ATPase and NHE3 is changing when angiotensin
II and insulin effects are combined in the presence of NO to more closely mimic
the in vivo environment.
In summary, we demonstrated that inhibition of NO production by chronic
L-NAME treatment impaired pressure-induced natriuresis and diuresis in lean,
normotensive but not in obese, hypertensive animals. In the lean rats, impaired
pressure natriuresis was paralleled by alterations in the abundance, expression
and distribution of apical NHE3 and the basolateral Na,K-ATPase in the proximal
tubule. The mechanism responsible for diverse regulation of both transporters in
obese and lean animals could evolve most likely from different metabolic states
of obese vs. lean rats. It could also involve an imbalance among the NO
signaling pathway, angiotensin II and insulin and eventually lead to differential
regulation of sodium transporters in both the acute and the long-term settings.
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SECTION 6
SUMMARY AND CONCLUSIONS

Excess weight contributes to increased blood pressure in a large
proportion of essential hypertensive patients. Epidemiological studies have
shown that hypertension is more prevalent in obese than in nonobese individuals
and that blood pressure is correlated to body weight, even in normotensive
subjects. There are many animal models of obesity available but not all of them
mimic closely enough the cardiovascular, renal, and neurohumoral changes
found in obese humans. In this study we used a rodent model previously
characterized by Dobrian et al. This rat model of diet-induced obesity develops
hypertension and shows vascular and renal changes similar to those observed in
obese hypertensive humans. Sprague-Dawley rats were fed a purified
moderately high-fat (MHF) diet that contains 32% kcal as fat, a value similar to
the average Western diet, and showed a bimodal pattern in body weight gain.
Approximately half of the rats gain weight rapidly (obesity-prone (OP)) and
develop mild hypertension while the other half (obesity-resistant (OR) group) gain
weight at a rate similar with chow-fed rats- and are normotensive.
Theoretical and experimental studies have shown that in all forms of
hypertension, including obesity hypertension, there is an abnormality of kidney
function characterized by a hypertensive shift in renal pressure natriuresis. In
addition, when obesity is induced by feed.ing a high fat diet, there is marked
sodium retention and expansion of extracellular fluid volume. Moreover, sodium
retention and altered pressure natriuresis appears to be caused mainly by

185
increased tubular sodium reabsorption. Based on this evidence we hypothesized
that development of hypertension in diet-induced obesity is due to the increase
in Na+ reabsorption by means of changes in activity of proximal tubule sodium
transporters. In summary, our study demonstrated that pressure-induced
natriuresis and diuresis were attenuated in obese rats compared to lean rats fed
high fat diet. This can explain the increased sodium reabsorption in the obese
rats, at least in part due to impaired proximal tubule function. These findings
were well correlated with higher protein expression and activity of the apical
NHE3 and the higher overall activity of basolateral Na,K-ATPase in the renal
proximal tubule. The mechanisms which contribute to these changes are likely
multifactorial. We provided evidence on the differences in NHE3 distribution
between lean and obese rats which could account for the differences in NHE3
activity and may explain the increased sodium retention seen in obese rats
during acute pressure natriuresis and diuresis. For future studies, it would be of
interest to examine other sodium transporters along the renal tubule as well as to
investigate the mechanism of sodium handling and transporters activity in the
obese and lean rats before the development of hypertension.
PPARy is implicated in the pathogenesis of obesity and is also involved in
blood pressure regulation. PPARy are molecular targets for TZDs (pioglitazone,
rosiglitazone) used in clinical practice to treat diabetes. Besides reducing blood
glucose levels these agents increase insulin sensitivity, lower blood pressure, but
can also cause sodium retention by effecting tubular reabsorption. While the
water retention induced by the TZDs is explained by a distal mechanism, the
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blood pressure lowering effects have no clear molecular explanation. Thus, we
hypothesized that PPARy activation lowers blood pressure by altering activity of
sodium transporters Na,K-ATPase and NHE3 and by modulating tubular sodium
reabsorption. Consequently, to address this hypothesis we examined the effects
of chronic pioglitazone administration on blood pressure, sodium handling, and
activity of proximal tubule transporters in obese and lean rats fed with a high fat
diet. Also, using an in vitro model of proximal tubule epithelial cells we tested
whether the pioglitazone effect on sodium transporters is mediated by
peroxisome proliferator-activated receptor gamma. In summary, in an animal
model of obesity-induced hypertension pioglitazone lowered blood pressure with
a strong tendency to increase sodium excretion. In normotensive lean rats,
pioglitazone had no effect on renal hemodynamics and blood pressure and at the
same time caused sodium and water retention. Na,K-ATPase protein expression
and activity were increased while NHE3 protein expression and activity were
decreased by pioglitazone in obese rats. In lean animals Na,K-ATPase
abundance was elevated while NHE3 protein expression was reduced.
Moreover, in lean group after pioglitazone treatment NHE3 had a tendency to be
redistributed to the active pool localized in the microvilli region. We concluded
that simultaneous reduction in NHE3 abundance and activity could be
responsible for blood pressure lowering effect of pioglitazone. Since we do not
have a good candidate responsible for increased sodium and water reabsorption
observed in lean rats we propose, that additional studies to analyze expression
and activity of other transporters are needed to account for this effect. Our in vitro
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experiments provided evidence that pioglitazone requires the expression of
peroxisome proliferator-activated receptor gamma in order to act on Na,KATPase and NHE3. Furthermore, additional in vitro studies will provide further
mechanistic understanding on PPARy effect on sodium transporters.
It has been shown that chronic inhibition of NO production produces
arterial hypertension. In the kidney NO plays an important role in the control of
renal hemodynamics and its net effect is to promote natriuresis and diuresis. This
mechanism is not well understood, but a direct effect on tubular transport seems
to be involved. Many in vitro and in vivo studies have demonstrated that at
proximal tubule level NO induces natriuresis by directly inhibiting activity of NHE3
and Na,K-ATPase through generation of cGMP and stimulation of PKG. There
are reports that in obesity-induced hypertension NO bioavailability and sensitivity
are altered. Moreover, NO is known to interact with pathways which are activated
in obesity such as renin-angiotensin system, renal sympathetic nerves and leptin.
Therefore, we hypothesized that NO may have different effects on Na+ handling
in obese and lean animals and its interaction with hormones such as angiotensin
II, insulin and leptin is relevant for the blood pressure control. We measured
GFR, fractional excretion of sodium and lithium at two different perfusion
pressures, and expression and activity of Na,K-ATPase and NHE3 in basolateral
or brush border membranes from renal cortex, respectively, in vivo. Moreover,
we analyzed changes in phosphorylation status of Na,K-ATPase and NHE3 after
treatment with angiotensin II or insulin in the presence of NO in vitro, in cell
culture. In summary, L-NAME treatment did not change MAP in either group. The
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changes in GFR were also not significantly different between groups. L-NAME
attenuated the natriuretic response to increases in RPP in OR while it had no
effect on pressure natriuresis and diuresis in the OP group. We have observed
after NO inhibition in lean rats an increase in protein expression of Na,K-ATPase
without changes in its activity and an increase in NHE3 abundance and activity
as well as redistribution of this transporter to the more active membrane pool. On
the other hand, in obese rats treated with L-NAME we report an increase in
abundance of NHE3 but no changes in its activity or in abundance and activity of
Na,K-ATPase. In conclusion, inhibition of NO production blunted pressureinduced natriuresis and diuresis in lean rats fed high fat diet most likely through
releasing tonic inhibitory effect of NO on the proximal tubule sodium transporters.
However, L-NAME treatment did not have any effect on renal hemodynamics and
kidney excretory function in obese animals, leading us to believe that metabolic
and hormonal differences between those animals are responsible for their
diverse responses to NO blockage.
Our in vitro studies demonstrated that phosphorylation of the oc1-subunit of
Na,K-ATPase at Ser16 was stimulated by angiotensin II and insulin in the
absence of NO while phosphorylation status of NHE3 at Ser552 was not
changed. However, in the presence of an NO donor only insulin effected
phosphorylation state of Na,K-ATPase but both: angiotensin II and insulin
modulated the phosphorylation status of NHE3. Available data suggest that
phosphorylation of Na,K-ATPase is usually associated with altered enzyme
activity while phosphorylation of NHE3 is necessary but not sufficient to regulate

189
its activity. Our study provides evidence that Na,K-ATPase and NHE3
phosphorylation status is changed after treatment with hormones in the presence
or absence of an NO donor but further studies are needed to extrapolate these
findings to changes in the transporters' activity.
Moreover, additional in vitro studies are necessary to evaluate whether the
changes are cGMP dependent by using a soluble guanylyl cyclase inhibitor, such
as ODQ. It is also imperative to measure how the phosphorylation status of
Na,K-ATPase and NHE3 is changing when angiotensin II and insulin effects are
combined in the presence of NO to more closely mimic in vivo environment.
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